P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
1.168e-09 | -20.57 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 17 | 19454 | 50 |
CLU,TRPM3,ATP1A2,CPE,MACF1,GPM6A,SLC1A3,ABLIM1,SPARCL1,SLC4A4,LSAMP,APOE,CAMK2G,NHSL1,MSI2,SORBS1,PTPRZ1 |
1.086e-08 | -18.34 | cell periphery | cellular component | GO:0071944 | 6020 | 35 | 19108 | 49 |
DTNA,NTRK2,CTNNA2,HIF3A,BMPR1B,GPM6A,TRPM3,PTPRZ1,FMN2,MACF1,SORBS1,APOE,ZNRF3,GPC5,SLC4A4,NRG3,TNIK,SLC1A2,ATP1A2,CST3,CTNND2,NRXN1,COL5A3,SLC1A3,CPE,SPARCL1,ATP13A4,NTM,PREX2,CLU,CDH20,FGFR3,RYR3,NKAIN3,LSAMP |
5.110e-08 | -16.79 | mouth | COSMIC cancer mutations | mouth | 9004 | 44 | 16828 | 49 |
CAMK2G,DTNA,FGFR3,ATP1A2,NRG3,HIF3A,CST3,MACF1,SLC1A3,ACSS1,NEBL,SOX5,RORA,SLC4A4,ABLIM1,PTPRZ1,FMN2,TNIK,CLU,LSAMP,CTNND2,APOE,NTRK2,ZBTB20,RANBP3L,TRPM3,PREX2,PITPNC1,NTM,SLC25A18,COL5A3,NPAS3,NRXN1,SORBS1,GPM6A,RYR3,PAMR1,SFXN5,ATP13A4,GPC5,ZNRF3,NHSL1,SLC1A2,CDH20 |
5.733e-08 | -16.67 | nervous system development | biological process | GO:0007399 | 2185 | 21 | 18204 | 49 |
CTNND2,NTM,NRXN1,SLC1A3,TNIK,NTRK2,RORA,PREX2,CLU,SLC1A2,GPM6A,CTNNA2,CAMK2G,LSAMP,MSI2,APOE,SOX5,PTPRZ1,NRG3,BMPR1B,ATP1A2 |
7.021e-08 | -16.47 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 14 | 19454 | 50 |
NTM,CTNNA2,TNIK,CLU,NEBL,GPM6A,ATP1A2,ABLIM1,SLC1A3,CTNND2,APOE,LSAMP,SLC1A2,SORBS1 |
7.462e-08 | -16.41 | multicellular organism development | biological process | GO:0007275 | 3957 | 28 | 18204 | 49 |
FGFR3,RORA,PREX2,NRXN1,SLC1A3,NTM,RANBP3L,NTRK2,SOX5,APOE,MSI2,ATP1A2,BMPR1B,SLC1A2,CDH20,ZNRF3,HIF3A,CAMK2G,CTNND2,TNIK,PTPRZ1,NRG3,CLU,CTNNA2,GPM6A,NEBL,CPE,LSAMP |
7.870e-08 | -16.36 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 21 | 18204 | 49 |
CDH20,GPM6A,CLU,CTNNA2,CPE,NEBL,HIF3A,PTPRZ1,SOX5,APOE,BMPR1B,NRG3,CTNND2,NRXN1,SLC1A3,TNIK,NTRK2,FGFR3,RORA,ABLIM1,PREX2 |
1.024e-07 | -16.09 | anatomical structure development | biological process | GO:0048856 | 5207 | 32 | 18204 | 49 |
COL5A3,LSAMP,CTNNA2,CLU,GPM6A,CPE,NEBL,NRG3,PTPRZ1,TNIK,CTNND2,ABLIM1,HIF3A,CAMK2G,CDH20,SLC1A2,FMN2,ZNRF3,BMPR1B,ATP1A2,SPARCL1,SOX5,MSI2,APOE,RANBP3L,NTRK2,NTM,NRXN1,SLC1A3,PREX2,FGFR3,RORA |
1.086e-07 | -16.04 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 19 | 16828 | 49 |
RYR3,CTNND2,GPM6A,DTNA,FGFR3,ATP13A4,NTRK2,SFXN5,NRG3,LSAMP,TNIK,CAMK2G,SLC1A3,NEBL,SOX5,ACSS1,TRPM3,GPC5,RANBP3L |
1.437e-07 | -15.76 | plasma membrane | cellular component | GO:0005886 | 5538 | 32 | 19108 | 49 |
LSAMP,FGFR3,RYR3,NKAIN3,NTM,PREX2,CDH20,CPE,ATP13A4,CTNND2,NRXN1,SLC1A3,CST3,ATP1A2,SLC4A4,NRG3,TNIK,SLC1A2,ZNRF3,GPC5,APOE,MACF1,SORBS1,FMN2,TRPM3,GPM6A,PTPRZ1,CTNNA2,HIF3A,BMPR1B,NTRK2,DTNA |
1.498e-07 | -15.71 | system development | biological process | GO:0048731 | 3533 | 26 | 18204 | 49 |
NEBL,CPE,GPM6A,CLU,CTNNA2,LSAMP,PTPRZ1,NRG3,CTNND2,TNIK,SLC1A2,CAMK2G,HIF3A,APOE,MSI2,SOX5,ATP1A2,BMPR1B,SLC1A3,NRXN1,NTM,NTRK2,RANBP3L,RORA,FGFR3,PREX2 |
2.457e-07 | -15.22 | developmental process | biological process | GO:0032502 | 5716 | 33 | 18204 | 49 |
NEBL,CPE,GPM6A,CLU,CTNNA2,LSAMP,NHSL1,COL5A3,PTPRZ1,NRG3,CTNND2,TNIK,ABLIM1,FMN2,ZNRF3,SLC1A2,CDH20,CAMK2G,HIF3A,APOE,MSI2,SPARCL1,SOX5,ATP1A2,BMPR1B,NRXN1,SLC1A3,NTM,NTRK2,RANBP3L,RORA,FGFR3,PREX2 |
2.559e-07 | -15.18 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 38 | 16828 | 49 |
LSAMP,CAMK2G,TNIK,CTNND2,FGFR3,DTNA,ATP1A2,ZBTB20,HIF3A,NRG3,MACF1,CST3,RANBP3L,TRPM3,PITPNC1,PREX2,NTM,NRXN1,SLC25A18,SOX5,NEBL,SORBS1,ACSS1,GPM6A,RYR3,SFXN5,ATP13A4,SLC4A4,PAMR1,RORA,ZNRF3,GPC5,ABLIM1,NHSL1,PTPRZ1,CDH20,SLC1A2,FMN2 |
3.322e-07 | -14.92 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 43 | 16828 | 49 |
NHSL1,ZNRF3,GPC5,CDH20,SLC1A2,SORBS1,NRXN1,COL5A3,NPAS3,SLC25A18,NKAIN3,SFXN5,ATP13A4,SPARCL1,GPM6A,RYR3,PITPNC1,PREX2,NTM,TRPM3,MSI2,CLU,LSAMP,TNIK,NTRK2,ZBTB20,CTNND2,APOE,ABLIM1,PTPRZ1,FMN2,SOX5,NEBL,SLC1A3,SLC4A4,RORA,CPE,MACF1,BMPR1B,HIF3A,NRG3,FGFR3,DTNA |
5.085e-07 | -14.49 | tibia | COSMIC cancer mutations | tibia | 836 | 13 | 16828 | 49 |
PREX2,TRPM3,ABLIM1,RANBP3L,MACF1,CPE,NKAIN3,FGFR3,CTNND2,GPM6A,ACSS1,TNIK,LSAMP |
6.096e-07 | -14.31 | nodular | COSMIC cancer mutations | nodular | 1515 | 17 | 16828 | 49 |
SLC4A4,HIF3A,NTRK2,ATP13A4,SPARCL1,CPE,CTNND2,ATP1A2,FGFR3,NEBL,NPAS3,PREX2,CDH20,FMN2,PTPRZ1,ABLIM1,MACF1 |
6.811e-07 | -14.20 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
SLC1A2,PREX2,TNIK,CAMK2G,BMPR1B,LSAMP,NPAS3,COL5A3,SOX5,ATP1A2,FGFR3,RYR3,NRG3,NKAIN3,NTRK2 |
6.811e-07 | -14.20 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 15 | 16828 | 49 |
NTRK2,NKAIN3,NRG3,RYR3,FGFR3,ATP1A2,SOX5,LSAMP,NPAS3,COL5A3,BMPR1B,TNIK,CAMK2G,PREX2,SLC1A2 |
9.146e-07 | -13.90 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 27 | 16828 | 49 |
PREX2,NTM,LSAMP,BMPR1B,TNIK,CTNND2,HIF3A,ZBTB20,NTRK2,NRG3,GPC5,PTPRZ1,FMN2,SLC1A2,NRXN1,COL5A3,SLC1A3,SOX5,NEBL,RYR3,GPM6A,SLC4A4,NKAIN3,ATP13A4,CPE,RORA,PAMR1 |
9.146e-07 | -13.90 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 27 | 16828 | 49 |
FMN2,SLC1A2,PTPRZ1,GPC5,RORA,PAMR1,CPE,ATP13A4,NKAIN3,SLC4A4,GPM6A,RYR3,NEBL,SOX5,SLC1A3,COL5A3,NRXN1,PREX2,NTM,NRG3,NTRK2,ZBTB20,HIF3A,CTNND2,TNIK,BMPR1B,LSAMP |
1.130e-06 | -13.69 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 24 | 16828 | 49 |
SOX5,NPAS3,SLC1A3,SFXN5,ATP13A4,NKAIN3,CPE,RORA,RYR3,GPM6A,PTPRZ1,ZNRF3,GPC5,CDH20,FMN2,SLC1A2,LSAMP,TNIK,ZBTB20,NRG3,CTNND2,FGFR3,RANBP3L,PREX2 |
1.275e-06 | -13.57 | neurogenesis | biological process | GO:0022008 | 1334 | 15 | 18204 | 49 |
SOX5,PTPRZ1,APOE,BMPR1B,CLU,GPM6A,CTNNA2,RORA,PREX2,NRXN1,SLC1A3,CTNND2,NTM,TNIK,NTRK2 |
1.354e-06 | -13.51 | generation of neurons | biological process | GO:0048699 | 1158 | 14 | 18204 | 49 |
GPM6A,CTNNA2,PTPRZ1,SOX5,APOE,BMPR1B,CTNND2,NTM,SLC1A3,NRXN1,NTRK2,TNIK,RORA,PREX2 |
1.606e-06 | -13.34 | cell morphogenesis | biological process | GO:0000902 | 687 | 11 | 18204 | 49 |
PTPRZ1,BMPR1B,PREX2,CDH20,CTNND2,CLU,SLC1A3,GPM6A,CTNNA2,NRXN1,TNIK |
1.623e-06 | -13.33 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 8 | 19454 | 50 |
CTNNA2,TNIK,NEBL,MACF1,ABLIM1,NHSL1,DTNA,SORBS1 |
2.071e-06 | -13.09 | neuron development | biological process | GO:0048666 | 859 | 12 | 18204 | 49 |
NTM,CTNND2,SLC1A3,NRXN1,NTRK2,TNIK,PREX2,GPM6A,CTNNA2,APOE,PTPRZ1,BMPR1B |
2.567e-06 | -12.87 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 10 | 16828 | 49 |
SOX5,LSAMP,GPC5,SFXN5,NKAIN3,NRG3,CTNND2,GPM6A,RYR3,FMN2 |
2.644e-06 | -12.84 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 21 | 16828 | 49 |
FMN2,CDH20,PREX2,GPC5,ZNRF3,PTPRZ1,RANBP3L,CTNND2,GPM6A,RYR3,RORA,NRG3,CPE,NKAIN3,SFXN5,ATP13A4,ZBTB20,SLC1A3,TNIK,LSAMP,SOX5 |
2.979e-06 | -12.72 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,SLC25A18 |
3.759e-06 | -12.49 | neuron differentiation | biological process | GO:0030182 | 1081 | 13 | 18204 | 49 |
APOE,PTPRZ1,BMPR1B,GPM6A,CTNNA2,RORA,PREX2,NTM,CTNND2,NRXN1,SLC1A3,TNIK,NTRK2 |
4.679e-06 | -12.27 | cell junction | cellular component | GO:0030054 | 2224 | 18 | 19108 | 49 |
SLC1A2,TNIK,NRG3,FGFR3,APOE,CLU,CDH20,SORBS1,SPARCL1,SLC1A3,NRXN1,CTNND2,PTPRZ1,GPM6A,ATP1A2,CTNNA2,NTRK2,DTNA |
4.871e-06 | -12.23 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 27 | 16828 | 49 |
CDH20,FMN2,SLC1A2,GPC5,RYR3,GPM6A,ATP13A4,NKAIN3,SPARCL1,CPE,RORA,SLC1A3,SOX5,NEBL,ACSS1,PREX2,MACF1,RANBP3L,CTNND2,ATP1A2,DTNA,FGFR3,NTRK2,NRG3,LSAMP,CLU,TNIK |
6.248e-06 | -11.98 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC25A18 |
6.364e-06 | -11.96 | acidic amino acid transport | biological process | GO:0015800 | 45 | 4 | 18204 | 49 |
SLC25A18,NTRK2,SLC1A3,SLC1A2 |
7.063e-06 | -11.86 | multicellular organismal process | biological process | GO:0032501 | 6177 | 32 | 18204 | 49 |
CAMK2G,HIF3A,ZNRF3,CDH20,SLC1A2,BMPR1B,ATP1A2,MSI2,APOE,SOX5,NTRK2,RANBP3L,NTM,SLC1A3,NRXN1,RYR3,PREX2,RORA,FGFR3,LSAMP,CPE,NEBL,GPM6A,CLU,CTNNA2,NRG3,PTPRZ1,TNIK,SLC4A4,CTNND2,DTNA,ABLIM1 |
7.388e-06 | -11.82 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 21 | 16828 | 49 |
NRG3,SLC4A4,NTRK2,ATP13A4,SFXN5,ATP1A2,DTNA,FGFR3,RYR3,CTNND2,SORBS1,CLU,NPAS3,PREX2,PITPNC1,SLC1A2,FMN2,PTPRZ1,NHSL1,GPC5,MACF1 |
8.073e-06 | -11.73 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 9 | 16828 | 49 |
GPC5,LSAMP,TRPM3,RYR3,GPM6A,CTNND2,NRG3,ATP13A4,SFXN5 |
9.320e-06 | -11.58 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 14 | 16828 | 49 |
ATP13A4,NTRK2,NRG3,PAMR1,RYR3,CTNND2,GPM6A,FGFR3,NEBL,TNIK,NTM,FMN2,ABLIM1,MACF1 |
9.320e-06 | -11.58 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 14 | 16828 | 49 |
NTRK2,ATP13A4,NRG3,PAMR1,RYR3,CTNND2,GPM6A,FGFR3,NEBL,TNIK,NTM,FMN2,ABLIM1,MACF1 |
9.417e-06 | -11.57 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 11 | 16828 | 49 |
COL5A3,LSAMP,GPC5,SOX5,RYR3,ATP1A2,SLC1A2,NTRK2,NKAIN3,PREX2,NRG3 |
1.002e-05 | -11.51 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 11 | 16828 | 49 |
ABLIM1,PTPRZ1,GPC5,NTRK2,CPE,NRG3,CTNND2,RYR3,NEBL,NRXN1,NPAS3 |
1.097e-05 | -11.42 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 24 | 16828 | 49 |
NPAS3,SLC1A3,SLC4A4,PAMR1,CPE,RYR3,PTPRZ1,GPC5,ZNRF3,FMN2,MSI2,CLU,LSAMP,TNIK,BMPR1B,NTRK2,NRG3,CTNND2,DTNA,RANBP3L,MACF1,PREX2,PITPNC1,TRPM3 |
1.097e-05 | -11.42 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 24 | 16828 | 49 |
PTPRZ1,ZNRF3,GPC5,FMN2,SLC1A3,NPAS3,CPE,PAMR1,SLC4A4,RYR3,RANBP3L,MACF1,PITPNC1,PREX2,TRPM3,MSI2,TNIK,BMPR1B,CLU,LSAMP,NRG3,NTRK2,DTNA,CTNND2 |
1.198e-05 | -11.33 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 14 | 16828 | 49 |
CDH20,PREX2,MACF1,PTPRZ1,ABLIM1,CTNND2,ATP1A2,HIF3A,ATP13A4,NTRK2,SPARCL1,CPE,NPAS3,NEBL |
1.272e-05 | -11.27 | synapse | cellular component | GO:0045202 | 1473 | 14 | 19108 | 49 |
DTNA,NTRK2,ATP1A2,PTPRZ1,GPM6A,SLC1A3,NRXN1,CTNND2,SPARCL1,APOE,CLU,SLC1A2,TNIK,NRG3 |
1.310e-05 | -11.24 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 36 | 16828 | 49 |
FGFR3,CTNND2,NRG3,ZBTB20,NTRK2,TNIK,LSAMP,TRPM3,PITPNC1,PREX2,NTM,MACF1,RANBP3L,RYR3,GPM6A,CPE,PAMR1,RORA,SLC4A4,SFXN5,NKAIN3,ATP13A4,SLC1A3,NPAS3,COL5A3,NRXN1,ACSS1,SORBS1,NEBL,SOX5,FMN2,SLC1A2,GPC5,PTPRZ1,ABLIM1,NHSL1 |
1.332e-05 | -11.23 | scalp | COSMIC cancer mutations | scalp | 2110 | 18 | 16828 | 49 |
PTPRZ1,MACF1,GPC5,PREX2,NTM,FMN2,SOX5,NEBL,SORBS1,COL5A3,LSAMP,NRXN1,CAMK2G,ATP13A4,SLC4A4,RORA,FGFR3,ATP1A2 |
1.390e-05 | -11.18 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC25A18 |
1.413e-05 | -11.17 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 18 | 16828 | 49 |
SOX5,BMPR1B,SLC1A3,NPAS3,LSAMP,CPE,NRG3,NTRK2,NKAIN3,ATP13A4,RYR3,CTNND2,GPM6A,NHSL1,GPC5,PREX2,SLC1A2,FMN2 |
1.413e-05 | -11.17 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 18 | 16828 | 49 |
ATP13A4,NTRK2,NKAIN3,CPE,NRG3,RYR3,CTNND2,GPM6A,SOX5,LSAMP,NPAS3,BMPR1B,SLC1A3,PREX2,FMN2,SLC1A2,NHSL1,GPC5 |
1.509e-05 | -11.10 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 10 | 16828 | 49 |
NPAS3,NRXN1,NEBL,ABLIM1,PTPRZ1,CTNND2,RYR3,NTRK2,NRG3,CPE |
1.529e-05 | -11.09 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 10 | 16828 | 49 |
PTPRZ1,NEBL,ABLIM1,NPAS3,NRXN1,NTRK2,CPE,NRG3,RYR3,CTNND2 |
1.702e-05 | -10.98 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 15 | 16828 | 49 |
NKAIN3,NTRK2,RORA,NRG3,CTNND2,RYR3,SOX5,NEBL,ACSS1,LSAMP,COL5A3,SLC1A3,PREX2,FMN2,GPC5 |
1.702e-05 | -10.98 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 15 | 16828 | 49 |
FMN2,PREX2,GPC5,CTNND2,RYR3,RORA,NRG3,NKAIN3,NTRK2,SLC1A3,LSAMP,COL5A3,ACSS1,NEBL,SOX5 |
1.766e-05 | -10.94 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 3 | 19454 | 50 |
CST3,NRXN1,CTNND2 |
1.782e-05 | -10.94 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 24 | 16828 | 49 |
ACSS1,SOX5,NEBL,CPE,SPARCL1,RORA,ATP13A4,NKAIN3,RYR3,GPM6A,GPC5,SLC1A2,FMN2,CDH20,TNIK,LSAMP,CLU,NRG3,ATP1A2,FGFR3,CTNND2,RANBP3L,MACF1,PREX2 |
2.023e-05 | -10.81 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 3 | 18204 | 49 |
SLC25A18,SLC1A2,SLC1A3 |
2.257e-05 | -10.70 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 10 | 18094 | 48 |
SLC4A4,RYR3,ATP1A2,SLC1A2,SLC1A3,SFXN5,GPM6A,ATP13A4,SLC25A18,TRPM3 |
2.544e-05 | -10.58 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 18 | 16828 | 49 |
COL5A3,LSAMP,SLC1A3,NEBL,SOX5,GPM6A,CTNND2,RYR3,FGFR3,NKAIN3,NTRK2,NRG3,GPC5,PTPRZ1,CDH20,FMN2,SLC1A2,PREX2 |
2.586e-05 | -10.56 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 37 | 16828 | 49 |
RANBP3L,MACF1,PREX2,TRPM3,TNIK,CAMK2G,BMPR1B,CLU,LSAMP,NRG3,NTRK2,FGFR3,ATP1A2,CTNND2,APOE,NHSL1,ABLIM1,PTPRZ1,GPC5,SLC1A2,FMN2,CDH20,ACSS1,SOX5,NEBL,SLC1A3,SLC25A18,COL5A3,PAMR1,RORA,CPE,SFXN5,NKAIN3,ATP13A4,SLC4A4,GPM6A,RYR3 |
2.743e-05 | -10.50 | amino acid transport | biological process | GO:0006865 | 132 | 5 | 18204 | 49 |
SLC1A3,SLC1A2,SFXN5,SLC25A18,NTRK2 |
2.908e-05 | -10.45 | bone | COSMIC cancer mutations | bone | 8157 | 38 | 16828 | 49 |
NKAIN3,SFXN5,ATP13A4,SLC4A4,PAMR1,RORA,CPE,SPARCL1,GPM6A,RYR3,NEBL,SOX5,SORBS1,ACSS1,NPAS3,NRXN1,COL5A3,SLC1A3,FMN2,ABLIM1,PTPRZ1,GPC5,NTRK2,HIF3A,ZBTB20,NRG3,CTNND2,DTNA,FGFR3,ATP1A2,LSAMP,TNIK,CAMK2G,PREX2,TRPM3,RANBP3L,MACF1,CST3 |
2.973e-05 | -10.42 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 47 | 16828 | 49 |
PTPRZ1,ABLIM1,FMN2,SLC1A3,ACSS1,SOX5,NEBL,CPE,RORA,SLC4A4,MACF1,CAMK2G,BMPR1B,ATP1A2,FGFR3,DTNA,NRG3,HIF3A,GPC5,ZNRF3,NHSL1,SLC1A2,CDH20,SLC25A18,NRXN1,COL5A3,NPAS3,SORBS1,RYR3,GPM6A,SPARCL1,PAMR1,ATP13A4,NKAIN3,SFXN5,RANBP3L,TRPM3,NTM,PREX2,PITPNC1,TNIK,CLU,LSAMP,MSI2,CTNND2,ZBTB20,NTRK2 |
3.532e-05 | -10.25 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 9 | 18094 | 48 |
ATP1A2,SLC1A2,SLC1A3,SLC4A4,RYR3,SLC25A18,ATP13A4,TRPM3,GPM6A |
4.043e-05 | -10.12 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 3 | 18204 | 49 |
SLC25A18,SLC1A3,SLC1A2 |
4.148e-05 | -10.09 | cell development | biological process | GO:0048468 | 2236 | 17 | 18204 | 49 |
RORA,PREX2,CTNND2,NTM,NRXN1,SLC1A3,NTRK2,TNIK,MSI2,APOE,PTPRZ1,BMPR1B,FMN2,NEBL,GPM6A,CTNNA2,CLU |
4.197e-05 | -10.08 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 8 | 18204 | 49 |
PREX2,BMPR1B,PTPRZ1,TNIK,NRXN1,CTNNA2,GPM6A,CTNND2 |
4.512e-05 | -10.01 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 8 | 18204 | 49 |
CTNNA2,GPM6A,NRXN1,CTNND2,TNIK,PTPRZ1,PREX2,BMPR1B |
4.562e-05 | -10.00 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,SLC25A18 |
4.581e-05 | -9.99 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 10 | 18204 | 49 |
SLC25A18,ATP1A2,RYR3,ATP13A4,TRPM3,SFXN5,SLC4A4,SLC1A3,GPM6A,SLC1A2 |
4.847e-05 | -9.93 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 8 | 18204 | 49 |
PREX2,BMPR1B,TNIK,GPM6A,NRXN1,CTNNA2,CTNND2,PTPRZ1 |
5.256e-05 | -9.85 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 31 |
SLC1A3,SLC1A2 |
5.256e-05 | -9.85 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 31 |
SLC1A3,SLC1A2 |
5.590e-05 | -9.79 | transporter activity | molecular function | GO:0005215 | 1211 | 12 | 18094 | 48 |
TRPM3,ATP13A4,SLC25A18,GPM6A,SFXN5,APOE,SLC1A3,SLC1A2,ATP1A2,RYR3,PITPNC1,SLC4A4 |
5.708e-05 | -9.77 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 4 | 18204 | 49 |
SLC1A2,SLC1A3,SLC25A18,NTRK2 |
6.099e-05 | -9.70 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 3 | 18094 | 48 |
SLC25A18,SLC1A3,SLC1A2 |
6.375e-05 | -9.66 | negative regulation of amyloid-beta formation | biological process | GO:1902430 | 29 | 3 | 18204 | 49 |
APOE,CLU,NTRK2 |
6.535e-05 | -9.64 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 20 | 16828 | 49 |
CTNND2,GPM6A,RYR3,NTRK2,SFXN5,ATP13A4,NKAIN3,HIF3A,NRG3,CPE,LSAMP,SLC1A3,NEBL,SOX5,TRPM3,FMN2,SLC1A2,PREX2,GPC5,ZNRF3 |
6.856e-05 | -9.59 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
6.856e-05 | -9.59 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
7.004e-05 | -9.57 | cell differentiation | biological process | GO:0030154 | 3645 | 22 | 18204 | 49 |
RORA,FGFR3,PREX2,NRXN1,SLC1A3,CTNND2,NTM,NTRK2,TNIK,RANBP3L,APOE,MSI2,PTPRZ1,SOX5,BMPR1B,NEBL,FMN2,CTNNA2,GPM6A,CLU,CAMK2G,NHSL1 |
7.061e-05 | -9.56 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
7.061e-05 | -9.56 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 2 | 18204 | 49 |
APOE,CLU |
7.061e-05 | -9.56 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
7.070e-05 | -9.56 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 49 |
ATP1A2,SLC1A3,SLC1A2 |
7.070e-05 | -9.56 | L-glutamate import | biological process | GO:0051938 | 30 | 3 | 18204 | 49 |
SLC25A18,SLC1A2,SLC1A3 |
7.095e-05 | -9.55 | cellular developmental process | biological process | GO:0048869 | 3648 | 22 | 18204 | 49 |
GPM6A,CTNNA2,CLU,FMN2,NEBL,NHSL1,CAMK2G,PTPRZ1,SOX5,MSI2,APOE,BMPR1B,NTM,CTNND2,NRXN1,SLC1A3,RANBP3L,NTRK2,TNIK,FGFR3,RORA,PREX2 |
7.654e-05 | -9.48 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 16 | 16828 | 49 |
FGFR3,GPM6A,RYR3,RORA,SLC4A4,ZBTB20,BMPR1B,TNIK,NPAS3,COL5A3,NRXN1,SOX5,NEBL,FMN2,ZNRF3,MACF1 |
7.700e-05 | -9.47 | cell body | cellular component | GO:0044297 | 556 | 8 | 19108 | 49 |
BMPR1B,ATP1A2,APOE,GPM6A,SLC1A3,SLC1A2,NRXN1,CTNND2 |
7.750e-05 | -9.47 | larynx | COSMIC cancer mutations | larynx | 1948 | 16 | 16828 | 49 |
FGFR3,GPM6A,RYR3,RORA,ZBTB20,SLC4A4,TNIK,BMPR1B,NPAS3,COL5A3,NRXN1,NEBL,SOX5,FMN2,ZNRF3,MACF1 |
7.813e-05 | -9.46 | negative regulation of amyloid precursor protein catabolic process | biological process | GO:1902992 | 31 | 3 | 18204 | 49 |
CLU,APOE,NTRK2 |
7.923e-05 | -9.44 | cell junction organization | biological process | GO:0034330 | 532 | 8 | 18204 | 49 |
NRG3,SPARCL1,SORBS1,APOE,CDH20,CTNND2,GPM6A,NRXN1 |
8.067e-05 | -9.43 | organic substance transport | biological process | GO:0071702 | 1881 | 15 | 18204 | 49 |
PITPNC1,ATP13A4,SFXN5,NTRK2,RANBP3L,SLC4A4,SLC1A3,SLC25A18,APOE,CAMK2G,CPE,FMN2,MACF1,SLC1A2,CLU |
8.215e-05 | -9.41 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 6 | 18094 | 48 |
SLC25A18,SLC1A2,SLC1A3,ATP13A4,ATP1A2,SLC4A4 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
GPM6A,NTM,LSAMP |
8.356e-05 | -9.39 | neuron projection development | biological process | GO:0031175 | 693 | 9 | 18204 | 49 |
PREX2,BMPR1B,APOE,PTPRZ1,TNIK,GPM6A,CTNNA2,NRXN1,CTNND2 |
8.364e-05 | -9.39 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 49 |
ATP1A2,SLC4A4,SLC1A2,SLC1A3 |
8.364e-05 | -9.39 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 49 |
SLC1A3,SLC1A2,SLC4A4,ATP1A2 |
8.422e-05 | -9.38 | leg | COSMIC cancer mutations | leg | 969 | 11 | 16828 | 49 |
COL5A3,NEBL,FGFR3,NRG3,ATP13A4,HIF3A,SLC4A4,ZBTB20,PTPRZ1,FMN2,NTM |
8.772e-05 | -9.34 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 17 | 16828 | 49 |
NRG3,NKAIN3,NTRK2,RYR3,GPM6A,CTNND2,NEBL,SOX5,SLC1A3,LSAMP,COL5A3,PREX2,SLC1A2,FMN2,CDH20,PTPRZ1,GPC5 |
8.772e-05 | -9.34 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 17 | 16828 | 49 |
GPC5,PTPRZ1,CDH20,FMN2,SLC1A2,PREX2,COL5A3,LSAMP,SLC1A3,SOX5,NEBL,CTNND2,GPM6A,RYR3,NTRK2,NKAIN3,NRG3 |
8.815e-05 | -9.34 | organic anion transport | biological process | GO:0015711 | 398 | 7 | 18204 | 49 |
SLC4A4,SLC1A2,SLC1A3,NTRK2,APOE,SFXN5,SLC25A18 |
9.447e-05 | -9.27 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 49 |
ATP1A2,SLC1A3,NRXN1 |
1.023e-04 | -9.19 | neuron projection | cellular component | GO:0043005 | 1331 | 12 | 19108 | 49 |
SLC1A2,CAMK2G,APOE,CLU,GPM6A,SLC1A3,CTNND2,NTRK2,DTNA,ATP1A2,CTNNA2,BMPR1B |
1.034e-04 | -9.18 | negative regulation of amide metabolic process | biological process | GO:0034249 | 34 | 3 | 18204 | 49 |
NTRK2,CLU,APOE |
1.057e-04 | -9.15 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.057e-04 | -9.15 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.191e-04 | -9.04 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 9 | 10285 | 31 |
RYR3,ATP1A2,TRPM3,SLC1A2,SLC4A4,ATP13A4,SLC1A3,CAMK2G,SLC25A18 |
1.275e-04 | -8.97 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 30 | 16828 | 49 |
PREX2,TRPM3,MACF1,NRG3,NTRK2,FGFR3,APOE,CTNND2,CAMK2G,CLU,LSAMP,SLC1A2,FMN2,CDH20,PTPRZ1,NHSL1,ZNRF3,GPC5,SPARCL1,PAMR1,RORA,NKAIN3,RYR3,GPM6A,SORBS1,SOX5,NEBL,SLC1A3,COL5A3,NPAS3 |
1.390e-04 | -8.88 | carboxylic acid transport | biological process | GO:0046942 | 297 | 6 | 18204 | 49 |
SFXN5,SLC1A3,SLC1A2,APOE,SLC25A18,NTRK2 |
1.416e-04 | -8.86 | organic acid transport | biological process | GO:0015849 | 298 | 6 | 18204 | 49 |
NTRK2,SLC1A2,SLC1A3,SLC25A18,APOE,SFXN5 |
1.437e-04 | -8.85 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 8 | 18094 | 48 |
SLC1A3,SLC1A2,ATP1A2,RYR3,SLC4A4,TRPM3,SLC25A18,GPM6A |
1.469e-04 | -8.83 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 4 | 19454 | 50 |
CLU,ABLIM1,SPARCL1,SORBS1 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.534e-04 | -8.78 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 7 | 18094 | 48 |
ATP1A2,SLC1A2,SLC1A3,SLC4A4,RYR3,GPM6A,TRPM3 |
1.546e-04 | -8.77 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 49 |
SLC1A3,SLC1A2 |
1.565e-04 | -8.76 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,RYR3 |
1.583e-04 | -8.75 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 13 | 16828 | 49 |
NHSL1,FMN2,SLC1A2,PITPNC1,PREX2,CLU,ATP1A2,FGFR3,CTNND2,SLC4A4,SFXN5,ATP13A4,NTRK2 |
1.583e-04 | -8.75 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 13 | 16828 | 49 |
NHSL1,SLC1A2,FMN2,PREX2,PITPNC1,CLU,CTNND2,FGFR3,ATP1A2,SFXN5,ATP13A4,NTRK2,SLC4A4 |
1.628e-04 | -8.72 | humerus | COSMIC cancer mutations | humerus | 546 | 8 | 16828 | 49 |
SOX5,NEBL,GPC5,NKAIN3,SFXN5,HIF3A,GPM6A,FMN2 |
1.712e-04 | -8.67 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 7 | 18204 | 49 |
CTNND2,SLC1A3,CTNNA2,NRXN1,PTPRZ1,BMPR1B,PREX2 |
1.810e-04 | -8.62 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 41 | 16828 | 49 |
SORBS1,NEBL,SOX5,SLC25A18,NRXN1,NPAS3,COL5A3,CPE,SPARCL1,PAMR1,RORA,SLC4A4,ATP13A4,NKAIN3,RYR3,GPM6A,PTPRZ1,ABLIM1,ZNRF3,GPC5,FMN2,CDH20,MSI2,CAMK2G,BMPR1B,TNIK,CLU,NRG3,HIF3A,NTRK2,ATP1A2,DTNA,FGFR3,CTNND2,RANBP3L,CST3,MACF1,PREX2,NTM,PITPNC1,TRPM3 |
1.838e-04 | -8.60 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 41 | 16828 | 49 |
RANBP3L,CST3,MACF1,NTM,PITPNC1,PREX2,TRPM3,MSI2,TNIK,BMPR1B,CAMK2G,CLU,NRG3,HIF3A,NTRK2,ATP1A2,DTNA,FGFR3,CTNND2,PTPRZ1,ABLIM1,ZNRF3,GPC5,FMN2,CDH20,SORBS1,SOX5,NEBL,SLC25A18,NPAS3,NRXN1,COL5A3,CPE,SPARCL1,PAMR1,RORA,SLC4A4,NKAIN3,ATP13A4,RYR3,GPM6A |
1.841e-04 | -8.60 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 48 |
CTNND2,CTNNA2,RORA,CDH20 |
1.874e-04 | -8.58 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 49 |
NKAIN3,CTNND2,LSAMP,GPM6A |
1.879e-04 | -8.58 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 44 |
SLC1A3,SLC1A2 |
1.967e-04 | -8.53 | protein import | biological process | GO:0017038 | 8 | 2 | 18204 | 49 |
CLU,APOE |
2.035e-04 | -8.50 | cell projection | cellular component | GO:0042995 | 2398 | 16 | 19108 | 49 |
SLC1A2,APOE,CLU,CAMK2G,MACF1,SLC1A3,ABLIM1,CTNND2,NRXN1,FMN2,GPM6A,CTNNA2,ATP1A2,BMPR1B,NTRK2,DTNA |
2.060e-04 | -8.49 | monoatomic ion transport | biological process | GO:0006811 | 964 | 10 | 18204 | 49 |
SFXN5,TRPM3,RYR3,ATP13A4,SLC25A18,ATP1A2,SLC1A3,GPM6A,SLC1A2,SLC4A4 |
2.071e-04 | -8.48 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 42 | 16828 | 49 |
PITPNC1,PREX2,NTM,TRPM3,RANBP3L,MACF1,HIF3A,ZBTB20,NTRK2,NRG3,APOE,CTNND2,ATP1A2,DTNA,FGFR3,LSAMP,TNIK,BMPR1B,CDH20,SLC1A2,FMN2,PTPRZ1,ABLIM1,GPC5,ZNRF3,SLC4A4,ATP13A4,SFXN5,NKAIN3,CPE,RORA,PAMR1,RYR3,GPM6A,SORBS1,SOX5,NEBL,NPAS3,COL5A3,NRXN1,SLC25A18,SLC1A3 |
2.071e-04 | -8.48 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 42 | 16828 | 49 |
PTPRZ1,ABLIM1,GPC5,ZNRF3,CDH20,SLC1A2,FMN2,SORBS1,SOX5,NEBL,COL5A3,NPAS3,NRXN1,SLC25A18,SLC1A3,SLC4A4,ATP13A4,NKAIN3,SFXN5,CPE,PAMR1,RORA,RYR3,GPM6A,RANBP3L,MACF1,PITPNC1,NTM,PREX2,TRPM3,LSAMP,BMPR1B,TNIK,ZBTB20,HIF3A,NTRK2,NRG3,APOE,CTNND2,ATP1A2,FGFR3,DTNA |
2.247e-04 | -8.40 | behavior | biological process | GO:0007610 | 619 | 8 | 18204 | 49 |
PTPRZ1,APOE,ATP1A2,PREX2,NRXN1,SLC1A2,SLC1A3,NTRK2 |
2.282e-04 | -8.39 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 6 | 16828 | 49 |
SFXN5,NKAIN3,FMN2,GPM6A,SOX5,GPC5 |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.333e-04 | -8.36 | neuronal cell body | cellular component | GO:0043025 | 489 | 7 | 19108 | 49 |
BMPR1B,APOE,ATP1A2,GPM6A,SLC1A3,NRXN1,CTNND2 |
2.383e-04 | -8.34 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 29 | 16828 | 49 |
PTPRZ1,ZNRF3,GPC5,CDH20,FMN2,SOX5,NEBL,SORBS1,COL5A3,NPAS3,SLC1A3,SLC25A18,NKAIN3,ATP13A4,SLC4A4,PAMR1,GPM6A,RYR3,MACF1,CST3,NTM,TRPM3,LSAMP,CLU,NTRK2,NRG3,CTNND2,DTNA,ATP1A2 |
2.383e-04 | -8.34 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 29 | 16828 | 49 |
SLC1A3,SLC25A18,COL5A3,NPAS3,NEBL,SOX5,SORBS1,GPM6A,RYR3,PAMR1,NKAIN3,ATP13A4,SLC4A4,GPC5,ZNRF3,PTPRZ1,FMN2,CDH20,CLU,LSAMP,DTNA,ATP1A2,CTNND2,NRG3,NTRK2,CST3,MACF1,TRPM3,NTM |
2.480e-04 | -8.30 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 19 | 16828 | 49 |
NPAS3,COL5A3,BMPR1B,NEBL,SOX5,ACSS1,RYR3,APOE,GPM6A,CTNND2,FGFR3,HIF3A,ZBTB20,NTRK2,MACF1,GPC5,PTPRZ1,CDH20,TRPM3 |
2.521e-04 | -8.29 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 9 | 19108 | 49 |
GPM6A,SLC1A3,NRXN1,CTNND2,NTRK2,BMPR1B,APOE,ATP1A2,CLU |
2.582e-04 | -8.26 | synapse organization | biological process | GO:0050808 | 333 | 6 | 18204 | 49 |
NRG3,GPM6A,NRXN1,SPARCL1,CTNND2,APOE |
2.594e-04 | -8.26 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 4 | 18094 | 48 |
SLC4A4,SLC25A18,SLC1A2,SLC1A3 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 44 |
SLC1A3,SLC1A2 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 44 |
SLC1A3,SLC1A2 |
2.660e-04 | -8.23 | central nervous system development | biological process | GO:0007417 | 995 | 10 | 18204 | 49 |
BMPR1B,ATP1A2,NRG3,PTPRZ1,MSI2,RORA,NTRK2,CTNNA2,SLC1A2,CLU |
2.700e-04 | -8.22 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 8 | 18204 | 49 |
TRPM3,SLC25A18,ATP1A2,ATP13A4,RYR3,SLC1A3,GPM6A,SLC4A4 |
2.806e-04 | -8.18 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 4 | 10285 | 31 |
SLC4A4,SLC1A3,SLC25A18,SLC1A2 |
2.904e-04 | -8.14 | membrane | cellular component | GO:0016020 | 9220 | 36 | 19108 | 49 |
ATP1A2,NRXN1,CTNND2,SLC1A3,CST3,CLU,SLC25A18,CDH20,PREX2,NTM,CPE,CAMK2G,ATP13A4,LSAMP,RYR3,FGFR3,NKAIN3,BMPR1B,CTNNA2,HIF3A,NTRK2,DTNA,FMN2,GPM6A,TRPM3,PTPRZ1,APOE,MACF1,SORBS1,NRG3,SLC4A4,SLC1A2,TNIK,SFXN5,GPC5,ZNRF3 |
2.911e-04 | -8.14 | regulation of amyloid-beta formation | biological process | GO:1902003 | 48 | 3 | 18204 | 49 |
NTRK2,APOE,CLU |
3.017e-04 | -8.11 | cell-cell signaling | biological process | GO:0007267 | 822 | 9 | 18204 | 49 |
DTNA,SLC1A2,SLC1A3,NRXN1,CPE,NTRK2,CAMK2G,FGFR3,APOE |
3.095e-04 | -8.08 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 24 | 16828 | 49 |
FMN2,CDH20,NHSL1,PTPRZ1,ATP13A4,SLC4A4,GPM6A,RYR3,ACSS1,SOX5,SORBS1,COL5A3,NTM,PREX2,TRPM3,RANBP3L,MACF1,NRG3,NTRK2,HIF3A,ZBTB20,FGFR3,CTNND2,TNIK |
3.150e-04 | -8.06 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.150e-04 | -8.06 | action potential propagation | biological process | GO:0098870 | 10 | 2 | 18204 | 49 |
NTRK2,ATP1A2 |
3.150e-04 | -8.06 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 2 | 18204 | 49 |
ATP1A2,NTRK2 |
3.190e-04 | -8.05 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 21 |
SLC1A3,SLC1A2 |
3.234e-04 | -8.04 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 31 | 16828 | 49 |
CLU,NRG3,HIF3A,ZBTB20,FGFR3,CTNND2,APOE,MACF1,NTM,PITPNC1,PREX2,TRPM3,ACSS1,SOX5,SORBS1,SLC1A3,SLC25A18,NPAS3,COL5A3,PAMR1,RORA,SFXN5,SLC4A4,GPM6A,RYR3,NHSL1,ABLIM1,GPC5,FMN2,SLC1A2,CDH20 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
SOX5,PREX2,SLC1A2,RYR3 |
3.648e-04 | -7.92 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 5 | 10285 | 31 |
ATP1A2,ATP13A4,RYR3,TRPM3,CAMK2G |
3.844e-04 | -7.86 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.918e-04 | -7.84 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 31 | 16828 | 49 |
PTPRZ1,ABLIM1,GPC5,FMN2,SORBS1,NEBL,SOX5,NRXN1,NPAS3,COL5A3,SLC25A18,SLC4A4,ATP13A4,SFXN5,SPARCL1,CPE,RYR3,GPM6A,RANBP3L,MACF1,PITPNC1,PREX2,TRPM3,TNIK,BMPR1B,ZBTB20,HIF3A,NRG3,CTNND2,ATP1A2,FGFR3 |
4.023e-04 | -7.82 | CSTL1 (cystatin like 1) | protein interactions | 128817 | 56 | 3 | 19454 | 50 |
CPE,APOE,CLU |
4.044e-04 | -7.81 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 15 | 16828 | 49 |
SORBS1,NEBL,BMPR1B,COL5A3,NRG3,CPE,SPARCL1,RORA,ATP13A4,ATP1A2,FGFR3,CTNND2,ABLIM1,PREX2,FMN2 |
4.044e-04 | -7.81 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 15 | 16828 | 49 |
ABLIM1,FMN2,PREX2,COL5A3,BMPR1B,SORBS1,NEBL,CTNND2,ATP1A2,FGFR3,ATP13A4,CPE,SPARCL1,NRG3,RORA |
4.129e-04 | -7.79 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 15 | 19108 | 49 |
SLC1A2,CLU,APOE,MACF1,CAMK2G,CTNND2,FMN2,ABLIM1,SLC1A3,GPM6A,ATP1A2,CTNNA2,BMPR1B,DTNA,NTRK2 |
4.203e-04 | -7.77 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 2 | 19454 | 50 |
APOE,CLU |
4.218e-04 | -7.77 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 18 | 16828 | 49 |
PREX2,FMN2,SLC1A2,ZNRF3,GPC5,NTRK2,SFXN5,NKAIN3,HIF3A,NRG3,CPE,CTNND2,GPM6A,RYR3,SOX5,NEBL,LSAMP,SLC1A3 |
4.357e-04 | -7.74 | regulation of amyloid precursor protein catabolic process | biological process | GO:1902991 | 55 | 3 | 18204 | 49 |
CLU,APOE,NTRK2 |
4.404e-04 | -7.73 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 50 |
FGFR3,NTM,NTRK2,LSAMP |
4.465e-04 | -7.71 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 21 | 16828 | 49 |
COL5A3,TNIK,SOX5,NEBL,RYR3,CTNND2,GPM6A,ATP1A2,SLC4A4,ZBTB20,NRG3,SPARCL1,PAMR1,MACF1,GPC5,PTPRZ1,NHSL1,ABLIM1,FMN2,TRPM3,PREX2 |
4.501e-04 | -7.71 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 21 | 16828 | 49 |
GPC5,MACF1,PTPRZ1,ABLIM1,NHSL1,FMN2,TRPM3,PREX2,TNIK,COL5A3,SOX5,NEBL,ATP1A2,RYR3,GPM6A,CTNND2,NRG3,SPARCL1,PAMR1,ZBTB20,SLC4A4 |
4.605e-04 | -7.68 | auditory behavior | biological process | GO:0031223 | 12 | 2 | 18204 | 49 |
NRXN1,SLC1A3 |
4.673e-04 | -7.67 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 15 | 16828 | 49 |
MSI2,NEBL,LSAMP,NRG3,RORA,GPM6A,FGFR3,PTPRZ1,ABLIM1,MACF1,GPC5,ZNRF3,PREX2,FMN2,TRPM3 |
4.733e-04 | -7.66 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 49 |
NTRK2,LSAMP,FGFR3,NTM |
4.895e-04 | -7.62 | trunk | COSMIC cancer mutations | trunk | 3554 | 21 | 16828 | 49 |
HIF3A,NTRK2,ATP13A4,CPE,NRG3,SPARCL1,RYR3,CTNND2,ATP1A2,FGFR3,SOX5,NEBL,NPAS3,NRXN1,LSAMP,SLC1A3,PREX2,CDH20,PTPRZ1,ABLIM1,MACF1 |
5.080e-04 | -7.58 | regulation of synapse organization | biological process | GO:0050807 | 246 | 5 | 18204 | 49 |
NTRK2,APOE,NRXN1,GPM6A,CTNNA2 |
5.090e-04 | -7.58 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 4 | 19454 | 50 |
CAMK2G,ZBTB20,ABLIM1,MACF1 |
5.095e-04 | -7.58 | nitrogen compound transport | biological process | GO:0071705 | 1507 | 12 | 18204 | 49 |
SLC1A3,NTRK2,RANBP3L,ATP13A4,CPE,FMN2,MACF1,CLU,SLC1A2,CAMK2G,APOE,SLC25A18 |
5.182e-04 | -7.57 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 33 | 16828 | 49 |
NTRK2,NRG3,APOE,CTNND2,ATP1A2,FGFR3,CLU,LSAMP,BMPR1B,PREX2,RANBP3L,MACF1,SLC4A4,ATP13A4,NKAIN3,SFXN5,CPE,PAMR1,RORA,RYR3,GPM6A,SOX5,NEBL,ACSS1,COL5A3,SLC25A18,SLC1A3,CDH20,SLC1A2,FMN2,ABLIM1,NHSL1,GPC5 |
5.266e-04 | -7.55 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 8 | 18094 | 48 |
SLC4A4,RYR3,ATP1A2,SLC25A18,SLC1A2,TRPM3,SLC1A3,GPM6A |
5.428e-04 | -7.52 | neurotransmitter transport | biological process | GO:0006836 | 140 | 4 | 18204 | 49 |
NRXN1,SLC1A2,SLC1A3,ATP1A2 |
5.432e-04 | -7.52 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 2 | 18204 | 49 |
APOE,CLU |
5.442e-04 | -7.52 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 21 |
ATP1A2,ATP13A4 |
5.584e-04 | -7.49 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 10 | 18094 | 48 |
GPM6A,TRPM3,SLC25A18,ATP13A4,SFXN5,SLC1A3,SLC1A2,ATP1A2,RYR3,SLC4A4 |
5.668e-04 | -7.48 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 5 | 18204 | 49 |
NTRK2,APOE,NRXN1,CTNNA2,GPM6A |
5.726e-04 | -7.47 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 4 | 18204 | 49 |
ZBTB20,APOE,SLC4A4,SORBS1 |
5.776e-04 | -7.46 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 2 | 19454 | 50 |
CLU,GPM6A |
5.776e-04 | -7.46 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 2 | 19454 | 50 |
CAMK2G,ZBTB20 |
5.776e-04 | -7.46 | C9 (complement C9) | protein interactions | 735 | 14 | 2 | 19454 | 50 |
CLU,APOE |
6.143e-04 | -7.40 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 18 | 16828 | 49 |
ZNRF3,MACF1,PTPRZ1,NHSL1,FMN2,TRPM3,PREX2,PITPNC1,TNIK,COL5A3,CLU,FGFR3,RYR3,CTNND2,NRG3,SPARCL1,SLC4A4,NKAIN3 |
6.143e-04 | -7.40 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 18 | 16828 | 49 |
TNIK,COL5A3,CLU,SPARCL1,NRG3,NKAIN3,SLC4A4,FGFR3,CTNND2,RYR3,NHSL1,PTPRZ1,ZNRF3,MACF1,PITPNC1,PREX2,TRPM3,FMN2 |
6.144e-04 | -7.39 | transport | biological process | GO:0006810 | 3615 | 20 | 18204 | 49 |
PITPNC1,RYR3,ATP13A4,SFXN5,NTRK2,RANBP3L,SLC4A4,NRXN1,SLC1A3,ATP1A2,SLC25A18,APOE,TRPM3,CAMK2G,MACF1,CPE,FMN2,SLC1A2,GPM6A,CLU |
6.169e-04 | -7.39 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 3 | 10285 | 31 |
CAMK2G,RYR3,ATP1A2 |
6.187e-04 | -7.39 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 6 | 19108 | 49 |
SPARCL1,GPM6A,APOE,TNIK,SLC1A2,NRG3 |
6.323e-04 | -7.37 | symporter activity | molecular function | GO:0015293 | 148 | 4 | 18094 | 48 |
SLC4A4,SLC1A3,SLC25A18,SLC1A2 |
6.327e-04 | -7.37 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 49 |
SLC4A4,ATP1A2 |
6.327e-04 | -7.37 | mechanosensory behavior | biological process | GO:0007638 | 14 | 2 | 18204 | 49 |
NRXN1,SLC1A3 |
6.356e-04 | -7.36 | adult behavior | biological process | GO:0030534 | 146 | 4 | 18204 | 49 |
ATP1A2,PREX2,NRXN1,SLC1A2 |
6.412e-04 | -7.35 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 7 | 18094 | 48 |
CTNND2,CPE,MACF1,PTPRZ1,CTNNA2,NRXN1,CDH20 |
6.523e-04 | -7.34 | MICB (MHC class I polypeptide-related sequence B) | protein interactions | 4277 | 66 | 3 | 19454 | 50 |
APOE,CLU,SFXN5 |
6.542e-04 | -7.33 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 47 | 16828 | 49 |
CST3,MACF1,DTNA,FGFR3,ATP1A2,NRG3,HIF3A,CAMK2G,BMPR1B,FMN2,ABLIM1,PTPRZ1,RORA,SLC4A4,SLC1A3,ACSS1,NEBL,SOX5,TRPM3,NTM,PREX2,PITPNC1,RANBP3L,CTNND2,APOE,NTRK2,ZBTB20,TNIK,CLU,LSAMP,MSI2,SLC1A2,CDH20,ZNRF3,GPC5,NHSL1,GPM6A,RYR3,PAMR1,SFXN5,ATP13A4,NKAIN3,SLC25A18,NRXN1,NPAS3,COL5A3,SORBS1 |
6.642e-04 | -7.32 | ACTB (actin beta) | protein interactions | 60 | 958 | 9 | 19454 | 50 |
APOE,SFXN5,NEBL,FMN2,MACF1,NHSL1,ABLIM1,SORBS1,DTNA |
6.654e-04 | -7.32 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 2 | 19454 | 50 |
CPE,CLU |
6.803e-04 | -7.29 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 49 |
PREX2,CTNNA2,CTNND2 |
6.839e-04 | -7.29 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 3 | 10285 | 31 |
ATP13A4,ATP1A2,CAMK2G |
6.989e-04 | -7.27 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 5 | 18094 | 48 |
SLC4A4,SFXN5,SLC1A3,SLC25A18,SLC1A2 |
7.130e-04 | -7.25 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 3 | 18094 | 48 |
SLC1A2,SLC25A18,SLC1A3 |
7.444e-04 | -7.20 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 3 | 18204 | 49 |
SLC25A18,SLC1A2,SLC1A3 |
7.549e-04 | -7.19 | collagen-containing extracellular matrix | cellular component | GO:0062023 | 428 | 6 | 19108 | 49 |
APOE,COL5A3,CLU,SPARCL1,GPC5,PTPRZ1 |
7.592e-04 | -7.18 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 2 | 19454 | 50 |
MACF1,CPE |
7.916e-04 | -7.14 | face | COSMIC cancer mutations | face | 2139 | 15 | 16828 | 49 |
PTPRZ1,ABLIM1,GPC5,ZNRF3,MACF1,PREX2,FMN2,TRPM3,MSI2,NEBL,LSAMP,NRG3,RORA,FGFR3,GPM6A |
8.077e-04 | -7.12 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2,ATP1A2 |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
LSAMP,ZBTB20 |
8.111e-04 | -7.12 | cell adhesion | biological process | GO:0007155 | 942 | 9 | 18204 | 49 |
SPARCL1,SORBS1,COL5A3,LSAMP,CTNND2,NTM,CDH20,NRXN1,CTNNA2 |
8.133e-04 | -7.11 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 5 | 18204 | 49 |
ATP1A2,SLC1A2,SLC1A3,SLC4A4,APOE |
8.315e-04 | -7.09 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 2 | 18204 | 49 |
APOE,ATP1A2 |
8.443e-04 | -7.08 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 10 | 18204 | 49 |
TNIK,CTNND2,NRXN1,CTNNA2,GPM6A,BMPR1B,PREX2,ABLIM1,PTPRZ1,APOE |
8.516e-04 | -7.07 | spindle | COSMIC cancer mutations | spindle | 386 | 6 | 16828 | 49 |
MACF1,CTNND2,TRPM3,FGFR3,PREX2,CPE |
8.541e-04 | -7.07 | learning or memory | biological process | GO:0007611 | 276 | 5 | 18204 | 49 |
APOE,NRXN1,PTPRZ1,NTRK2,ATP1A2 |
8.727e-04 | -7.04 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 7 | 18204 | 49 |
ATP1A2,RYR3,ATP13A4,ZBTB20,APOE,SLC1A3,SLC4A4 |
9.247e-04 | -6.99 | monoatomic cation transport | biological process | GO:0006812 | 766 | 8 | 18204 | 49 |
TRPM3,SLC25A18,ATP1A2,ATP13A4,RYR3,GPM6A,SLC1A3,SLC4A4 |
9.296e-04 | -6.98 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 16 | 16828 | 49 |
PAMR1,SPARCL1,FGFR3,RYR3,APOE,SORBS1,SLC1A3,NPAS3,CLU,PREX2,TRPM3,FMN2,CDH20,NHSL1,ZNRF3,MACF1 |
9.296e-04 | -6.98 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 16 | 16828 | 49 |
NPAS3,CLU,SLC1A3,SORBS1,APOE,RYR3,FGFR3,SPARCL1,PAMR1,MACF1,ZNRF3,NHSL1,CDH20,FMN2,TRPM3,PREX2 |
9.407e-04 | -6.97 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 2 | 18204 | 49 |
APOE,CLU |
9.407e-04 | -6.97 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 2 | 18204 | 49 |
APOE,CLU |
9.443e-04 | -6.97 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 22 | 16828 | 49 |
SLC1A2,FMN2,PREX2,PITPNC1,ZNRF3,MACF1,NHSL1,PTPRZ1,FGFR3,ATP1A2,CTNND2,GPM6A,RYR3,NTRK2,SLC4A4,HIF3A,CAMK2G,TNIK,COL5A3,NPAS3,ACSS1,NEBL |
9.479e-04 | -6.96 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 44 | 16828 | 49 |
RANBP3L,TRPM3,PREX2,PITPNC1,NTM,LSAMP,TNIK,CTNND2,NTRK2,ZBTB20,GPC5,ZNRF3,NHSL1,CDH20,SLC1A2,COL5A3,NRXN1,NPAS3,SLC25A18,SORBS1,GPM6A,RYR3,SFXN5,ATP13A4,PAMR1,SPARCL1,MACF1,CST3,BMPR1B,FGFR3,DTNA,ATP1A2,HIF3A,NRG3,ABLIM1,PTPRZ1,FMN2,SLC1A3,NEBL,SOX5,ACSS1,SLC4A4,RORA,CPE |
9.554e-04 | -6.95 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 5 | 18204 | 49 |
TNIK,CTNND2,ZNRF3,CPE,MACF1 |
9.587e-04 | -6.95 | cervix | COSMIC cancer mutations | cervix | 11793 | 44 | 16828 | 49 |
ABLIM1,PTPRZ1,FMN2,SLC1A3,SOX5,NEBL,ACSS1,SLC4A4,RORA,CPE,MACF1,CST3,BMPR1B,DTNA,FGFR3,ATP1A2,HIF3A,NRG3,ZNRF3,GPC5,NHSL1,CDH20,SLC1A2,NRXN1,NPAS3,COL5A3,SLC25A18,SORBS1,GPM6A,RYR3,ATP13A4,SFXN5,PAMR1,SPARCL1,RANBP3L,TRPM3,PITPNC1,PREX2,NTM,LSAMP,TNIK,CTNND2,NTRK2,ZBTB20 |
9.621e-04 | -6.95 | dendrite | cellular component | GO:0030425 | 620 | 7 | 19108 | 49 |
GPM6A,CTNND2,NTRK2,ATP1A2,APOE,BMPR1B,CLU |
9.623e-04 | -6.95 | actin binding | molecular function | GO:0003779 | 434 | 6 | 18094 | 48 |
CTNNA2,FMN2,MACF1,SORBS1,ABLIM1,NEBL |
9.696e-04 | -6.94 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 6 | 18204 | 49 |
SLC4A4,SLC1A3,ATP1A2,RYR3,ATP13A4,APOE |
9.763e-04 | -6.93 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 5 | 16828 | 49 |
PREX2,SOX5,FGFR3,SLC1A2,RYR3 |
9.803e-04 | -6.93 | dendritic tree | cellular component | GO:0097447 | 622 | 7 | 19108 | 49 |
CTNND2,GPM6A,APOE,ATP1A2,BMPR1B,CLU,NTRK2 |
9.825e-04 | -6.93 | signaling | biological process | GO:0023052 | 4968 | 24 | 18204 | 49 |
PITPNC1,RYR3,PREX2,SORBS1,RORA,FGFR3,NTRK2,TNIK,CTNND2,SLC1A3,NRXN1,DTNA,NRG3,BMPR1B,ATP1A2,APOE,SPARCL1,CAMK2G,FMN2,ZNRF3,MACF1,CPE,CLU,SLC1A2 |
9.860e-04 | -6.92 | cell junction assembly | biological process | GO:0034329 | 285 | 5 | 18204 | 49 |
NRG3,SORBS1,CDH20,GPM6A,NRXN1 |
1.005e-03 | -6.90 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 6 | 18204 | 49 |
DTNA,NRXN1,SLC1A3,SLC1A2,APOE,NTRK2 |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
GPM6A,NTM,LSAMP |
1.030e-03 | -6.88 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 6 | 19454 | 50 |
ABLIM1,SOX5,FMN2,DTNA,SORBS1,MACF1 |
1.053e-03 | -6.86 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 6 | 19454 | 50 |
DTNA,CTNND2,SLC25A18,CAMK2G,FMN2,MACF1 |
1.061e-03 | -6.85 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 3 | 19454 | 50 |
SOX5,SLC25A18,MSI2 |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.079e-03 | -6.83 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 6 | 18204 | 49 |
ATP1A2,ATP13A4,RYR3,APOE,SLC4A4,SLC1A3 |
1.082e-03 | -6.83 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 6 | 18094 | 48 |
SLC4A4,ATP1A2,SLC1A2,SLC1A3,ATP13A4,SLC25A18 |
1.105e-03 | -6.81 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 49 |
ATP1A2,ATP13A4 |
1.118e-03 | -6.80 | cell communication | biological process | GO:0007154 | 5010 | 24 | 18204 | 49 |
NRG3,CPE,CLU,SORBS1,PITPNC1,DTNA,CTNND2,TNIK,APOE,SPARCL1,ATP1A2,BMPR1B,MACF1,FMN2,ZNRF3,SLC1A2,CAMK2G,RORA,FGFR3,PREX2,RYR3,SLC1A3,NRXN1,NTRK2 |
1.154e-03 | -6.76 | cell projection organization | biological process | GO:0030030 | 1200 | 10 | 18204 | 49 |
CTNNA2,NRXN1,GPM6A,CTNND2,TNIK,PTPRZ1,APOE,PREX2,ABLIM1,BMPR1B |
1.158e-03 | -6.76 | regulation of neuron projection development | biological process | GO:0010975 | 443 | 6 | 18204 | 49 |
TNIK,CAMK2G,NTRK2,MACF1,CTNNA2,APOE |
1.172e-03 | -6.75 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 5 | 19454 | 50 |
ABLIM1,TNIK,FMN2,DTNA,MACF1 |
1.179e-03 | -6.74 | regulation of amyloid-beta clearance | biological process | GO:1900221 | 19 | 2 | 18204 | 49 |
CLU,APOE |
1.179e-03 | -6.74 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.186e-03 | -6.74 | PAS_fold | interpro domains | IPR013767 | 19 | 2 | 18521 | 50 |
NPAS3,HIF3A |
1.190e-03 | -6.73 | endoplasmic reticulum lumen | cellular component | GO:0005788 | 312 | 5 | 19108 | 49 |
CST3,SPARCL1,APOE,COL5A3,CLU |
1.194e-03 | -6.73 | PON1 (paraoxonase 1) | protein interactions | 5444 | 20 | 2 | 19454 | 50 |
SFXN5,CLU |
1.210e-03 | -6.72 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 3 | 18204 | 49 |
SLC4A4,ZBTB20,SORBS1 |
1.233e-03 | -6.70 | PAS | pfam domains | PF00989 | 19 | 2 | 17795 | 49 |
NPAS3,HIF3A |
1.247e-03 | -6.69 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2 |
1.250e-03 | -6.68 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 7 | 18204 | 49 |
SLC25A18,ATP1A2,RYR3,TRPM3,SLC1A3,GPM6A,SLC4A4 |
1.293e-03 | -6.65 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 3 | 18094 | 48 |
BMPR1B,FGFR3,NTRK2 |
1.303e-03 | -6.64 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 32 | 16828 | 49 |
RYR3,SLC4A4,SFXN5,ATP13A4,RORA,NPAS3,COL5A3,NRXN1,NEBL,SOX5,ACSS1,CDH20,SLC1A2,FMN2,ZNRF3,PTPRZ1,NHSL1,CTNND2,ATP1A2,FGFR3,ZBTB20,NTRK2,NRG3,CLU,LSAMP,TRPM3,NTM,PITPNC1,PREX2,MACF1,CST3,RANBP3L |
1.303e-03 | -6.64 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 32 | 16828 | 49 |
MACF1,CST3,RANBP3L,TRPM3,PREX2,NTM,PITPNC1,LSAMP,CLU,CTNND2,FGFR3,ATP1A2,NTRK2,ZBTB20,NRG3,ZNRF3,NHSL1,PTPRZ1,CDH20,FMN2,SLC1A2,NRXN1,COL5A3,NPAS3,SOX5,NEBL,ACSS1,RYR3,SFXN5,ATP13A4,SLC4A4,RORA |
1.307e-03 | -6.64 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.314e-03 | -6.63 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 8 | 16828 | 49 |
SLC1A3,ACSS1,SOX5,NEBL,RANBP3L,DTNA,CTNND2,NTRK2 |
1.318e-03 | -6.63 | TENM1 (teneurin transmembrane protein 1) | protein interactions | 10178 | 21 | 2 | 19454 | 50 |
MACF1,SORBS1 |
1.349e-03 | -6.61 | regulation of amide metabolic process | biological process | GO:0034248 | 81 | 3 | 18204 | 49 |
NTRK2,CLU,APOE |
1.361e-03 | -6.60 | adherens junction | cellular component | GO:0005912 | 188 | 4 | 19108 | 49 |
CTNND2,CDH20,CTNNA2,SORBS1 |
1.389e-03 | -6.58 | synaptic signaling | biological process | GO:0099536 | 459 | 6 | 18204 | 49 |
SLC1A2,SLC1A3,DTNA,NRXN1,APOE,NTRK2 |
1.397e-03 | -6.57 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 3 | 19108 | 49 |
ABLIM1,NEBL,SORBS1 |
1.397e-03 | -6.57 | stress fiber | cellular component | GO:0001725 | 86 | 3 | 19108 | 49 |
ABLIM1,NEBL,SORBS1 |
1.414e-03 | -6.56 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 12 | 18204 | 49 |
RORA,SFXN5,NTRK2,NRXN1,ATP1A2,BMPR1B,ZBTB20,APOE,PTPRZ1,SOX5,MACF1,CLU |
1.443e-03 | -6.54 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.443e-03 | -6.54 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.443e-03 | -6.54 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.443e-03 | -6.54 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.459e-03 | -6.53 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 7 | 16828 | 49 |
MACF1,RANBP3L,TRPM3,FGFR3,CTNND2,CPE,PREX2 |
1.471e-03 | -6.52 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 4 | 18204 | 49 |
SORBS1,RORA,ZBTB20,SLC4A4 |
1.478e-03 | -6.52 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 4 | 18094 | 48 |
SFXN5,SLC1A3,SLC25A18,SLC1A2 |
1.498e-03 | -6.50 | L-amino acid transport | biological process | GO:0015807 | 84 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,SLC25A18 |
1.507e-03 | -6.50 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 4 | 18094 | 48 |
SFXN5,SLC1A2,SLC25A18,SLC1A3 |
1.550e-03 | -6.47 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 36 |
ATP1A2,ATP13A4 |
1.550e-03 | -6.47 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 3 | 18204 | 49 |
NTRK2,CLU,PTPRZ1 |
1.550e-03 | -6.47 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 3 | 18204 | 49 |
BMPR1B,FGFR3,SOX5 |
1.584e-03 | -6.45 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 49 |
ATP1A2,SLC1A3 |
1.594e-03 | -6.44 | DEP_dom | interpro domains | IPR000591 | 22 | 2 | 18521 | 50 |
FMN2,PREX2 |
1.595e-03 | -6.44 | establishment of localization | biological process | GO:0051234 | 3887 | 20 | 18204 | 49 |
FMN2,MACF1,CPE,GPM6A,CLU,SLC1A2,CAMK2G,TRPM3,APOE,SLC25A18,ATP1A2,SLC4A4,SLC1A3,NRXN1,NTRK2,RANBP3L,SFXN5,PITPNC1,RYR3,ATP13A4 |
1.620e-03 | -6.43 | OCLN (occludin) | protein interactions | 100506658 | 495 | 6 | 19454 | 50 |
DTNA,ABLIM1,MACF1,FMN2,NTRK2,TNIK |
1.624e-03 | -6.42 | cognition | biological process | GO:0050890 | 319 | 5 | 18204 | 49 |
APOE,NRXN1,PTPRZ1,NTRK2,ATP1A2 |
1.683e-03 | -6.39 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
1.689e-03 | -6.38 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 12 | 16828 | 49 |
RORA,SLC4A4,ATP13A4,ATP1A2,FGFR3,PTPRZ1,SOX5,GPC5,COL5A3,LSAMP,MACF1,NRXN1 |
1.695e-03 | -6.38 | actomyosin | cellular component | GO:0042641 | 92 | 3 | 19108 | 49 |
ABLIM1,SORBS1,NEBL |
1.696e-03 | -6.38 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 3 | 18094 | 48 |
CLU,APOE,CST3 |
1.708e-03 | -6.37 | transmembrane transport | biological process | GO:0055085 | 1264 | 10 | 18204 | 49 |
RYR3,ATP13A4,SLC25A18,ATP1A2,SFXN5,TRPM3,SLC1A3,SLC1A2,GPM6A,SLC4A4 |
1.715e-03 | -6.37 | human chr5p13.2 | chromosome location | human chr5p13.2 | 32 | 2 | 26134 | 50 |
SLC1A3,RANBP3L |
1.750e-03 | -6.35 | eye | COSMIC cancer mutations | eye | 606 | 7 | 16828 | 49 |
CTNND2,TRPM3,FGFR3,PREX2,CPE,MACF1,RANBP3L |
1.757e-03 | -6.34 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 4 | 19454 | 50 |
ATP1A2,RYR3,DTNA,CAMK2G |
1.769e-03 | -6.34 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 3 | 18204 | 49 |
SORBS1,APOE,ZBTB20 |
1.781e-03 | -6.33 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 41 | 16828 | 49 |
MACF1,CST3,RANBP3L,TRPM3,PREX2,NTM,LSAMP,CLU,TNIK,CAMK2G,BMPR1B,MSI2,CTNND2,DTNA,FGFR3,ATP1A2,NTRK2,ZBTB20,NRG3,ZNRF3,GPC5,NHSL1,PTPRZ1,CDH20,SLC1A2,FMN2,NRXN1,COL5A3,NPAS3,SLC1A3,NEBL,SOX5,SORBS1,ACSS1,RYR3,ATP13A4,SFXN5,SLC4A4,RORA,PAMR1,CPE |
1.817e-03 | -6.31 | GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) | protein interactions | 2902 | 94 | 3 | 19454 | 50 |
CAMK2G,FGFR3,NTRK2 |
1.832e-03 | -6.30 | low-density lipoprotein particle receptor binding | molecular function | GO:0050750 | 24 | 2 | 18094 | 48 |
CLU,APOE |
1.832e-03 | -6.30 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
1.832e-03 | -6.30 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.837e-03 | -6.30 | export from cell | biological process | GO:0140352 | 485 | 6 | 18204 | 49 |
ATP1A2,CAMK2G,NTRK2,NRXN1,SLC4A4,CPE |
1.848e-03 | -6.29 | cell surface | cellular component | GO:0009986 | 896 | 8 | 19108 | 49 |
FGFR3,GPC5,NRXN1,SLC4A4,SLC1A2,SLC1A3,CLU,ATP1A2 |
1.907e-03 | -6.26 | SNCA (synuclein alpha) | protein interactions | 6622 | 696 | 7 | 19454 | 50 |
CLU,TNIK,APOE,MACF1,GPM6A,NTRK2,CAMK2G |
1.909e-03 | -6.26 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 12 | 16828 | 49 |
PREX2,FMN2,CDH20,PTPRZ1,ABLIM1,MACF1,CPE,RORA,DTNA,FGFR3,CTNND2,SORBS1 |
1.909e-03 | -6.26 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 12 | 16828 | 49 |
FMN2,DTNA,FGFR3,CTNND2,CDH20,CPE,RORA,PREX2,MACF1,PTPRZ1,SORBS1,ABLIM1 |
1.909e-03 | -6.26 | regulation of small molecule metabolic process | biological process | GO:0062012 | 331 | 5 | 18204 | 49 |
SLC4A4,APOE,RORA,ZBTB20,SORBS1 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.913e-03 | -6.26 | human chr9q21.12-q21.13 | chromosome location | human chr9q21.12-q21.13 | 1 | 1 | 26134 | 50 |
TRPM3 |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.915e-03 | -6.26 | actin filament bundle | cellular component | GO:0032432 | 96 | 3 | 19108 | 49 |
ABLIM1,NEBL,SORBS1 |
1.918e-03 | -6.26 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 7 | 18204 | 49 |
APOE,CTNNA2,GPM6A,MACF1,NTRK2,CAMK2G,TNIK |
1.920e-03 | -6.26 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 28 | 16828 | 49 |
HIF3A,ZBTB20,NTRK2,NRG3,ATP1A2,FGFR3,DTNA,CLU,CAMK2G,PREX2,TRPM3,MACF1,SLC4A4,SFXN5,ATP13A4,SPARCL1,GPM6A,SORBS1,NEBL,ACSS1,NRXN1,COL5A3,SLC1A3,CDH20,FMN2,PTPRZ1,ABLIM1,GPC5 |
1.931e-03 | -6.25 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 28 | 16828 | 49 |
GPC5,ABLIM1,PTPRZ1,FMN2,CDH20,SLC1A3,COL5A3,NRXN1,ACSS1,NEBL,SORBS1,GPM6A,SPARCL1,ATP13A4,SFXN5,SLC4A4,MACF1,TRPM3,PREX2,CAMK2G,CLU,DTNA,FGFR3,ATP1A2,NRG3,NTRK2,ZBTB20,HIF3A |
2.013e-03 | -6.21 | high-density lipoprotein particle | cellular component | GO:0034364 | 26 | 2 | 19108 | 49 |
CLU,APOE |
2.015e-03 | -6.21 | modulation of chemical synaptic transmission | biological process | GO:0050804 | 494 | 6 | 18204 | 49 |
NTRK2,SLC1A3,NRXN1,NRG3,ATP1A2,APOE |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.035e-03 | -6.20 | regulation of trans-synaptic signaling | biological process | GO:0099177 | 495 | 6 | 18204 | 49 |
ATP1A2,NTRK2,NRG3,NRXN1,SLC1A3,APOE |
2.045e-03 | -6.19 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 6 | 19108 | 49 |
FMN2,ABLIM1,CTNNA2,NEBL,MACF1,SORBS1 |
2.047e-03 | -6.19 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 3 | 19454 | 50 |
SORBS1,NTRK2,FGFR3 |
2.118e-03 | -6.16 | regulation of Wnt signaling pathway | biological process | GO:0030111 | 339 | 5 | 18204 | 49 |
CTNND2,APOE,MACF1,ZNRF3,GPC5 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
DTNA,CTNNA2,CDH20 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
ABLIM1,DTNA |
2.185e-03 | -6.13 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 7 | 19454 | 50 |
ABLIM1,SLC1A3,DTNA,MSI2,TNIK,FMN2,MACF1 |
2.200e-03 | -6.12 | EZR (ezrin) | protein interactions | 7430 | 526 | 6 | 19454 | 50 |
MACF1,DTNA,NEBL,SORBS1,TNIK,ABLIM1 |
2.212e-03 | -6.11 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 7 | 18204 | 49 |
TNIK,CAMK2G,NTRK2,MACF1,GPM6A,CTNNA2,APOE |
2.220e-03 | -6.11 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 21 | 16828 | 49 |
MACF1,ZNRF3,PTPRZ1,FMN2,SLC1A2,PREX2,PITPNC1,COL5A3,NPAS3,CAMK2G,TNIK,NEBL,ACSS1,RYR3,CTNND2,GPM6A,ATP1A2,FGFR3,SLC4A4,HIF3A,NTRK2 |
2.227e-03 | -6.11 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 21 | 16828 | 49 |
PTPRZ1,ZNRF3,MACF1,PITPNC1,PREX2,SLC1A2,FMN2,ACSS1,NEBL,TNIK,CAMK2G,COL5A3,NPAS3,SLC4A4,HIF3A,NTRK2,ATP1A2,FGFR3,RYR3,GPM6A,CTNND2 |
2.250e-03 | -6.10 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 6 | 18204 | 49 |
ATP1A2,ATP13A4,RYR3,APOE,SLC1A3,SLC4A4 |
2.261e-03 | -6.09 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 7 | 16828 | 49 |
PREX2,NTM,FMN2,NEBL,PTPRZ1,SORBS1,CAMK2G |
2.262e-03 | -6.09 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,SLC25A18 |
2.302e-03 | -6.07 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 32 | 16828 | 49 |
SLC1A3,COL5A3,NRXN1,NPAS3,ACSS1,SORBS1,SOX5,NEBL,RYR3,SPARCL1,RORA,PAMR1,SLC4A4,NKAIN3,ATP13A4,PTPRZ1,ABLIM1,FMN2,CAMK2G,TNIK,ATP1A2,FGFR3,DTNA,CTNND2,NRG3,ZBTB20,HIF3A,NTRK2,CST3,MACF1,TRPM3,PREX2 |
2.324e-03 | -6.06 | cellular homeostasis | biological process | GO:0019725 | 689 | 7 | 18204 | 49 |
SLC1A3,SLC4A4,ATP1A2,ATP13A4,RYR3,APOE,ZBTB20 |
2.328e-03 | -6.06 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 31 |
SLC1A3,SLC1A2 |
2.341e-03 | -6.06 | actin filament binding | molecular function | GO:0051015 | 211 | 4 | 18094 | 48 |
CTNNA2,ABLIM1,MACF1,NEBL |
2.345e-03 | -6.06 | LRRC7 (leucine rich repeat containing 7) | protein interactions | 57554 | 28 | 2 | 19454 | 50 |
CTNND2,CAMK2G |
2.366e-03 | -6.05 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 3 | 18094 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
2.414e-03 | -6.03 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | 1440 | 11 | 16828 | 49 |
NRXN1,COL5A3,MACF1,NEBL,PTPRZ1,CTNND2,CDH20,RYR3,FGFR3,FMN2,PREX2 |
2.414e-03 | -6.03 | hairy_cell_leukaemia | COSMIC cancer mutations | hairy_cell_leukaemia | 1440 | 11 | 16828 | 49 |
CTNND2,RYR3,FGFR3,NEBL,COL5A3,NRXN1,PREX2,CDH20,FMN2,PTPRZ1,MACF1 |
2.467e-03 | -6.00 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,RYR3 |
2.482e-03 | -6.00 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 6 | 18204 | 49 |
ATP1A2,ATP13A4,RYR3,APOE,SLC4A4,SLC1A3 |
2.564e-03 | -5.97 | perinuclear endoplasmic reticulum lumen | cellular component | GO:0099020 | 1 | 1 | 19108 | 49 |
CLU |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.570e-03 | -5.96 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Bdnf (brain derived neurotrophic factor) | protein interactions | 12064 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 50 |
NRXN1 |
2.570e-03 | -5.96 | Dynlt1 (dynein light chain Tctex-type 1) | protein interactions | 83462 | 1 | 1 | 19454 | 50 |
NTRK2 |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.579e-03 | -5.96 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 7 | 16828 | 49 |
PREX2,TRPM3,FGFR3,ACSS1,ABLIM1,TNIK,MACF1 |
2.593e-03 | -5.95 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
2.609e-03 | -5.95 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 24 |
ATP1A2,SLC4A4 |
2.609e-03 | -5.95 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 24 |
ATP1A2,SLC4A4 |
2.626e-03 | -5.94 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 16 | 16828 | 49 |
PTPRZ1,MACF1,ZNRF3,PREX2,TRPM3,FMN2,SORBS1,COL5A3,NPAS3,CAMK2G,RORA,SPARCL1,CTNND2,RYR3,APOE,FGFR3 |
2.626e-03 | -5.94 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 16 | 16828 | 49 |
APOE,RYR3,CTNND2,FGFR3,SPARCL1,RORA,NPAS3,COL5A3,CAMK2G,SORBS1,FMN2,TRPM3,PREX2,MACF1,ZNRF3,PTPRZ1 |
2.653e-03 | -5.93 | metal chelating activity | molecular function | GO:0046911 | 1 | 1 | 18094 | 48 |
APOE |
2.653e-03 | -5.93 | brain-derived neurotrophic factor receptor activity | molecular function | GO:0060175 | 1 | 1 | 18094 | 48 |
NTRK2 |
2.671e-03 | -5.93 | human chr20p11.21 | chromosome location | human chr20p11.21 | 40 | 2 | 26134 | 50 |
ACSS1,CST3 |
2.673e-03 | -5.92 | lipoprotein particle receptor binding | molecular function | GO:0070325 | 29 | 2 | 18094 | 48 |
CLU,APOE |
2.692e-03 | -5.92 | positive regulation of lipid transport across blood-brain barrier | biological process | GO:1903002 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of neuronal signal transduction | biological process | GO:1902847 | 1 | 1 | 18204 | 49 |
CLU |
2.692e-03 | -5.92 | directional guidance of interneurons involved in migration from the subpallium to the cortex | biological process | GO:0021840 | 1 | 1 | 18204 | 49 |
NRG3 |
2.692e-03 | -5.92 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | regulation of transport across blood-brain barrier | biological process | GO:0150200 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 49 |
CST3 |
2.692e-03 | -5.92 | homologous chromosome movement towards spindle pole in meiosis I anaphase | biological process | GO:0051758 | 1 | 1 | 18204 | 49 |
FMN2 |
2.692e-03 | -5.92 | positive regulation of heparan sulfate proteoglycan binding | biological process | GO:1905860 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 49 |
ATP1A2 |
2.692e-03 | -5.92 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 49 |
CST3 |
2.692e-03 | -5.92 | intermediate-density lipoprotein particle clearance | biological process | GO:0071831 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | trans-synaptic signaling by neuropeptide, modulating synaptic transmission | biological process | GO:0099551 | 1 | 1 | 18204 | 49 |
NTRK2 |
2.692e-03 | -5.92 | regulation of heparan sulfate proteoglycan binding | biological process | GO:1905858 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of transport across blood-brain barrier | biological process | GO:0150201 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | trans-synaptic signaling by neuropeptide | biological process | GO:0099540 | 1 | 1 | 18204 | 49 |
NTRK2 |
2.692e-03 | -5.92 | regulation of lipid transport across blood-brain barrier | biological process | GO:1903000 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of cellular response to very-low-density lipoprotein particle stimulus | biological process | GO:1905890 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of neurofibrillary tangle assembly | biological process | GO:1902998 | 1 | 1 | 18204 | 49 |
CLU |
2.692e-03 | -5.92 | chemorepulsion involved in interneuron migration from the subpallium to the cortex | biological process | GO:0021842 | 1 | 1 | 18204 | 49 |
NRG3 |
2.700e-03 | -5.91 | SORBS1_SH3_1 | interpro domains | IPR035610 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | SORBS1_SH3 | interpro domains | IPR035606 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.700e-03 | -5.91 | Clusterin | interpro domains | IPR016016 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | SORBS1_SH3_2 | interpro domains | IPR035611 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | Clusterin_CS | interpro domains | IPR033986 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | Nebulette_SH3 | interpro domains | IPR035631 | 1 | 1 | 18521 | 50 |
NEBL |
2.700e-03 | -5.91 | ZNRF3_Znf_RING | interpro domains | IPR045903 | 1 | 1 | 18521 | 50 |
ZNRF3 |
2.700e-03 | -5.91 | M14_CPE_CPD | interpro domains | IPR034232 | 1 | 1 | 18521 | 50 |
CPE |
2.700e-03 | -5.91 | NTRK2 | interpro domains | IPR020455 | 1 | 1 | 18521 | 50 |
NTRK2 |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
SLC1A3,SOX5,NEBL,ACSS1,SLC4A4,RORA,CPE,ABLIM1,PTPRZ1,FMN2,BMPR1B,CAMK2G,DTNA,FGFR3,ATP1A2,HIF3A,NRG3,MACF1,CST3,NRXN1,NPAS3,COL5A3,SLC25A18,SORBS1,GPM6A,RYR3,ATP13A4,SFXN5,NKAIN3,PAMR1,SPARCL1,GPC5,ZNRF3,NHSL1,CDH20,SLC1A2,LSAMP,CLU,TNIK,CTNND2,APOE,NTRK2,ZBTB20,RANBP3L,TRPM3,PREX2,NTM,PITPNC1 |
2.751e-03 | -5.90 | postsynaptic membrane organization | biological process | GO:0001941 | 29 | 2 | 18204 | 49 |
APOE,NRXN1 |
2.754e-03 | -5.89 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 49 |
FGFR3 |
2.774e-03 | -5.89 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 6 | 16828 | 49 |
NTRK2,FGFR3,CAMK2G,TNIK,BMPR1B,MACF1 |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
SLC1A2,CDH20,ZNRF3,GPC5,NHSL1,GPM6A,RYR3,PAMR1,SPARCL1,NKAIN3,SFXN5,ATP13A4,SLC25A18,COL5A3,NPAS3,NRXN1,SORBS1,TRPM3,NTM,PREX2,PITPNC1,RANBP3L,CTNND2,APOE,NTRK2,ZBTB20,TNIK,LSAMP,CLU,FMN2,ABLIM1,PTPRZ1,RORA,CPE,SLC4A4,SLC1A3,ACSS1,NEBL,SOX5,CST3,MACF1,FGFR3,DTNA,ATP1A2,NRG3,HIF3A,BMPR1B,CAMK2G |
2.828e-03 | -5.87 | chemical homeostasis | biological process | GO:0048878 | 914 | 8 | 18204 | 49 |
SLC4A4,SLC1A3,ATP1A2,RYR3,ATP13A4,ZBTB20,APOE,RORA |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CTNNA2,CDH20 |
2.859e-03 | -5.86 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 7 | 18204 | 49 |
GPM6A,SLC1A3,SLC4A4,TRPM3,RYR3,SLC25A18,ATP1A2 |
2.870e-03 | -5.85 | SH2B1 (SH2B adaptor protein 1) | protein interactions | 25970 | 31 | 2 | 19454 | 50 |
FGFR3,NTRK2 |
2.919e-03 | -5.84 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 6 | 16828 | 49 |
TNIK,BMPR1B,CAMK2G,MACF1,FGFR3,NTRK2 |
2.934e-03 | -5.83 | extracellular matrix | cellular component | GO:0031012 | 559 | 6 | 19108 | 49 |
GPC5,PTPRZ1,COL5A3,SPARCL1,APOE,CLU |
2.952e-03 | -5.83 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 9 | 18204 | 49 |
NTRK2,SLC1A2,SLC1A3,ATP1A2,BMPR1B,RYR3,FGFR3,SOX5,SORBS1 |
2.960e-03 | -5.82 | external encapsulating structure | cellular component | GO:0030312 | 560 | 6 | 19108 | 49 |
PTPRZ1,GPC5,COL5A3,SPARCL1,APOE,CLU |
3.014e-03 | -5.80 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 31 |
FGFR3 |
3.041e-03 | -5.80 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 44 |
FGFR3 |
3.055e-03 | -5.79 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 7 | 19454 | 50 |
MACF1,NEBL,CTNNA2,CTNND2,SORBS1,NHSL1,ABLIM1 |
3.072e-03 | -5.79 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 11 | 16828 | 49 |
PTPRZ1,GPC5,MACF1,PREX2,FMN2,SORBS1,NPAS3,NRG3,DTNA,FGFR3,RYR3 |
3.108e-03 | -5.77 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 4 | 10285 | 31 |
RYR3,ATP1A2,CAMK2G,SORBS1 |
3.149e-03 | -5.76 | postsynapse organization | biological process | GO:0099173 | 109 | 3 | 18204 | 49 |
APOE,CTNND2,NRXN1 |
3.210e-03 | -5.74 | Salivary secretion | KEGG pathways | ko04970 | 90 | 3 | 7161 | 24 |
CST3,RYR3,ATP1A2 |
3.210e-03 | -5.74 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 3 | 7161 | 24 |
ATP1A2,CST3,RYR3 |
3.219e-03 | -5.74 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 4 | 16828 | 49 |
COL5A3,SLC4A4,NTM,ATP13A4 |
3.224e-03 | -5.74 | human chr11p13 | chromosome location | human chr11p13 | 44 | 2 | 26134 | 50 |
PAMR1,SLC1A2 |
3.249e-03 | -5.73 | VLDLR (very low density lipoprotein receptor) | protein interactions | 7436 | 33 | 2 | 19454 | 50 |
CLU,APOE |
3.282e-03 | -5.72 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
3.344e-03 | -5.70 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
3.344e-03 | -5.70 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 49 |
BMPR1B,SOX5 |
3.344e-03 | -5.70 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
3.401e-03 | -5.68 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 5 | 18521 | 50 |
TNIK,NTRK2,FGFR3,BMPR1B,CAMK2G |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.465e-03 | -5.67 | CEACAM8 (CEA cell adhesion molecule 8) | protein interactions | 1088 | 118 | 3 | 19454 | 50 |
CPE,CLU,APOE |
3.486e-03 | -5.66 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 49 |
PREX2,CTNND2,CTNNA2 |
3.495e-03 | -5.66 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
3.611e-03 | -5.62 | CLUSTERIN_2 | prosite domains | PS00493 | 1 | 1 | 12186 | 44 |
CLU |
3.611e-03 | -5.62 | CLUSTERIN_1 | prosite domains | PS00492 | 1 | 1 | 12186 | 44 |
CLU |
3.621e-03 | -5.62 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 41 | 16828 | 49 |
ZNRF3,GPC5,NHSL1,PTPRZ1,SLC1A2,FMN2,CDH20,SLC1A3,COL5A3,NPAS3,NRXN1,ACSS1,SOX5,NEBL,SORBS1,RYR3,RORA,PAMR1,CPE,SFXN5,ATP13A4,SLC4A4,CST3,MACF1,RANBP3L,TRPM3,PREX2,NTM,BMPR1B,CAMK2G,TNIK,CLU,LSAMP,MSI2,DTNA,FGFR3,ATP1A2,CTNND2,NRG3,NTRK2,ZBTB20 |
3.688e-03 | -5.60 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 48 |
TRPM3,GPM6A,RYR3 |
3.705e-03 | -5.60 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 36 |
MACF1 |
3.769e-03 | -5.58 | exploration behavior | biological process | GO:0035640 | 34 | 2 | 18204 | 49 |
ATP1A2,APOE |
3.772e-03 | -5.58 | localization | biological process | GO:0051179 | 4474 | 21 | 18204 | 49 |
TNIK,NTRK2,RANBP3L,SLC4A4,SLC1A3,NRXN1,PITPNC1,RYR3,ATP13A4,SFXN5,CAMK2G,FMN2,MACF1,CPE,CLU,SLC1A2,GPM6A,SLC25A18,ATP1A2,TRPM3,APOE |
3.792e-03 | -5.57 | PAS-like_dom_sf | interpro domains | IPR035965 | 34 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.792e-03 | -5.57 | PAS | interpro domains | IPR000014 | 34 | 2 | 18521 | 50 |
HIF3A,NPAS3 |
3.795e-03 | -5.57 | PAS | smart domains | SM00091 | 25 | 2 | 9717 | 36 |
HIF3A,NPAS3 |
3.839e-03 | -5.56 | plasma lipoprotein particle | cellular component | GO:0034358 | 36 | 2 | 19108 | 49 |
CLU,APOE |
3.839e-03 | -5.56 | lipoprotein particle | cellular component | GO:1990777 | 36 | 2 | 19108 | 49 |
CLU,APOE |
3.857e-03 | -5.56 | SLC5A5 (solute carrier family 5 member 5) | protein interactions | 6528 | 36 | 2 | 19454 | 50 |
SFXN5,CAMK2G |
3.878e-03 | -5.55 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
FGFR3,NTM,NTRK2,LSAMP |
3.936e-03 | -5.54 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 21 | 16828 | 49 |
SORBS1,CLU,COL5A3,NPAS3,SLC1A3,CAMK2G,PAMR1,RORA,SPARCL1,CTNND2,RYR3,APOE,FGFR3,NHSL1,PTPRZ1,MACF1,ZNRF3,PREX2,CDH20,TRPM3,FMN2 |
3.937e-03 | -5.54 | synapse assembly | biological process | GO:0007416 | 118 | 3 | 18204 | 49 |
NRG3,GPM6A,NRXN1 |
3.969e-03 | -5.53 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 4 | 19454 | 50 |
NHSL1,TNIK,NTRK2,SORBS1 |
3.978e-03 | -5.53 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 5 | 16828 | 49 |
CPE,PREX2,TRPM3,CTNND2,MACF1 |
4.007e-03 | -5.52 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 31 | 16828 | 49 |
GPC5,ABLIM1,NHSL1,PTPRZ1,FMN2,SLC1A2,CDH20,SLC1A3,COL5A3,ACSS1,SOX5,NEBL,GPM6A,RYR3,RORA,PAMR1,CPE,SPARCL1,NKAIN3,ATP13A4,SFXN5,MACF1,RANBP3L,PREX2,BMPR1B,TNIK,LSAMP,CLU,CTNND2,NRG3,NTRK2 |
4.018e-03 | -5.52 | NTKRECEPTOR2 | prints domains | PR01941 | 1 | 1 | 5227 | 21 |
NTRK2 |
4.071e-03 | -5.50 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 50 |
GPM6A,CST3 |
4.099e-03 | -5.50 | proteoglycan binding | molecular function | GO:0043394 | 36 | 2 | 18094 | 48 |
APOE,COL5A3 |
4.127e-03 | -5.49 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 49 |
DTNA,ATP1A2,RYR3 |
4.161e-03 | -5.48 | cytoskeletal protein binding | molecular function | GO:0008092 | 989 | 8 | 18094 | 48 |
APOE,CTNNA2,FMN2,NEBL,MACF1,SORBS1,CLU,ABLIM1 |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.258e-03 | -5.46 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 3 | 19454 | 50 |
ABLIM1,MACF1,DTNA |
4.289e-03 | -5.45 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 9 | 16828 | 49 |
SORBS1,COL5A3,MACF1,SLC4A4,PREX2,ATP13A4,NTM,FGFR3,CTNND2 |
4.290e-03 | -5.45 | MMP3 (matrix metallopeptidase 3) | protein interactions | 4314 | 38 | 2 | 19454 | 50 |
APOE,CLU |
4.335e-03 | -5.44 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 40 | 16828 | 49 |
NPAS3,NRXN1,COL5A3,SLC1A3,SLC25A18,SOX5,NEBL,SORBS1,ACSS1,GPM6A,RYR3,SFXN5,NKAIN3,ATP13A4,RORA,PAMR1,SPARCL1,CPE,GPC5,ABLIM1,NHSL1,PTPRZ1,CDH20,FMN2,SLC1A2,LSAMP,CLU,TNIK,CAMK2G,CTNND2,FGFR3,DTNA,ATP1A2,NTRK2,ZBTB20,NRG3,MACF1,RANBP3L,TRPM3,PREX2 |
4.413e-03 | -5.42 | arm | COSMIC cancer mutations | arm | 1331 | 10 | 16828 | 49 |
MACF1,NPAS3,COL5A3,SORBS1,ATP1A2,FGFR3,TRPM3,SLC4A4,ZBTB20,NTM |
4.451e-03 | -5.41 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
4.451e-03 | -5.41 | positive regulation of glucose import | biological process | GO:0046326 | 37 | 2 | 18204 | 49 |
SLC1A2,SORBS1 |
4.451e-03 | -5.41 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.493e-03 | -5.41 | protein-lipid complex | cellular component | GO:0032994 | 39 | 2 | 19108 | 49 |
APOE,CLU |
4.506e-03 | -5.40 | cellular component assembly | biological process | GO:0022607 | 2472 | 14 | 18204 | 49 |
NEBL,FMN2,CLU,GPM6A,SLC1A2,CDH20,NRG3,APOE,TRPM3,TNIK,NRXN1,ABLIM1,RYR3,SORBS1 |
4.523e-03 | -5.40 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 3 | 18204 | 49 |
ZBTB20,APOE,SORBS1 |
4.543e-03 | -5.39 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 8 | 18204 | 49 |
FGFR3,SOX5,NRG3,ABLIM1,BMPR1B,CPE,CTNNA2,NTRK2 |
4.602e-03 | -5.38 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 6 | 19454 | 50 |
DTNA,FGFR3,NHSL1,ABLIM1,TNIK,CLU |
4.616e-03 | -5.38 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
FMN2,ABLIM1,PTPRZ1,GPC5,ZNRF3,RORA,PAMR1,CPE,ATP13A4,SLC4A4,RYR3,SOX5,NRXN1,NTM,PITPNC1,PREX2,TRPM3,MACF1,NRG3,NTRK2,ZBTB20,FGFR3,ATP1A2,CTNND2,CAMK2G,TNIK,BMPR1B,CLU |
4.616e-03 | -5.38 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
MACF1,TRPM3,PREX2,NTM,PITPNC1,CAMK2G,BMPR1B,TNIK,CLU,FGFR3,ATP1A2,CTNND2,NRG3,NTRK2,ZBTB20,GPC5,ZNRF3,ABLIM1,PTPRZ1,FMN2,NRXN1,SOX5,RYR3,PAMR1,RORA,CPE,ATP13A4,SLC4A4 |
4.668e-03 | -5.37 | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 377 | 5 | 16828 | 49 |
TRPM3,FGFR3,COL5A3,NRXN1,MACF1 |
4.691e-03 | -5.36 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
4.705e-03 | -5.36 | plasma membrane region | cellular component | GO:0098590 | 1278 | 9 | 19108 | 49 |
GPM6A,SLC1A2,SLC1A3,TNIK,NRXN1,SLC4A4,SORBS1,MACF1,ATP1A2 |
4.744e-03 | -5.35 | DZIP1 (DAZ interacting zinc finger protein 1) | protein interactions | 22873 | 40 | 2 | 19454 | 50 |
NTRK2,CAMK2G |
4.753e-03 | -5.35 | endoplasmic reticulum | cellular component | GO:0005783 | 2051 | 12 | 19108 | 49 |
CST3,COL5A3,NRXN1,FMN2,ATP1A2,FGFR3,RYR3,SPARCL1,ATP13A4,CAMK2G,APOE,CLU |
4.815e-03 | -5.34 | kidney-Wilms_tumour | COSMIC cancer mutations | kidney-Wilms_tumour | 545 | 6 | 16828 | 49 |
FGFR3,FMN2,CAMK2G,TNIK,BMPR1B,NTRK2 |
4.852e-03 | -5.33 | cellular process | biological process | GO:0009987 | 14996 | 47 | 18204 | 49 |
NRG3,SLC25A18,TRPM3,PTPRZ1,CST3,CPE,CLU,CTNNA2,ABLIM1,SORBS1,TNIK,GPC5,DTNA,BMPR1B,MSI2,FMN2,MACF1,FGFR3,SFXN5,RANBP3L,NRXN1,ZBTB20,LSAMP,NHSL1,COL5A3,NEBL,GPM6A,PITPNC1,SLC4A4,CTNND2,ATP1A2,APOE,SPARCL1,SOX5,CAMK2G,HIF3A,ZNRF3,SLC1A2,CDH20,PREX2,RYR3,ATP13A4,RORA,NTRK2,ACSS1,SLC1A3,NTM |
4.858e-03 | -5.33 | Wilms_tumour | COSMIC cancer mutations | Wilms_tumour | 546 | 6 | 16828 | 49 |
CAMK2G,BMPR1B,TNIK,NTRK2,FMN2,FGFR3 |
4.936e-03 | -5.31 | positive regulation of nitric oxide biosynthetic process | biological process | GO:0045429 | 39 | 2 | 18204 | 49 |
APOE,CLU |
4.936e-03 | -5.31 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 49 |
ATP1A2,SLC1A3 |
4.945e-03 | -5.31 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 3 | 19454 | 50 |
CPE,GPM6A,NTM |
4.977e-03 | -5.30 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 21 | 16828 | 49 |
ZNRF3,MACF1,NHSL1,PTPRZ1,TRPM3,FMN2,CDH20,PREX2,SLC1A3,CAMK2G,COL5A3,CLU,NPAS3,SORBS1,FGFR3,CTNND2,RYR3,APOE,PAMR1,RORA,SPARCL1 |
5.029e-03 | -5.29 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 5 | 18204 | 49 |
APOE,NRXN1,SLC1A3,DTNA,SLC1A2 |
5.029e-03 | -5.29 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 5 | 18204 | 49 |
NRXN1,SLC1A3,DTNA,SLC1A2,APOE |
5.042e-03 | -5.29 | testis | COSMIC cancer mutations | testis | 733 | 7 | 16828 | 49 |
PREX2,NTRK2,FGFR3,BMPR1B,CAMK2G,TNIK,MACF1 |
5.049e-03 | -5.29 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 3 | 19454 | 50 |
ABLIM1,DTNA,NTRK2 |
5.122e-03 | -5.27 | chylomicron remnant | cellular component | GO:0034360 | 2 | 1 | 19108 | 49 |
APOE |
5.122e-03 | -5.27 | discoidal high-density lipoprotein particle | cellular component | GO:0034365 | 2 | 1 | 19108 | 49 |
APOE |
5.127e-03 | -5.27 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 4 | 18521 | 50 |
RYR3,DTNA,MACF1,SPARCL1 |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.135e-03 | -5.27 | prostate | COSMIC cancer mutations | prostate | 13883 | 47 | 16828 | 49 |
ATP1A2,DTNA,FGFR3,NRG3,HIF3A,BMPR1B,MACF1,CPE,RORA,SLC4A4,SLC1A3,ACSS1,SOX5,NEBL,FMN2,PTPRZ1,ABLIM1,APOE,CTNND2,ZBTB20,NTRK2,TNIK,CLU,LSAMP,MSI2,TRPM3,PITPNC1,PREX2,NTM,RANBP3L,RYR3,GPM6A,SPARCL1,PAMR1,ATP13A4,NKAIN3,SFXN5,SLC25A18,COL5A3,NRXN1,NPAS3,SORBS1,SLC1A2,CDH20,ZNRF3,GPC5,NHSL1 |
5.157e-03 | -5.27 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 8 | 16828 | 49 |
BMPR1B,TNIK,CAMK2G,MACF1,FGFR3,ATP1A2,NTRK2,PREX2 |
5.187e-03 | -5.26 | positive regulation of nitric oxide metabolic process | biological process | GO:1904407 | 40 | 2 | 18204 | 49 |
APOE,CLU |
5.198e-03 | -5.26 | RDX (radixin) | protein interactions | 5962 | 272 | 4 | 19454 | 50 |
ABLIM1,MACF1,FGFR3,NEBL |
5.198e-03 | -5.26 | PAS | prosite domains | PS50112 | 30 | 2 | 12186 | 44 |
HIF3A,NPAS3 |
5.210e-03 | -5.26 | fibula | COSMIC cancer mutations | fibula | 387 | 5 | 16828 | 49 |
FGFR3,TRPM3,MACF1,COL5A3,NRXN1 |
5.251e-03 | -5.25 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 49 |
CDH20,DTNA,FGFR3 |
5.271e-03 | -5.25 | carboxylic acid transmembrane transport | biological process | GO:1905039 | 131 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,SLC25A18 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
5.376e-03 | -5.23 | acetate biosynthetic process | biological process | GO:0019413 | 2 | 1 | 18204 | 49 |
ACSS1 |
5.376e-03 | -5.23 | regulation of neurofibrillary tangle assembly | biological process | GO:1902996 | 2 | 1 | 18204 | 49 |
CLU |
5.376e-03 | -5.23 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 49 |
CST3 |
5.376e-03 | -5.23 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 49 |
FGFR3 |
5.376e-03 | -5.23 | Wnt receptor catabolic process | biological process | GO:0038018 | 2 | 1 | 18204 | 49 |
ZNRF3 |
5.376e-03 | -5.23 | acetyl-CoA biosynthetic process from acetate | biological process | GO:0019427 | 2 | 1 | 18204 | 49 |
ACSS1 |
5.376e-03 | -5.23 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 49 |
CST3 |
5.376e-03 | -5.23 | propionate biosynthetic process | biological process | GO:0019542 | 2 | 1 | 18204 | 49 |
ACSS1 |
5.376e-03 | -5.23 | mesenchymal cell differentiation involved in bone development | biological process | GO:1901706 | 2 | 1 | 18204 | 49 |
RANBP3L |
5.376e-03 | -5.23 | lipid transport involved in lipid storage | biological process | GO:0010877 | 2 | 1 | 18204 | 49 |
APOE |
5.392e-03 | -5.22 | Clusterin_N | interpro domains | IPR016014 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Ac_CoA_lig | interpro domains | IPR011904 | 2 | 1 | 18521 | 50 |
ACSS1 |
5.392e-03 | -5.22 | Clusterin-like | interpro domains | IPR000753 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | ZNRF-3_ecto | interpro domains | IPR040700 | 2 | 1 | 18521 | 50 |
ZNRF3 |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | Clusterin_C | interpro domains | IPR016015 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Formin_Cappuccino_subfam | interpro domains | IPR001265 | 2 | 1 | 18521 | 50 |
FMN2 |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.440e-03 | -5.21 | sarcoplasmic reticulum membrane | cellular component | GO:0033017 | 43 | 2 | 19108 | 49 |
RYR3,CAMK2G |
5.493e-03 | -5.20 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 3 | 17795 | 49 |
FGFR3,NTRK2,BMPR1B |
5.500e-03 | -5.20 | Clusterin | pfam domains | PF01093 | 2 | 1 | 17795 | 49 |
CLU |
5.500e-03 | -5.20 | ZNRF_3_ecto | pfam domains | PF18212 | 2 | 1 | 17795 | 49 |
ZNRF3 |
5.545e-03 | -5.19 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
5.547e-03 | -5.19 | Ser-Thr/Tyr_kinase_cat_dom | interpro domains | IPR001245 | 133 | 3 | 18521 | 50 |
FGFR3,BMPR1B,NTRK2 |
5.565e-03 | -5.19 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 4 | 18204 | 49 |
ZNRF3,APOE,CTNND2,GPC5 |
5.612e-03 | -5.18 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 48 |
RYR3,GPM6A,TRPM3 |
5.706e-03 | -5.17 | triglyceride homeostasis | biological process | GO:0070328 | 42 | 2 | 18204 | 49 |
APOE,RORA |
5.729e-03 | -5.16 | organic acid transmembrane transport | biological process | GO:1903825 | 135 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,SLC25A18 |
5.755e-03 | -5.16 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 49 |
APOE,CTNND2,ZBTB20,NTRK2,LSAMP,CLU,TNIK,MSI2,TRPM3,PITPNC1,PREX2,RANBP3L,RYR3,GPM6A,NKAIN3,ATP13A4,SFXN5,SPARCL1,PAMR1,COL5A3,NRXN1,NPAS3,SLC25A18,SORBS1,CDH20,SLC1A2,GPC5,ZNRF3,NHSL1,ATP1A2,DTNA,FGFR3,HIF3A,NRG3,CAMK2G,BMPR1B,MACF1,SLC4A4,CPE,RORA,SLC1A3,NEBL,SOX5,ACSS1,FMN2,PTPRZ1,ABLIM1 |
5.755e-03 | -5.16 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 47 | 16828 | 49 |
NHSL1,ZNRF3,GPC5,SLC1A2,CDH20,SORBS1,SLC25A18,COL5A3,NPAS3,NRXN1,SPARCL1,PAMR1,NKAIN3,ATP13A4,SFXN5,RYR3,GPM6A,RANBP3L,PITPNC1,PREX2,TRPM3,MSI2,TNIK,LSAMP,CLU,ZBTB20,NTRK2,APOE,CTNND2,PTPRZ1,ABLIM1,FMN2,ACSS1,SOX5,NEBL,SLC1A3,CPE,RORA,SLC4A4,MACF1,CAMK2G,BMPR1B,NRG3,HIF3A,ATP1A2,DTNA,FGFR3 |
5.767e-03 | -5.16 | sarcolemma | cellular component | GO:0042383 | 142 | 3 | 19108 | 49 |
RYR3,DTNA,ATP1A2 |
5.806e-03 | -5.15 | tau protein binding | molecular function | GO:0048156 | 43 | 2 | 18094 | 48 |
APOE,CLU |
5.968e-03 | -5.12 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 4 | 16828 | 49 |
TNIK,ZNRF3,FGFR3,MACF1 |
5.974e-03 | -5.12 | acylglycerol homeostasis | biological process | GO:0055090 | 43 | 2 | 18204 | 49 |
APOE,RORA |
6.004e-03 | -5.12 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 5 | 18204 | 49 |
APOE,SLC1A3,RYR3,ATP13A4,ATP1A2 |
6.073e-03 | -5.10 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 44 |
RYR3 |
6.073e-03 | -5.10 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 44 |
CTNNA2 |
6.081e-03 | -5.10 | system process | biological process | GO:0003008 | 2015 | 12 | 18204 | 49 |
ATP1A2,APOE,PTPRZ1,SLC1A2,CTNNA2,ABLIM1,RYR3,NTRK2,SLC4A4,SLC1A3,NRXN1,DTNA |
6.088e-03 | -5.10 | regulation of generation of precursor metabolites and energy | biological process | GO:0043467 | 138 | 3 | 18204 | 49 |
SORBS1,ZBTB20,SLC4A4 |
6.224e-03 | -5.08 | cellular component organization | biological process | GO:0016043 | 5636 | 24 | 18204 | 49 |
NEBL,GPM6A,CLU,CTNNA2,COL5A3,CST3,TRPM3,PTPRZ1,NRG3,CTNND2,TNIK,SORBS1,PITPNC1,ABLIM1,FMN2,MACF1,SLC1A2,CDH20,APOE,SPARCL1,BMPR1B,NRXN1,PREX2,RYR3 |
6.247e-03 | -5.08 | positive regulation of glucose transmembrane transport | biological process | GO:0010828 | 44 | 2 | 18204 | 49 |
SORBS1,SLC1A2 |
6.272e-03 | -5.07 | DSCR9 (Down syndrome critical region 9) | protein interactions | 257203 | 146 | 3 | 19454 | 50 |
CLU,MACF1,SPARCL1 |
6.281e-03 | -5.07 | animal organ development | biological process | GO:0048513 | 2846 | 15 | 18204 | 49 |
RANBP3L,NTRK2,ABLIM1,FGFR3,RORA,COL5A3,CTNNA2,SLC1A2,GPM6A,NEBL,CPE,ATP1A2,BMPR1B,NRG3,SOX5 |
6.348e-03 | -5.06 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 4 | 19454 | 50 |
FMN2,SORBS1,NEBL,NHSL1 |
6.391e-03 | -5.05 | MOB4 (MOB family member 4, phocein) | protein interactions | 25843 | 147 | 3 | 19454 | 50 |
ABLIM1,CAMK2G,TNIK |
6.414e-03 | -5.05 | telencephalon development | biological process | GO:0021537 | 276 | 4 | 18204 | 49 |
ATP1A2,NRG3,NTRK2,SLC1A2 |
6.429e-03 | -5.05 | extremity | COSMIC cancer mutations | extremity | 1876 | 12 | 16828 | 49 |
ACSS1,NEBL,PTPRZ1,COL5A3,ATP13A4,PREX2,PITPNC1,NTRK2,FGFR3,FMN2,CDH20,RYR3 |
6.500e-03 | -5.04 | BDNF (brain derived neurotrophic factor) | protein interactions | 627 | 47 | 2 | 19454 | 50 |
CPE,NTRK2 |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
PTPRZ1,GPM6A |
6.550e-03 | -5.03 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 2 | 14470 | 44 |
NPAS3,HIF3A |
6.588e-03 | -5.02 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,SLC4A4 |
6.624e-03 | -5.02 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 49 |
SLC1A3,GPM6A,SLC4A4,TRPM3,ATP1A2,RYR3 |
6.660e-03 | -5.01 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 4 | 16828 | 49 |
FMN2,PTPRZ1,SLC4A4,ATP13A4 |
6.743e-03 | -5.00 | PFN1 (profilin 1) | protein interactions | 5216 | 466 | 5 | 19454 | 50 |
CAMK2G,ABLIM1,NHSL1,FMN2,MACF1 |
6.812e-03 | -4.99 | receptor clustering | biological process | GO:0043113 | 46 | 2 | 18204 | 49 |
APOE,NRXN1 |
6.875e-03 | -4.98 | Ig_3 | pfam domains | PF13927 | 141 | 3 | 17795 | 49 |
LSAMP,FGFR3,NTM |
6.881e-03 | -4.98 | TNIK (TRAF2 and NCK interacting kinase) | protein interactions | 23043 | 151 | 3 | 19454 | 50 |
TNIK,CLU,MACF1 |
6.941e-03 | -4.97 | bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | bronchioloalveolar_adenocarcinoma | 778 | 7 | 16828 | 49 |
TNIK,CAMK2G,BMPR1B,SOX5,FGFR3,CTNND2,NTRK2 |
6.941e-03 | -4.97 | lung-carcinoma-bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-bronchioloalveolar_adenocarcinoma | 778 | 7 | 16828 | 49 |
CTNND2,FGFR3,NTRK2,CAMK2G,BMPR1B,TNIK,SOX5 |
7.103e-03 | -4.95 | regulation of neuron migration | biological process | GO:2001222 | 47 | 2 | 18204 | 49 |
NRG3,CTNNA2 |
7.144e-03 | -4.94 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 4 | 18094 | 48 |
SLC4A4,SLC1A3,SLC25A18,SLC1A2 |
7.209e-03 | -4.93 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.209e-03 | -4.93 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.306e-03 | -4.92 | Statin Pathway | WikiPathways | WP430 | 33 | 2 | 5310 | 21 |
APOE,ACSS1 |
7.396e-03 | -4.91 | CLa | smart domains | SM00035 | 2 | 1 | 9717 | 36 |
CLU |
7.396e-03 | -4.91 | CLb | smart domains | SM00030 | 2 | 1 | 9717 | 36 |
CLU |
7.404e-03 | -4.91 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 4 | 16828 | 49 |
SOX5,RYR3,APOE,CDH20 |
7.426e-03 | -4.90 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 44 |
ATP1A2,ATP13A4 |
7.456e-03 | -4.90 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 9 | 16828 | 49 |
LSAMP,TNIK,GPC5,RANBP3L,SOX5,CTNND2,NKAIN3,NRG3,RORA |
7.519e-03 | -4.89 | neuromuscular process | biological process | GO:0050905 | 149 | 3 | 18204 | 49 |
NRXN1,SLC1A3,CTNNA2 |
7.592e-03 | -4.88 | enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
ZNRF3,MACF1 |
7.592e-03 | -4.88 | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
ZNRF3,MACF1 |
7.617e-03 | -4.88 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 50 |
NHSL1,MACF1 |
7.688e-03 | -4.87 | Retinoid metabolism and transport | REACTOME pathways | R-HSA-975634 | 44 | 2 | 10285 | 31 |
GPC5,APOE |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 50 |
NRXN1 |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Lrrc7 (leucine rich repeat containing 7) | protein interactions | 117284 | 3 | 1 | 19454 | 50 |
CAMK2G |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | Lep (leptin) | protein interactions | 16846 | 3 | 1 | 19454 | 50 |
CLU |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.700e-03 | -4.87 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 3 | 16828 | 49 |
GPC5,FGFR3,NRG3 |
7.720e-03 | -4.86 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 10 | 16828 | 49 |
SLC4A4,CTNND2,RYR3,TRPM3,FMN2,SORBS1,NRXN1,LSAMP,GPC5,TNIK |
7.750e-03 | -4.86 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 21 | 16828 | 49 |
PREX2,TRPM3,FMN2,ABLIM1,NHSL1,PTPRZ1,RANBP3L,MACF1,ZNRF3,HIF3A,NRG3,GPM6A,CTNND2,RYR3,FGFR3,DTNA,ATP1A2,SOX5,ACSS1,CLU,SLC1A3 |
7.750e-03 | -4.86 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 21 | 16828 | 49 |
TRPM3,FMN2,PREX2,ZNRF3,MACF1,NHSL1,ABLIM1,PTPRZ1,RANBP3L,DTNA,FGFR3,ATP1A2,GPM6A,CTNND2,RYR3,NRG3,HIF3A,SLC1A3,CLU,ACSS1,SOX5 |
7.847e-03 | -4.85 | protein localization to membrane | biological process | GO:0072657 | 462 | 5 | 18204 | 49 |
NRXN1,MACF1,CPE,APOE,TNIK |
7.909e-03 | -4.84 | SH2B2 (SH2B adaptor protein 2) | protein interactions | 10603 | 52 | 2 | 19454 | 50 |
NTRK2,SORBS1 |
7.928e-03 | -4.84 | TYRO3 (TYRO3 protein tyrosine kinase) | protein interactions | 7301 | 159 | 3 | 19454 | 50 |
CLU,SLC1A3,APOE |
7.938e-03 | -4.84 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 48 |
SLC1A2 |
7.987e-03 | -4.83 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 5 | 18204 | 49 |
ATP1A2,RYR3,SLC1A3,SLC1A2,RORA |
8.020e-03 | -4.83 | FORMIN | prints domains | PR00828 | 2 | 1 | 5227 | 21 |
FMN2 |
8.054e-03 | -4.82 | very-low-density lipoprotein particle clearance | biological process | GO:0034447 | 3 | 1 | 18204 | 49 |
APOE |
8.054e-03 | -4.82 | formin-nucleated actin cable assembly | biological process | GO:0070649 | 3 | 1 | 18204 | 49 |
FMN2 |
8.054e-03 | -4.82 | meiotic chromosome movement towards spindle pole | biological process | GO:0016344 | 3 | 1 | 18204 | 49 |
FMN2 |
8.054e-03 | -4.82 | protein targeting to lysosome involved in chaperone-mediated autophagy | biological process | GO:0061740 | 3 | 1 | 18204 | 49 |
CLU |
8.054e-03 | -4.82 | trans-synaptic signaling by BDNF, modulating synaptic transmission | biological process | GO:0099183 | 3 | 1 | 18204 | 49 |
NTRK2 |
8.054e-03 | -4.82 | mammary placode formation | biological process | GO:0060596 | 3 | 1 | 18204 | 49 |
NRG3 |
8.054e-03 | -4.82 | immune complex clearance | biological process | GO:0002434 | 3 | 1 | 18204 | 49 |
CLU |
8.054e-03 | -4.82 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | cardiac muscle thin filament assembly | biological process | GO:0071691 | 3 | 1 | 18204 | 49 |
NEBL |
8.054e-03 | -4.82 | acetate metabolic process | biological process | GO:0006083 | 3 | 1 | 18204 | 49 |
ACSS1 |
8.054e-03 | -4.82 | formin-nucleated actin cable organization | biological process | GO:0110009 | 3 | 1 | 18204 | 49 |
FMN2 |
8.054e-03 | -4.82 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 49 |
NRXN1 |
8.054e-03 | -4.82 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 49 |
ATP1A2 |
8.054e-03 | -4.82 | positive regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032805 | 3 | 1 | 18204 | 49 |
APOE |
8.054e-03 | -4.82 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 49 |
CTNNA2 |
8.061e-03 | -4.82 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 5 | 16828 | 49 |
BMPR1B,TNIK,CAMK2G,FGFR3,NTRK2 |
8.061e-03 | -4.82 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 5 | 16828 | 49 |
NTRK2,FGFR3,TNIK,BMPR1B,CAMK2G |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NTRK_LRRCT | interpro domains | IPR031635 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 50 |
HIF3A |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 50 |
RORA |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | NTRK | interpro domains | IPR020777 | 3 | 1 | 18521 | 50 |
NTRK2 |
8.078e-03 | -4.82 | Neuregulin | interpro domains | IPR040180 | 3 | 1 | 18521 | 50 |
NRG3 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SoHo_dom | interpro domains | IPR003127 | 3 | 1 | 18521 | 50 |
SORBS1 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.100e-03 | -4.82 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 4 | 19454 | 50 |
DTNA,SORBS1,MACF1,NRXN1 |
8.172e-03 | -4.81 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 4 | 18204 | 49 |
PTPRZ1,NRXN1,MACF1,NTRK2 |
8.230e-03 | -4.80 | learning | biological process | GO:0007612 | 154 | 3 | 18204 | 49 |
NTRK2,ATP1A2,NRXN1 |
8.238e-03 | -4.80 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 49 |
GPM6A |
8.238e-03 | -4.80 | Sorb | pfam domains | PF02208 | 3 | 1 | 17795 | 49 |
SORBS1 |
8.238e-03 | -4.80 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 49 |
HIF3A |
8.238e-03 | -4.80 | LRRCT_2 | pfam domains | PF16920 | 3 | 1 | 17795 | 49 |
NTRK2 |
8.238e-03 | -4.80 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 49 |
MACF1 |
8.320e-03 | -4.79 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 49 |
NRXN1,SLC1A3 |
8.446e-03 | -4.77 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 21 |
ATP13A4,ATP1A2 |
8.525e-03 | -4.76 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 3 | 18204 | 49 |
NTRK2,BMPR1B,GPM6A |
8.585e-03 | -4.76 | regulation of signaling | biological process | GO:0023051 | 3534 | 17 | 18204 | 49 |
APOE,BMPR1B,ATP1A2,NRG3,CLU,ZNRF3,MACF1,FGFR3,SORBS1,RORA,PREX2,CTNND2,SLC1A3,NRXN1,GPC5,TNIK,NTRK2 |
8.613e-03 | -4.75 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 20 | 16828 | 49 |
TRPM3,ZNRF3,GPC5,MACF1,PTPRZ1,ATP1A2,DTNA,FGFR3,RYR3,CTNND2,SPARCL1,CPE,HIF3A,ATP13A4,TNIK,LSAMP,COL5A3,NRXN1,ACSS1,SOX5 |
8.638e-03 | -4.75 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
8.638e-03 | -4.75 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
8.638e-03 | -4.75 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
8.675e-03 | -4.75 | positive regulation of synaptic transmission | biological process | GO:0050806 | 157 | 3 | 18204 | 49 |
NTRK2,NRXN1,SLC1A3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.712e-03 | -4.74 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
8.730e-03 | -4.74 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 31 |
CAMK2G,ATP1A2,RYR3 |
8.748e-03 | -4.74 | ZYX (zyxin) | protein interactions | 7791 | 316 | 4 | 19454 | 50 |
ABLIM1,SORBS1,NEBL,MACF1 |
8.758e-03 | -4.74 | regulation of cell communication | biological process | GO:0010646 | 3541 | 17 | 18204 | 49 |
CLU,MACF1,ZNRF3,APOE,BMPR1B,ATP1A2,NRG3,CTNND2,NRXN1,SLC1A3,GPC5,TNIK,NTRK2,FGFR3,SORBS1,RORA,PREX2 |
8.772e-03 | -4.74 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 5 | 16828 | 49 |
BMPR1B,TNIK,CAMK2G,FGFR3,NTRK2 |
8.814e-03 | -4.73 | SYN1 (synapsin I) | protein interactions | 6853 | 55 | 2 | 19454 | 50 |
GPM6A,CAMK2G |
8.917e-03 | -4.72 | SCLT1 (sodium channel and clathrin linker 1) | protein interactions | 132320 | 166 | 3 | 19454 | 50 |
NEBL,ATP1A2,ABLIM1 |
8.962e-03 | -4.71 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 2 | 18204 | 49 |
BMPR1B,SOX5 |
8.962e-03 | -4.71 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
8.979e-03 | -4.71 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 49 |
SLC4A4,SLC1A2,SLC1A3 |
9.053e-03 | -4.70 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 7 | 19454 | 50 |
APOE,NHSL1,CTNNA2,DTNA,PTPRZ1,SORBS1,CTNND2 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 44 |
CTNNA2 |
9.095e-03 | -4.70 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 44 |
RYR3 |
9.147e-03 | -4.69 | presynaptic membrane | cellular component | GO:0042734 | 168 | 3 | 19108 | 49 |
GPM6A,NRXN1,SLC1A2 |
9.191e-03 | -4.69 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 4 | 14470 | 44 |
SPARCL1,MACF1,DTNA,RYR3 |
9.290e-03 | -4.68 | negative regulation of supramolecular fiber organization | biological process | GO:1902904 | 161 | 3 | 18204 | 49 |
APOE,CTNNA2,CLU |
9.303e-03 | -4.68 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 5 | 18521 | 50 |
NTRK2,TNIK,CAMK2G,FGFR3,BMPR1B |
9.442e-03 | -4.66 | NXPH3 (neurexophilin 3) | protein interactions | 11248 | 57 | 2 | 19454 | 50 |
CTNNA2,NRXN1 |
9.613e-03 | -4.64 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 2 | 5310 | 21 |
SLC1A2,CST3 |
9.616e-03 | -4.64 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 48 | 16828 | 49 |
APOE,CTNND2,ZBTB20,NTRK2,TNIK,LSAMP,CLU,MSI2,TRPM3,PITPNC1,PREX2,NTM,RANBP3L,RYR3,GPM6A,SPARCL1,PAMR1,NKAIN3,ATP13A4,SFXN5,SLC25A18,NRXN1,NPAS3,COL5A3,SORBS1,SLC1A2,CDH20,ZNRF3,GPC5,NHSL1,ATP1A2,DTNA,FGFR3,NRG3,HIF3A,CAMK2G,BMPR1B,MACF1,CPE,RORA,SLC4A4,SLC1A3,ACSS1,SOX5,NEBL,FMN2,PTPRZ1,ABLIM1 |
9.625e-03 | -4.64 | intermembrane lipid transfer | biological process | GO:0120009 | 55 | 2 | 18204 | 49 |
PITPNC1,APOE |
9.625e-03 | -4.64 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
9.634e-03 | -4.64 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 49 | 16828 | 49 |
NHSL1,GPC5,ZNRF3,CDH20,SLC1A2,SORBS1,NRXN1,NPAS3,COL5A3,SLC25A18,ATP13A4,SFXN5,NKAIN3,PAMR1,SPARCL1,GPM6A,RYR3,RANBP3L,PREX2,PITPNC1,NTM,TRPM3,MSI2,LSAMP,CLU,TNIK,NTRK2,ZBTB20,CTNND2,APOE,ABLIM1,PTPRZ1,FMN2,NEBL,SOX5,ACSS1,SLC1A3,SLC4A4,RORA,CPE,MACF1,CST3,CAMK2G,BMPR1B,HIF3A,NRG3,FGFR3,DTNA,ATP1A2 |
9.687e-03 | -4.64 | lipid transfer activity | molecular function | GO:0120013 | 56 | 2 | 18094 | 48 |
PITPNC1,APOE |
9.751e-03 | -4.63 | dendritic spine | cellular component | GO:0043197 | 172 | 3 | 19108 | 49 |
ATP1A2,NTRK2,GPM6A |
9.763e-03 | -4.63 | CILK1 (ciliogenesis associated kinase 1) | protein interactions | 22858 | 58 | 2 | 19454 | 50 |
MSI2,CAMK2G |
9.767e-03 | -4.63 | negative regulation of neuron apoptotic process | biological process | GO:0043524 | 164 | 3 | 18204 | 49 |
PTPRZ1,CLU,NTRK2 |
9.847e-03 | -4.62 | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 6023 | 26 | 16828 | 49 |
SLC1A3,COL5A3,NPAS3,SOX5,NEBL,RYR3,SPARCL1,PAMR1,RORA,SLC4A4,NKAIN3,ATP13A4,PTPRZ1,ABLIM1,CAMK2G,ATP1A2,FGFR3,DTNA,CTNND2,NRG3,ZBTB20,NTRK2,CST3,MACF1,TRPM3,PREX2 |
9.871e-03 | -4.62 | cell-cell junction | cellular component | GO:0005911 | 513 | 5 | 19108 | 49 |
SORBS1,ATP1A2,CTNNA2,CDH20,CTNND2 |
9.929e-03 | -4.61 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,ATP1A2 |
1.006e-02 | -4.60 | neuron spine | cellular component | GO:0044309 | 174 | 3 | 19108 | 49 |
ATP1A2,NTRK2,GPM6A |
1.009e-02 | -4.60 | VEGFA (vascular endothelial growth factor A) | protein interactions | 7422 | 59 | 2 | 19454 | 50 |
PTPRZ1,CLU |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
CTNNA2,CDH20,DTNA |
1.022e-02 | -4.58 | collagen type V trimer | cellular component | GO:0005588 | 4 | 1 | 19108 | 49 |
COL5A3 |
1.022e-02 | -4.58 | intermediate-density lipoprotein particle | cellular component | GO:0034363 | 4 | 1 | 19108 | 49 |
APOE |
1.023e-02 | -4.58 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 31 |
SLC1A2,SLC1A3 |
1.023e-02 | -4.58 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 5 | 16828 | 49 |
BMPR1B,TNIK,CAMK2G,FGFR3,NTRK2 |
1.024e-02 | -4.58 | CALML4 (calmodulin like 4) | protein interactions | 91860 | 4 | 1 | 19454 | 50 |
CAMK2G |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 50 |
RORA |
1.031e-02 | -4.57 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 49 |
ATP1A2,SLC1A2 |
1.032e-02 | -4.57 | cellular component organization or biogenesis | biological process | GO:0071840 | 5850 | 24 | 18204 | 49 |
BMPR1B,APOE,SPARCL1,FMN2,MACF1,SLC1A2,CDH20,PREX2,RYR3,NRXN1,NRG3,TRPM3,PTPRZ1,CST3,COL5A3,NEBL,GPM6A,CLU,CTNNA2,PITPNC1,ABLIM1,SORBS1,TNIK,CTNND2 |
1.032e-02 | -4.57 | SLC-mediated transmembrane transport | REACTOME pathways | R-HSA-425407 | 287 | 4 | 10285 | 31 |
SLC1A3,SLC1A2,SLC25A18,SLC4A4 |
1.037e-02 | -4.57 | cellular component biogenesis | biological process | GO:0044085 | 2716 | 14 | 18204 | 49 |
FMN2,NEBL,CDH20,SLC1A2,GPM6A,CLU,TRPM3,APOE,NRG3,NRXN1,TNIK,SORBS1,RYR3,ABLIM1 |
1.042e-02 | -4.56 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 5 | 16828 | 49 |
FGFR3,TNIK,CAMK2G,BMPR1B,NTRK2 |
1.042e-02 | -4.56 | ITGA8 (integrin subunit alpha 8) | protein interactions | 8516 | 60 | 2 | 19454 | 50 |
CLU,ZNRF3 |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
DTNA,FGFR3 |
1.057e-02 | -4.55 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 48 |
RYR3 |
1.057e-02 | -4.55 | brain-derived neurotrophic factor binding | molecular function | GO:0048403 | 4 | 1 | 18094 | 48 |
NTRK2 |
1.057e-02 | -4.55 | acetate-CoA ligase activity | molecular function | GO:0003987 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.057e-02 | -4.55 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | very-low-density lipoprotein particle receptor binding | molecular function | GO:0070326 | 4 | 1 | 18094 | 48 |
APOE |
1.057e-02 | -4.55 | propionate-CoA ligase activity | molecular function | GO:0050218 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.057e-02 | -4.55 | short-chain fatty acid-CoA ligase activity | molecular function | GO:0031955 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.061e-02 | -4.55 | SYNPO (synaptopodin) | protein interactions | 11346 | 177 | 3 | 19454 | 50 |
ABLIM1,CAMK2G,ZBTB20 |
1.072e-02 | -4.54 | regulation of phospholipid efflux | biological process | GO:1902994 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | short-chain fatty acid biosynthetic process | biological process | GO:0051790 | 4 | 1 | 18204 | 49 |
ACSS1 |
1.072e-02 | -4.54 | malate-aspartate shuttle | biological process | GO:0043490 | 4 | 1 | 18204 | 49 |
SLC25A18 |
1.072e-02 | -4.54 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 49 |
SOX5 |
1.072e-02 | -4.54 | positive regulation of inclusion body assembly | biological process | GO:0090261 | 4 | 1 | 18204 | 49 |
CLU |
1.072e-02 | -4.54 | NMDA glutamate receptor clustering | biological process | GO:0097114 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | trans-synaptic signaling by BDNF | biological process | GO:0099191 | 4 | 1 | 18204 | 49 |
NTRK2 |
1.072e-02 | -4.54 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 49 |
CST3 |
1.072e-02 | -4.54 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 49 |
CPE |
1.072e-02 | -4.54 | positive regulation of phospholipid efflux | biological process | GO:1902995 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 49 |
ATP1A2 |
1.072e-02 | -4.54 | brain-derived neurotrophic factor receptor signaling pathway | biological process | GO:0031547 | 4 | 1 | 18204 | 49 |
NTRK2 |
1.072e-02 | -4.54 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 49 |
BMPR1B |
1.072e-02 | -4.54 | response to caloric restriction | biological process | GO:0061771 | 4 | 1 | 18204 | 49 |
APOE |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | ACAS_N | interpro domains | IPR032387 | 4 | 1 | 18521 | 50 |
ACSS1 |
1.076e-02 | -4.53 | TRPM_tetra_sf | interpro domains | IPR037162 | 4 | 1 | 18521 | 50 |
TRPM3 |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | ApoA_E | interpro domains | IPR000074 | 4 | 1 | 18521 | 50 |
APOE |
1.076e-02 | -4.53 | TRPM_tetra | interpro domains | IPR032415 | 4 | 1 | 18521 | 50 |
TRPM3 |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | Ca/CaM-dep_prot_kinase-assoc | interpro domains | IPR013543 | 4 | 1 | 18521 | 50 |
CAMK2G |
1.076e-02 | -4.53 | Nebulin_repeat | interpro domains | IPR000900 | 4 | 1 | 18521 | 50 |
NEBL |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.079e-02 | -4.53 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 44 |
GPM6A |
1.079e-02 | -4.53 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 44 |
GPM6A |
1.079e-02 | -4.53 | SOHO | prosite domains | PS50831 | 3 | 1 | 12186 | 44 |
SORBS1 |
1.079e-02 | -4.53 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 44 |
CTNNA2 |
1.090e-02 | -4.52 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 6 | 16828 | 49 |
CAMK2G,BMPR1B,TNIK,PREX2,NTRK2,FGFR3 |
1.097e-02 | -4.51 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | Nebulin | pfam domains | PF00880 | 4 | 1 | 17795 | 49 |
NEBL |
1.097e-02 | -4.51 | Apolipoprotein | pfam domains | PF01442 | 4 | 1 | 17795 | 49 |
APOE |
1.097e-02 | -4.51 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 49 |
NKAIN3 |
1.097e-02 | -4.51 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 49 |
ABLIM1 |
1.097e-02 | -4.51 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 49 |
MACF1 |
1.097e-02 | -4.51 | TRPM_tetra | pfam domains | PF16519 | 4 | 1 | 17795 | 49 |
TRPM3 |
1.097e-02 | -4.51 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 49 |
NHSL1 |
1.097e-02 | -4.51 | CaMKII_AD | pfam domains | PF08332 | 4 | 1 | 17795 | 49 |
CAMK2G |
1.097e-02 | -4.51 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 49 |
ATP13A4 |
1.097e-02 | -4.51 | ACAS_N | pfam domains | PF16177 | 4 | 1 | 17795 | 49 |
ACSS1 |
1.097e-02 | -4.51 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 49 |
MACF1 |
1.098e-02 | -4.51 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 5 | 16828 | 49 |
NTRK2,FGFR3,TNIK,BMPR1B,CAMK2G |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
FMN2,PTPRZ1,ABLIM1,CPE,RORA,SLC4A4,SLC1A3,ACSS1,NEBL,SOX5,CST3,MACF1,ATP1A2,DTNA,FGFR3,NRG3,HIF3A,BMPR1B,CAMK2G,SLC1A2,CDH20,GPC5,ZNRF3,NHSL1,RYR3,GPM6A,SPARCL1,PAMR1,NKAIN3,SFXN5,ATP13A4,SLC25A18,COL5A3,NRXN1,NPAS3,SORBS1,TRPM3,PITPNC1,PREX2,NTM,RANBP3L,APOE,CTNND2,ZBTB20,NTRK2,TNIK,CLU,LSAMP,MSI2 |
1.101e-02 | -4.51 | Metabolism of fat-soluble vitamins | REACTOME pathways | R-HSA-6806667 | 53 | 2 | 10285 | 31 |
APOE,GPC5 |
1.101e-02 | -4.51 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 49 |
BMPR1B,FGFR3 |
1.107e-02 | -4.50 | Sorb | smart domains | SM00459 | 3 | 1 | 9717 | 36 |
SORBS1 |
1.107e-02 | -4.50 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 36 |
GPM6A |
1.113e-02 | -4.50 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 5 | 12186 | 44 |
CAMK2G,BMPR1B,TNIK,FGFR3,NTRK2 |
1.113e-02 | -4.50 | cell migration | biological process | GO:0016477 | 921 | 7 | 18204 | 49 |
NTRK2,GPC5,FMN2,CTNNA2,GPM6A,CDH20,NRG3 |
1.118e-02 | -4.49 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 4 | 16828 | 49 |
PAMR1,MACF1,RYR3,GPC5 |
1.121e-02 | -4.49 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 7 | 19454 | 50 |
FGFR3,MACF1,PITPNC1,SORBS1,CAMK2G,ABLIM1,NHSL1 |
1.128e-02 | -4.48 | cartilage development | biological process | GO:0051216 | 173 | 3 | 18204 | 49 |
FGFR3,SOX5,BMPR1B |
1.134e-02 | -4.48 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 36 |
NTRK2,LSAMP,FGFR3,NTM |
1.137e-02 | -4.48 | transmission of nerve impulse | biological process | GO:0019226 | 60 | 2 | 18204 | 49 |
NTRK2,ATP1A2 |
1.137e-02 | -4.48 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 49 |
SLC4A4,ATP1A2 |
1.137e-02 | -4.48 | regulation of glucose import | biological process | GO:0046324 | 60 | 2 | 18204 | 49 |
SLC1A2,SORBS1 |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.144e-02 | -4.47 | NLGN2 (neuroligin 2) | protein interactions | 57555 | 63 | 2 | 19454 | 50 |
CLU,NRXN1 |
1.148e-02 | -4.47 | regulation of lipid metabolic process | biological process | GO:0019216 | 327 | 4 | 18204 | 49 |
APOE,ZBTB20,RORA,SORBS1 |
1.153e-02 | -4.46 | circulatory system process | biological process | GO:0003013 | 508 | 5 | 18204 | 49 |
SLC4A4,APOE,SLC1A3,SLC1A2,ATP1A2 |
1.153e-02 | -4.46 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 9 | 18204 | 49 |
NTRK2,SLC1A3,SLC1A2,ATP1A2,BMPR1B,RYR3,FGFR3,SOX5,SORBS1 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.171e-02 | -4.45 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 40 | 16828 | 49 |
CDH20,FMN2,SLC1A2,PTPRZ1,NHSL1,ABLIM1,GPC5,SLC4A4,NKAIN3,SFXN5,ATP13A4,CPE,SPARCL1,PAMR1,RORA,RYR3,NEBL,SOX5,ACSS1,COL5A3,NPAS3,NRXN1,SLC1A3,PREX2,NTM,TRPM3,RANBP3L,MACF1,HIF3A,NTRK2,NRG3,CTNND2,ATP1A2,DTNA,FGFR3,MSI2,LSAMP,TNIK,BMPR1B,CAMK2G |
1.178e-02 | -4.44 | transmembrane receptor protein tyrosine kinase activity | molecular function | GO:0004714 | 62 | 2 | 18094 | 48 |
NTRK2,FGFR3 |
1.182e-02 | -4.44 | central nervous system neuron differentiation | biological process | GO:0021953 | 176 | 3 | 18204 | 49 |
RORA,NTRK2,BMPR1B |
1.184e-02 | -4.44 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 48 |
CTNNA2,CDH20,MACF1,CTNND2 |
1.201e-02 | -4.42 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 21 |
RORA |
1.201e-02 | -4.42 | NTKRECEPTOR | prints domains | PR01939 | 3 | 1 | 5227 | 21 |
NTRK2 |
1.201e-02 | -4.42 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 21 |
RYR3 |
1.201e-02 | -4.42 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 21 |
GPM6A |
1.205e-02 | -4.42 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 20 | 19454 | 50 |
ACSS1,CST3,NTM,CTNNA2,TNIK,CLU,GPM6A,PITPNC1,MACF1,ATP1A2,SLC1A3,DTNA,CTNND2,APOE,LSAMP,SLC4A4,CAMK2G,PTPRZ1,SLC25A18,MSI2 |
1.211e-02 | -4.41 | TRPM, tetramerisation domain | gene3d domains | 1.20.5.1010 | 4 | 1 | 14470 | 44 |
TRPM3 |
1.211e-02 | -4.41 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 44 |
MACF1 |
1.211e-02 | -4.41 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.216e-02 | -4.41 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 5 | 16828 | 49 |
RYR3,MACF1,GPM6A,GPC5,PAMR1 |
1.219e-02 | -4.41 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 9 | 16828 | 49 |
SORBS1,NPAS3,MACF1,COL5A3,ZBTB20,SLC4A4,NTM,ATP1A2,TRPM3 |
1.221e-02 | -4.41 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 7 | 16828 | 49 |
FGFR3,PREX2,NTRK2,MACF1,CAMK2G,TNIK,BMPR1B |
1.228e-02 | -4.40 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 6 | 16828 | 49 |
FGFR3,TNIK,CAMK2G,BMPR1B,NTRK2,SPARCL1 |
1.237e-02 | -4.39 | lipid homeostasis | biological process | GO:0055088 | 179 | 3 | 18204 | 49 |
RORA,APOE,ZBTB20 |
1.249e-02 | -4.38 | regulation of nitric oxide biosynthetic process | biological process | GO:0045428 | 63 | 2 | 18204 | 49 |
APOE,CLU |
1.249e-02 | -4.38 | back | COSMIC cancer mutations | back | 310 | 4 | 16828 | 49 |
PREX2,FGFR3,ATP1A2,TNIK |
1.262e-02 | -4.37 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 6 | 16828 | 49 |
FGFR3,NTRK2,SPARCL1,CAMK2G,TNIK,BMPR1B |
1.265e-02 | -4.37 | brain development | biological process | GO:0007420 | 724 | 6 | 18204 | 49 |
RORA,NRG3,ATP1A2,SLC1A2,CTNNA2,NTRK2 |
1.276e-02 | -4.36 | calcium- and calmodulin-dependent protein kinase complex | cellular component | GO:0005954 | 5 | 1 | 19108 | 49 |
CAMK2G |
1.276e-02 | -4.36 | neurofibrillary tangle | cellular component | GO:0097418 | 5 | 1 | 19108 | 49 |
CLU |
1.279e-02 | -4.36 | TRPM6 (transient receptor potential cation channel subfamily M member 6) | protein interactions | 140803 | 5 | 1 | 19454 | 50 |
TRPM3 |
1.279e-02 | -4.36 | CAMK2N2 (calcium/calmodulin dependent protein kinase II inhibitor 2) | protein interactions | 94032 | 5 | 1 | 19454 | 50 |
CAMK2G |
1.279e-02 | -4.36 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 50 |
NRXN1 |
1.279e-02 | -4.36 | EPPIN (epididymal peptidase inhibitor) | protein interactions | 57119 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | SLC10A3 (solute carrier family 10 member 3) | protein interactions | 8273 | 5 | 1 | 19454 | 50 |
SORBS1 |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | ADCYAP1R1 (ADCYAP receptor type I) | protein interactions | 117 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | TRH (thyrotropin releasing hormone) | protein interactions | 7200 | 5 | 1 | 19454 | 50 |
CPE |
1.287e-02 | -4.35 | actin filament bundle assembly | biological process | GO:0051017 | 64 | 2 | 18204 | 49 |
SORBS1,FMN2 |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
NHSL1,GPC5,ZNRF3,SLC1A2,CDH20,SORBS1,SLC25A18,COL5A3,NPAS3,NRXN1,PAMR1,SPARCL1,SFXN5,NKAIN3,ATP13A4,GPM6A,RYR3,RANBP3L,PREX2,NTM,PITPNC1,TRPM3,MSI2,TNIK,LSAMP,CLU,NTRK2,ZBTB20,CTNND2,APOE,ABLIM1,PTPRZ1,FMN2,ACSS1,NEBL,SOX5,SLC1A3,RORA,CPE,SLC4A4,CST3,MACF1,CAMK2G,BMPR1B,NRG3,HIF3A,FGFR3,ATP1A2 |
1.304e-02 | -4.34 | SH3_9 | pfam domains | PF14604 | 63 | 2 | 17795 | 49 |
SORBS1,NEBL |
1.313e-02 | -4.33 | Kinase-like_dom_sf | interpro domains | IPR011009 | 523 | 5 | 18521 | 50 |
TNIK,NTRK2,CAMK2G,FGFR3,BMPR1B |
1.320e-02 | -4.33 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 1 | 18094 | 48 |
NRXN1 |
1.320e-02 | -4.33 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 48 |
FGFR3 |
1.320e-02 | -4.33 | neurotrophin receptor activity | molecular function | GO:0005030 | 5 | 1 | 18094 | 48 |
NTRK2 |
1.320e-02 | -4.33 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 48 |
BMPR1B |
1.323e-02 | -4.33 | CXADR (CXADR Ig-like cell adhesion molecule) | protein interactions | 1525 | 357 | 4 | 19454 | 50 |
TNIK,SORBS1,NEBL,MACF1 |
1.325e-02 | -4.32 | positive regulation of synapse assembly | biological process | GO:0051965 | 65 | 2 | 18204 | 49 |
NTRK2,NRXN1 |
1.325e-02 | -4.32 | regulation of nitric oxide metabolic process | biological process | GO:0080164 | 65 | 2 | 18204 | 49 |
CLU,APOE |
1.328e-02 | -4.32 | signal transduction | biological process | GO:0007165 | 4637 | 20 | 18204 | 49 |
APOE,SPARCL1,NRG3,ATP1A2,BMPR1B,ZNRF3,FMN2,MACF1,CPE,CLU,RORA,SORBS1,FGFR3,PITPNC1,PREX2,RYR3,DTNA,CTNND2,NTRK2,TNIK |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.339e-02 | -4.31 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 49 |
SFXN5 |
1.339e-02 | -4.31 | glutamate receptor clustering | biological process | GO:0097688 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 49 |
ATP1A2 |
1.339e-02 | -4.31 | chylomicron remnant clearance | biological process | GO:0034382 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | central nervous system myelin maintenance | biological process | GO:0032286 | 5 | 1 | 18204 | 49 |
CLU |
1.339e-02 | -4.31 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 49 |
SFXN5 |
1.339e-02 | -4.31 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 49 |
NRXN1 |
1.339e-02 | -4.31 | synaptic signaling via neuropeptide | biological process | GO:0099538 | 5 | 1 | 18204 | 49 |
NTRK2 |
1.339e-02 | -4.31 | positive regulation of dendritic spine maintenance | biological process | GO:1902952 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | polar body extrusion after meiotic divisions | biological process | GO:0040038 | 5 | 1 | 18204 | 49 |
FMN2 |
1.339e-02 | -4.31 | AMPA glutamate receptor clustering | biological process | GO:0097113 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | propionate metabolic process | biological process | GO:0019541 | 5 | 1 | 18204 | 49 |
ACSS1 |
1.339e-02 | -4.31 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 49 |
BMPR1B |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 50 |
SFXN5 |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
RANBP3L,NTM,PREX2,TRPM3,MSI2,LSAMP,CLU,TNIK,NTRK2,ZBTB20,CTNND2,APOE,NHSL1,GPC5,ZNRF3,CDH20,SLC1A2,SORBS1,NRXN1,COL5A3,NPAS3,SLC25A18,ATP13A4,NKAIN3,SFXN5,PAMR1,SPARCL1,GPM6A,RYR3,MACF1,CST3,CAMK2G,BMPR1B,HIF3A,NRG3,FGFR3,DTNA,ATP1A2,ABLIM1,PTPRZ1,FMN2,NEBL,SOX5,ACSS1,SLC1A3,SLC4A4,RORA,CPE |
1.369e-02 | -4.29 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 49 |
PITPNC1 |
1.369e-02 | -4.29 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 49 |
SPARCL1 |
1.369e-02 | -4.29 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 49 |
SFXN5 |
1.369e-02 | -4.29 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 49 |
CTNNA2 |
1.404e-02 | -4.27 | cholesterol transport | biological process | GO:0030301 | 67 | 2 | 18204 | 49 |
APOE,CLU |
1.404e-02 | -4.27 | collagen binding | molecular function | GO:0005518 | 68 | 2 | 18094 | 48 |
SPARCL1,COL5A3 |
1.410e-02 | -4.26 | signal release | biological process | GO:0023061 | 188 | 3 | 18204 | 49 |
NRXN1,CPE,CAMK2G |
1.412e-02 | -4.26 | membrane protein complex | cellular component | GO:0098796 | 1261 | 8 | 19108 | 49 |
SLC1A3,SLC1A2,RYR3,CDH20,BMPR1B,CTNNA2,ATP1A2,SORBS1 |
1.424e-02 | -4.25 | EGF | pfam domains | PF00008 | 66 | 2 | 17795 | 49 |
NRXN1,PAMR1 |
1.429e-02 | -4.25 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 12 | 16828 | 49 |
PREX2,NTRK2,SLC4A4,FGFR3,DTNA,ATP1A2,SOX5,PTPRZ1,TNIK,CAMK2G,BMPR1B,SLC25A18 |
1.430e-02 | -4.25 | regulation of lipid biosynthetic process | biological process | GO:0046890 | 189 | 3 | 18204 | 49 |
APOE,ZBTB20,SORBS1 |
1.437e-02 | -4.24 | NEBULIN | prosite domains | PS51216 | 4 | 1 | 12186 | 44 |
NEBL |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
GPM6A,TNIK |
1.444e-02 | -4.24 | actin filament bundle organization | biological process | GO:0061572 | 68 | 2 | 18204 | 49 |
FMN2,SORBS1 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.451e-02 | -4.23 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 4 | 19454 | 50 |
NTRK2,CLU,TNIK,ABLIM1 |
1.457e-02 | -4.23 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 8 | 16828 | 49 |
GPC5,SOX5,CDH20,RYR3,FMN2,SLC1A2,ATP13A4,NRG3 |
1.474e-02 | -4.22 | NEBU | smart domains | SM00227 | 4 | 1 | 9717 | 36 |
NEBL |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.488e-02 | -4.21 | human chr19q13.32 | chromosome location | human chr19q13.32 | 97 | 2 | 26134 | 50 |
HIF3A,APOE |
1.493e-02 | -4.20 | presynapse | cellular component | GO:0098793 | 569 | 5 | 19108 | 49 |
TNIK,SLC1A2,NRXN1,GPM6A,NTRK2 |
1.498e-02 | -4.20 | NGF-independant TRKA activation | REACTOME pathways | R-HSA-187024 | 5 | 1 | 10285 | 31 |
NTRK2 |
1.501e-02 | -4.20 | lung-carcinoid-endocrine_tumour | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour | 502 | 5 | 16828 | 49 |
NTRK2,BMPR1B,CAMK2G,TNIK,FGFR3 |
1.511e-02 | -4.19 | - | gene3d domains | 6.10.140.620 | 5 | 1 | 14470 | 44 |
CAMK2G |
1.511e-02 | -4.19 | Apolipoprotein | gene3d domains | 1.20.120.20 | 5 | 1 | 14470 | 44 |
APOE |
1.529e-02 | -4.18 | multivesicular body, internal vesicle | cellular component | GO:0097487 | 6 | 1 | 19108 | 49 |
APOE |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 50 |
NRXN1 |
1.532e-02 | -4.18 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | FXYD7 (FXYD domain containing ion transport regulator 7) | protein interactions | 53822 | 6 | 1 | 19454 | 50 |
APOE |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | Taok2 (TAO kinase 2) | protein interactions | 381921 | 6 | 1 | 19454 | 50 |
CLU |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | LCAT (lecithin-cholesterol acyltransferase) | protein interactions | 3931 | 6 | 1 | 19454 | 50 |
APOE |
1.532e-02 | -4.18 | Zbtb2 (zinc finger and BTB domain containing 2) | protein interactions | 381990 | 6 | 1 | 19454 | 50 |
SORBS1 |
1.532e-02 | -4.18 | RSPO3 (R-spondin 3) | protein interactions | 84870 | 6 | 1 | 19454 | 50 |
ZNRF3 |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | CIBAR2 (CBY1 interacting BAR domain containing 2) | protein interactions | 339145 | 6 | 1 | 19454 | 50 |
CAMK2G |
1.535e-02 | -4.18 | cell-cell adhesion | biological process | GO:0098609 | 546 | 5 | 18204 | 49 |
CTNNA2,NRXN1,CDH20,SPARCL1,CTNND2 |
1.549e-02 | -4.17 | seminoma | COSMIC cancer mutations | seminoma | 700 | 6 | 16828 | 49 |
CAMK2G,BMPR1B,TNIK,FGFR3,PREX2,NTRK2 |
1.550e-02 | -4.17 | LIM | pfam domains | PF00412 | 69 | 2 | 17795 | 49 |
NEBL,ABLIM1 |
1.552e-02 | -4.17 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 3 | 19454 | 50 |
ABLIM1,NRXN1,DTNA |
1.554e-02 | -4.16 | bone development | biological process | GO:0060348 | 195 | 3 | 18204 | 49 |
FGFR3,BMPR1B,RANBP3L |
1.567e-02 | -4.16 | peptide hormone secretion | biological process | GO:0030072 | 71 | 2 | 18204 | 49 |
CPE,CAMK2G |
1.568e-02 | -4.16 | localization within membrane | biological process | GO:0051668 | 549 | 5 | 18204 | 49 |
NRXN1,APOE,CPE,MACF1,TNIK |
1.573e-02 | -4.15 | lung-carcinoid-endocrine_tumour-atypical | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour-atypical | 508 | 5 | 16828 | 49 |
BMPR1B,TNIK,CAMK2G,FGFR3,NTRK2 |
1.576e-02 | -4.15 | Znf_LIM | interpro domains | IPR001781 | 71 | 2 | 18521 | 50 |
ABLIM1,NEBL |
1.581e-02 | -4.15 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 48 |
SLC4A4 |
1.581e-02 | -4.15 | amino acid:proton symporter activity | molecular function | GO:0005280 | 6 | 1 | 18094 | 48 |
SLC25A18 |
1.581e-02 | -4.15 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 48 |
RYR3 |
1.581e-02 | -4.15 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 48 |
ATP1A2 |
1.581e-02 | -4.15 | phosphatidylcholine-sterol O-acyltransferase activator activity | molecular function | GO:0060228 | 6 | 1 | 18094 | 48 |
APOE |
1.597e-02 | -4.14 | locomotory behavior | biological process | GO:0007626 | 197 | 3 | 18204 | 49 |
PREX2,ATP1A2,APOE |
1.598e-02 | -4.14 | Transferase(Phosphotransferase) domain 1 | gene3d domains | 1.10.510.10 | 490 | 5 | 14470 | 44 |
FGFR3,NTRK2,BMPR1B,TNIK,CAMK2G |
1.598e-02 | -4.14 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 21 |
CTNNA2 |
1.599e-02 | -4.14 | regulation of protein catabolic process | biological process | GO:0042176 | 361 | 4 | 18204 | 49 |
APOE,FMN2,CLU,CST3 |
1.599e-02 | -4.14 | positive regulation of cell projection organization | biological process | GO:0031346 | 361 | 4 | 18204 | 49 |
GPM6A,MACF1,APOE,NTRK2 |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
HIF3A,NRG3,FGFR3,DTNA,ATP1A2,BMPR1B,CAMK2G,MACF1,CST3,SLC4A4,RORA,CPE,NEBL,SOX5,ACSS1,SLC1A3,FMN2,ABLIM1,PTPRZ1,NTRK2,ZBTB20,CTNND2,APOE,MSI2,LSAMP,CLU,TNIK,NTM,PREX2,TRPM3,RANBP3L,ATP13A4,NKAIN3,SFXN5,PAMR1,SPARCL1,GPM6A,RYR3,SORBS1,NRXN1,NPAS3,COL5A3,SLC25A18,CDH20,SLC1A2,NHSL1,GPC5,ZNRF3 |
1.604e-02 | -4.13 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 49 |
NRG3 |
1.604e-02 | -4.13 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 49 |
SLC1A3 |
1.604e-02 | -4.13 | establishment of meiotic spindle localization | biological process | GO:0051295 | 6 | 1 | 18204 | 49 |
FMN2 |
1.604e-02 | -4.13 | vocal learning | biological process | GO:0042297 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032803 | 6 | 1 | 18204 | 49 |
APOE |
1.604e-02 | -4.13 | triglyceride-rich lipoprotein particle clearance | biological process | GO:0071830 | 6 | 1 | 18204 | 49 |
APOE |
1.604e-02 | -4.13 | ERBB4-ERBB4 signaling pathway | biological process | GO:0038138 | 6 | 1 | 18204 | 49 |
NRG3 |
1.604e-02 | -4.13 | imitative learning | biological process | GO:0098596 | 6 | 1 | 18204 | 49 |
NRXN1 |
1.604e-02 | -4.13 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 49 |
BMPR1B |
1.604e-02 | -4.13 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 49 |
CST3 |
1.604e-02 | -4.13 | protein targeting to vacuole involved in autophagy | biological process | GO:0071211 | 6 | 1 | 18204 | 49 |
CLU |
1.604e-02 | -4.13 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 49 |
SOX5 |
1.609e-02 | -4.13 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | RIH_dom | interpro domains | IPR000699 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 50 |
NRXN1 |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 49 |
SLC4A4,ZBTB20 |
1.616e-02 | -4.13 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 3 | 16828 | 49 |
GPC5,RYR3,NRG3 |
1.625e-02 | -4.12 | Constitutive Signaling by Aberrant PI3K in Cancer | REACTOME pathways | R-HSA-2219530 | 65 | 2 | 10285 | 31 |
NRG3,FGFR3 |
1.627e-02 | -4.12 | sarcoplasmic reticulum | cellular component | GO:0016529 | 76 | 2 | 19108 | 49 |
RYR3,CAMK2G |
1.633e-02 | -4.11 | BCL2L1 (BCL2 like 1) | protein interactions | 598 | 208 | 3 | 19454 | 50 |
RYR3,CLU,ABLIM1 |
1.640e-02 | -4.11 | positive regulation of ERK1 and ERK2 cascade | biological process | GO:0070374 | 199 | 3 | 18204 | 49 |
FGFR3,APOE,NTRK2 |
1.641e-02 | -4.11 | RYDR_ITPR | pfam domains | PF01365 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 49 |
NRXN1 |
1.641e-02 | -4.11 | RIH_assoc | pfam domains | PF08454 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 49 |
GPC5 |
1.641e-02 | -4.11 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 49 |
MACF1 |
1.641e-02 | -4.11 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 49 |
DTNA |
1.652e-02 | -4.10 | regulation of cartilage development | biological process | GO:0061035 | 73 | 2 | 18204 | 49 |
SOX5,BMPR1B |
1.652e-02 | -4.10 | peptide metabolic process | biological process | GO:0006518 | 73 | 2 | 18204 | 49 |
CPE,SLC1A2 |
1.660e-02 | -4.10 | atypical | COSMIC cancer mutations | atypical | 515 | 5 | 16828 | 49 |
TNIK,BMPR1B,CAMK2G,FGFR3,NTRK2 |
1.673e-02 | -4.09 | axonogenesis | biological process | GO:0007409 | 366 | 4 | 18204 | 49 |
BMPR1B,NRXN1,CTNNA2,PTPRZ1 |
1.675e-02 | -4.09 | ABI1 (abl interactor 1) | protein interactions | 10006 | 210 | 3 | 19454 | 50 |
SLC1A3,NHSL1,SORBS1 |
1.695e-02 | -4.08 | sterol transport | biological process | GO:0015918 | 74 | 2 | 18204 | 49 |
CLU,APOE |
1.696e-02 | -4.08 | CDK6 (cyclin dependent kinase 6) | protein interactions | 1021 | 211 | 3 | 19454 | 50 |
FGFR3,SORBS1,SOX5 |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.706e-02 | -4.07 | intracellular calcium ion homeostasis | biological process | GO:0006874 | 202 | 3 | 18204 | 49 |
APOE,RYR3,ATP13A4 |
1.709e-02 | -4.07 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 11 | 16828 | 49 |
FMN2,RYR3,CDH20,NTRK2,ATP13A4,PITPNC1,PREX2,COL5A3,ACSS1,PTPRZ1,NEBL |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.710e-02 | -4.07 | head development | biological process | GO:0060322 | 774 | 6 | 18204 | 49 |
RORA,NRG3,ATP1A2,CTNNA2,SLC1A2,NTRK2 |
1.717e-02 | -4.06 | LRP8 (LDL receptor related protein 8) | protein interactions | 7804 | 78 | 2 | 19454 | 50 |
CLU,APOE |
1.717e-02 | -4.06 | IFIT3 (interferon induced protein with tetratricopeptide repeats 3) | protein interactions | 3437 | 78 | 2 | 19454 | 50 |
ATP1A2,APOE |
1.717e-02 | -4.06 | Nedd4 (NEDD4 E3 ubiquitin protein ligase) | protein interactions | 25489 | 78 | 2 | 19454 | 50 |
BMPR1B,NTRK2 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.738e-02 | -4.05 | peptide secretion | biological process | GO:0002790 | 75 | 2 | 18204 | 49 |
CPE,CAMK2G |
1.754e-02 | -4.04 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 21 |
SLC1A3,ATP1A2 |
1.761e-02 | -4.04 | NCK1 (NCK adaptor protein 1) | protein interactions | 4690 | 214 | 3 | 19454 | 50 |
NHSL1,TNIK,NTRK2 |
1.765e-02 | -4.04 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 8 | 18204 | 49 |
TNIK,CTNNA2,NEBL,MACF1,FMN2,ABLIM1,APOE,SORBS1 |
1.769e-02 | -4.03 | bone-tibia-chondrosarcoma | COSMIC cancer mutations | bone-tibia-chondrosarcoma | 70 | 2 | 16828 | 49 |
RANBP3L,CPE |
1.769e-02 | -4.03 | prostate-adenoma | COSMIC cancer mutations | prostate-adenoma | 1634 | 10 | 16828 | 49 |
TRPM3,ZBTB20,HIF3A,MACF1,COL5A3,NPAS3,GPC5,PTPRZ1,SOX5,NEBL |
1.774e-02 | -4.03 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 3 | 18204 | 49 |
RYR3,TRPM3,GPM6A |
1.782e-02 | -4.03 | regulation of axon extension | biological process | GO:0030516 | 76 | 2 | 18204 | 49 |
MACF1,APOE |
1.786e-02 | -4.03 | C8B (complement C8 beta chain) | protein interactions | 732 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | CYP4F8 (cytochrome P450 family 4 subfamily F member 8) | protein interactions | 11283 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | SOAT2 (sterol O-acyltransferase 2) | protein interactions | 8435 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | C7 (complement C7) | protein interactions | 730 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 50 |
FGFR3 |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 50 |
ZBTB20 |
1.795e-02 | -4.02 | Activation of TRKA receptors | REACTOME pathways | R-HSA-187015 | 6 | 1 | 10285 | 31 |
NTRK2 |
1.795e-02 | -4.02 | protein kinase activity | molecular function | GO:0004672 | 577 | 5 | 18094 | 48 |
BMPR1B,FGFR3,TNIK,CAMK2G,NTRK2 |
1.801e-02 | -4.02 | MAP2 (microtubule associated protein 2) | protein interactions | 4133 | 80 | 2 | 19454 | 50 |
APOE,GPM6A |
1.811e-02 | -4.01 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 1 | 14470 | 44 |
RYR3 |
1.821e-02 | -4.01 | SMAD binding | molecular function | GO:0046332 | 78 | 2 | 18094 | 48 |
BMPR1B,RANBP3L |
1.826e-02 | -4.00 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 3 | 19454 | 50 |
NKAIN3,ABLIM1,RORA |
1.827e-02 | -4.00 | positive regulation of axonogenesis | biological process | GO:0050772 | 77 | 2 | 18204 | 49 |
NTRK2,MACF1 |
1.827e-02 | -4.00 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 49 |
ATP1A2,NRXN1 |
1.827e-02 | -4.00 | neural retina development | biological process | GO:0003407 | 77 | 2 | 18204 | 49 |
GPM6A,NTRK2 |
1.836e-02 | -4.00 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 5 | 19108 | 49 |
CDH20,BMPR1B,ATP1A2,CTNNA2,SORBS1 |
1.843e-02 | -3.99 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | calcium-dependent protein serine/threonine phosphatase activity | molecular function | GO:0004723 | 7 | 1 | 18094 | 48 |
CAMK2G |
1.843e-02 | -3.99 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 48 |
PITPNC1 |
1.869e-02 | -3.98 | observational learning | biological process | GO:0098597 | 7 | 1 | 18204 | 49 |
NRXN1 |
1.869e-02 | -3.98 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 49 |
RYR3 |
1.869e-02 | -3.98 | negative regulation of non-canonical Wnt signaling pathway | biological process | GO:2000051 | 7 | 1 | 18204 | 49 |
ZNRF3 |
1.869e-02 | -3.98 | high-density lipoprotein particle clearance | biological process | GO:0034384 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | chromosome movement towards spindle pole | biological process | GO:0051305 | 7 | 1 | 18204 | 49 |
FMN2 |
1.869e-02 | -3.98 | positive regulation of receptor catabolic process | biological process | GO:2000646 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 49 |
PTPRZ1 |
1.869e-02 | -3.98 | very-low-density lipoprotein particle remodeling | biological process | GO:0034372 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | interneuron migration from the subpallium to the cortex | biological process | GO:0021830 | 7 | 1 | 18204 | 49 |
NRG3 |
1.869e-02 | -3.98 | chaperone-mediated autophagy | biological process | GO:0061684 | 7 | 1 | 18204 | 49 |
CLU |
1.869e-02 | -3.98 | parallel actin filament bundle assembly | biological process | GO:0030046 | 7 | 1 | 18204 | 49 |
FMN2 |
1.869e-02 | -3.98 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 49 |
CTNNA2 |
1.872e-02 | -3.98 | regulation of glucose transmembrane transport | biological process | GO:0010827 | 78 | 2 | 18204 | 49 |
SORBS1,SLC1A2 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.884e-02 | -3.97 | extracellular region | cellular component | GO:0005576 | 4350 | 18 | 19108 | 49 |
COL5A3,PTPRZ1,CST3,GPM6A,ATP1A2,PAMR1,TNIK,SLC4A4,NRG3,LSAMP,GPC5,FGFR3,APOE,NTM,CLU,SPARCL1,CPE,NEBL |
1.889e-02 | -3.97 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 47 | 16828 | 49 |
RANBP3L,TRPM3,NTM,PREX2,PITPNC1,LSAMP,CLU,TNIK,MSI2,CTNND2,NTRK2,ZBTB20,ZNRF3,GPC5,NHSL1,CDH20,SLC1A2,NPAS3,COL5A3,NRXN1,SLC25A18,SORBS1,GPM6A,RYR3,NKAIN3,ATP13A4,SFXN5,PAMR1,SPARCL1,MACF1,CAMK2G,BMPR1B,FGFR3,DTNA,ATP1A2,HIF3A,NRG3,ABLIM1,PTPRZ1,FMN2,SLC1A3,SOX5,NEBL,ACSS1,SLC4A4,RORA,CPE |
1.912e-02 | -3.96 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 49 |
BMPR1B |
1.912e-02 | -3.96 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 49 |
SPARCL1 |
1.914e-02 | -3.96 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.921e-02 | -3.95 | caveola | cellular component | GO:0005901 | 83 | 2 | 19108 | 49 |
ATP1A2,SORBS1 |
1.925e-02 | -3.95 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 6 | 19454 | 50 |
MACF1,FMN2,DTNA,TNIK,SLC1A3,ABLIM1 |
1.929e-02 | -3.95 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 49 |
BMPR1B,NPAS3,NEBL,MSI2,FGFR3,ATP1A2,SPARCL1,NRG3,NTRK2,SLC4A4,HIF3A,MACF1,TRPM3,FMN2,NTM |
1.929e-02 | -3.95 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 15 | 16828 | 49 |
NPAS3,BMPR1B,NEBL,MSI2,FGFR3,ATP1A2,NTRK2,SLC4A4,HIF3A,NRG3,SPARCL1,MACF1,TRPM3,FMN2,NTM |
1.930e-02 | -3.95 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 50 |
NRXN1,GPM6A |
1.930e-02 | -3.95 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 50 |
GPM6A,FGFR3 |
1.932e-02 | -3.95 | positive regulation of cell communication | biological process | GO:0010647 | 1792 | 10 | 18204 | 49 |
BMPR1B,SORBS1,APOE,FGFR3,NTRK2,TNIK,GPC5,MACF1,NRXN1,SLC1A3 |
1.939e-02 | -3.94 | PSEN1 (presenilin 1) | protein interactions | 5663 | 222 | 3 | 19454 | 50 |
APOE,CTNND2,DTNA |
1.943e-02 | -3.94 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
TRPM3,SLC1A2,FMN2,PREX2,ATP13A4,MACF1,GPC5 |
1.943e-02 | -3.94 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
MACF1,GPC5,PREX2,ATP13A4,TRPM3,SLC1A2,FMN2 |
1.946e-02 | -3.94 | positive regulation of signaling | biological process | GO:0023056 | 1794 | 10 | 18204 | 49 |
TNIK,NTRK2,GPC5,MACF1,SLC1A3,NRXN1,BMPR1B,APOE,SORBS1,FGFR3 |
1.962e-02 | -3.93 | Axon guidance | KEGG pathways | hsa04360 | 174 | 3 | 7161 | 24 |
CAMK2G,ABLIM1,BMPR1B |
1.962e-02 | -3.93 | Axon guidance | KEGG pathways | ko04360 | 174 | 3 | 7161 | 24 |
CAMK2G,BMPR1B,ABLIM1 |
1.964e-02 | -3.93 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.974e-02 | -3.93 | Tyr_kinase_cat_dom | interpro domains | IPR020635 | 80 | 2 | 18521 | 50 |
NTRK2,FGFR3 |
1.985e-02 | -3.92 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 3 | 19454 | 50 |
ABLIM1,GPM6A,MACF1 |
1.989e-02 | -3.92 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 4 | 10285 | 31 |
NRXN1,SLC1A2,SLC1A3,CAMK2G |
1.993e-02 | -3.92 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 21 |
PITPNC1 |
1.993e-02 | -3.92 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 21 |
SLC4A4 |
2.002e-02 | -3.91 | YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta) | protein interactions | 7533 | 1083 | 7 | 19454 | 50 |
MACF1,PITPNC1,FMN2,CAMK2G,ABLIM1,NHSL1,SORBS1 |
2.009e-02 | -3.91 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 49 |
PREX2,ATP1A2 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.032e-02 | -3.90 | Ethanol Degradation | SMPDB pathways | SMP0000449 | 7 | 1 | 1369 | 4 |
ACSS1 |
2.034e-02 | -3.90 | zonula adherens | cellular component | GO:0005915 | 8 | 1 | 19108 | 49 |
SORBS1 |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.034e-02 | -3.90 | spherical high-density lipoprotein particle | cellular component | GO:0034366 | 8 | 1 | 19108 | 49 |
CLU |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | CCK (cholecystokinin) | protein interactions | 885 | 8 | 1 | 19454 | 50 |
CPE |
2.038e-02 | -3.89 | Chmp2a (charged multivesicular body protein 2A) | protein interactions | 68953 | 8 | 1 | 19454 | 50 |
CLU |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | INSM1 (INSM transcriptional repressor 1) | protein interactions | 3642 | 8 | 1 | 19454 | 50 |
SORBS1 |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.043e-02 | -3.89 | acral_lentiginous | COSMIC cancer mutations | acral_lentiginous | 745 | 6 | 16828 | 49 |
MACF1,FGFR3,CDH20,NRG3,PREX2,ATP13A4 |
2.059e-02 | -3.88 | positive regulation of cellular catabolic process | biological process | GO:0031331 | 217 | 3 | 18204 | 49 |
APOE,ZBTB20,SLC4A4 |
2.059e-02 | -3.88 | regulation of cell junction assembly | biological process | GO:1901888 | 217 | 3 | 18204 | 49 |
NTRK2,NRXN1,MACF1 |
2.063e-02 | -3.88 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 50 |
GPM6A,SORBS1 |
2.063e-02 | -3.88 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 50 |
FGFR3,HIF3A |
2.072e-02 | -3.88 | Cysteine Rich Protein | gene3d domains | 2.10.110.10 | 73 | 2 | 14470 | 44 |
NEBL,ABLIM1 |
2.091e-02 | -3.87 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 31 |
FGFR3 |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
MACF1,SPARCL1,RYR3 |
2.103e-02 | -3.86 | peptide transport | biological process | GO:0015833 | 83 | 2 | 18204 | 49 |
CAMK2G,CPE |
2.103e-02 | -3.86 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 48 |
BMPR1B |
2.103e-02 | -3.86 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 48 |
SLC1A3 |
2.103e-02 | -3.86 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.109e-02 | -3.86 | glial cell differentiation | biological process | GO:0010001 | 219 | 3 | 18204 | 49 |
NTRK2,PTPRZ1,CLU |
2.115e-02 | -3.86 | supramolecular fiber organization | biological process | GO:0097435 | 593 | 5 | 18204 | 49 |
NEBL,SORBS1,FMN2,CST3,COL5A3 |
2.125e-02 | -3.85 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
2.125e-02 | -3.85 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 12 | 16828 | 49 |
SOX5,TNIK,SLC25A18,CAMK2G,BMPR1B,SLC4A4,NTRK2,ATP1A2,FGFR3,DTNA,PTPRZ1,PREX2 |
2.126e-02 | -3.85 | skin-leg-malignant_melanoma | COSMIC cancer mutations | skin-leg-malignant_melanoma | 549 | 5 | 16828 | 49 |
ZBTB20,PTPRZ1,HIF3A,NEBL,NRG3 |
2.127e-02 | -3.85 | ConA-like_dom_sf | interpro domains | IPR013320 | 219 | 3 | 18521 | 50 |
NRXN1,RYR3,COL5A3 |
2.127e-02 | -3.85 | DST (dystonin) | protein interactions | 667 | 230 | 3 | 19454 | 50 |
TNIK,ATP1A2,NTRK2 |
2.134e-02 | -3.85 | insulin processing | biological process | GO:0030070 | 8 | 1 | 18204 | 49 |
CPE |
2.134e-02 | -3.85 | meiotic cytokinesis | biological process | GO:0033206 | 8 | 1 | 18204 | 49 |
FMN2 |
2.134e-02 | -3.85 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 49 |
CTNNA2 |
2.134e-02 | -3.85 | positive regulation of amyloid-beta clearance | biological process | GO:1900223 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 49 |
ATP1A2 |
2.134e-02 | -3.85 | triglyceride-rich lipoprotein particle remodeling | biological process | GO:0034370 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | regulation of Cdc42 protein signal transduction | biological process | GO:0032489 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | positive regulation of CoA-transferase activity | biological process | GO:1905920 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 49 |
SLC1A3 |
2.134e-02 | -3.85 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 49 |
RORA |
2.134e-02 | -3.85 | ERBB4 signaling pathway | biological process | GO:0038130 | 8 | 1 | 18204 | 49 |
NRG3 |
2.134e-02 | -3.85 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 49 |
ATP1A2,SLC1A3,NRXN1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | TRPM_SLOG | interpro domains | IPR041491 | 8 | 1 | 18521 | 50 |
TRPM3 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.147e-02 | -3.84 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 44 |
MACF1 |
2.147e-02 | -3.84 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 44 |
GPC5 |
2.151e-02 | -3.84 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 49 |
NKAIN3,ATP1A2 |
2.153e-02 | -3.84 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 50 |
TNIK,BMPR1B |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
FGFR3,NTM,LSAMP,NTRK2 |
2.175e-02 | -3.83 | CTSB (cathepsin B) | protein interactions | 1508 | 232 | 3 | 19454 | 50 |
APOE,CST3,MSI2 |
2.182e-02 | -3.82 | LSDAT_euk | pfam domains | PF18139 | 8 | 1 | 17795 | 49 |
TRPM3 |
2.182e-02 | -3.82 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 49 |
ABLIM1 |
2.203e-02 | -3.82 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 36 |
MACF1 |
2.203e-02 | -3.82 | SH3_domain | interpro domains | IPR001452 | 222 | 3 | 18521 | 50 |
MACF1,SORBS1,NEBL |
2.246e-02 | -3.80 | CTDSPL (CTD small phosphatase like) | protein interactions | 10217 | 90 | 2 | 19454 | 50 |
FMN2,DTNA |
2.246e-02 | -3.80 | FGFR1OP2 (FGFR1 oncogene partner 2) | protein interactions | 26127 | 90 | 2 | 19454 | 50 |
CAMK2G,TNIK |
2.249e-02 | -3.79 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 3 | 19454 | 50 |
DTNA,NTRK2,MACF1 |
2.262e-02 | -3.79 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 7 | 16828 | 49 |
NRG3,RORA,NKAIN3,CTNND2,SOX5,GPC5,LSAMP |
2.268e-02 | -3.79 | lobular_carcinoma | COSMIC cancer mutations | lobular_carcinoma | 763 | 6 | 16828 | 49 |
CAMK2G,BMPR1B,TNIK,CDH20,FGFR3,NTRK2 |
2.268e-02 | -3.79 | breast-carcinoma-lobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-lobular_carcinoma | 763 | 6 | 16828 | 49 |
NTRK2,FGFR3,CDH20,CAMK2G,TNIK,BMPR1B |
2.285e-02 | -3.78 | flotillin complex | cellular component | GO:0016600 | 9 | 1 | 19108 | 49 |
SORBS1 |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | LINC02582 (long intergenic non-protein coding RNA 2582) | protein interactions | 100505817 | 9 | 1 | 19454 | 50 |
APOE |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.290e-02 | -3.78 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | CAMK2N1 (calcium/calmodulin dependent protein kinase II inhibitor 1) | protein interactions | 55450 | 9 | 1 | 19454 | 50 |
CAMK2G |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | CACNA2D3 (calcium voltage-gated channel auxiliary subunit alpha2delta 3) | protein interactions | 55799 | 9 | 1 | 19454 | 50 |
APOE |
2.292e-02 | -3.78 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 2 | 19454 | 50 |
SORBS1,TNIK |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
GPM6A,NTM |
2.293e-02 | -3.78 | cytoplasmic vesicle | cellular component | GO:0031410 | 2521 | 12 | 19108 | 49 |
CAMK2G,CPE,NTRK2,ATP13A4,CLU,ATP1A2,APOE,FGFR3,CST3,FMN2,TNIK,SLC1A3 |
2.299e-02 | -3.77 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 50 |
GPM6A,CAMK2G,SOX5 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.309e-02 | -3.77 | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | salivary_gland-parotid-carcinoma-adenoid_cystic_carcinoma | 561 | 5 | 16828 | 49 |
TNIK,CAMK2G,FGFR3,RYR3,NTRK2 |
2.320e-02 | -3.76 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 4 |
FGFR3 |
2.324e-02 | -3.76 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 24 |
ATP1A2,SLC4A4 |
2.324e-02 | -3.76 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 24 |
SLC4A4,ATP1A2 |
2.324e-02 | -3.76 | LCOR (ligand dependent nuclear receptor corepressor) | protein interactions | 84458 | 238 | 3 | 19454 | 50 |
CLU,SPARCL1,MACF1 |
2.325e-02 | -3.76 | forearm | COSMIC cancer mutations | forearm | 81 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.332e-02 | -3.76 | intracellular vesicle | cellular component | GO:0097708 | 2527 | 12 | 19108 | 49 |
ATP1A2,NTRK2,SLC1A3,FMN2,CST3,APOE,CLU,ATP13A4,CAMK2G,CPE,TNIK,FGFR3 |
2.339e-02 | -3.76 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 50 |
FGFR3,TNIK |
2.339e-02 | -3.76 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 50 |
FGFR3,DTNA |
2.341e-02 | -3.75 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 3 | 18204 | 49 |
FGFR3,SOX5,BMPR1B |
2.363e-02 | -3.75 | L-aspartate transmembrane transporter activity | molecular function | GO:0015183 | 9 | 1 | 18094 | 48 |
SLC25A18 |
2.384e-02 | -3.74 | DISC1 (DISC1 scaffold protein) | protein interactions | 27185 | 427 | 4 | 19454 | 50 |
SPARCL1,MACF1,TNIK,CLU |
2.385e-02 | -3.74 | forebrain development | biological process | GO:0030900 | 408 | 4 | 18204 | 49 |
SLC1A2,ATP1A2,NRG3,NTRK2 |
2.386e-02 | -3.74 | Adherens junction | KEGG pathways | hsa04520 | 72 | 2 | 7161 | 24 |
CTNNA2,SORBS1 |
2.386e-02 | -3.74 | Adherens junction | KEGG pathways | ko04520 | 72 | 2 | 7161 | 24 |
SORBS1,CTNNA2 |
2.387e-02 | -3.74 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 31 |
GPC5 |
2.387e-02 | -3.74 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 50 |
ABLIM1,BMPR1B |
2.388e-02 | -3.73 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 21 |
BMPR1B |
2.388e-02 | -3.73 | hand | COSMIC cancer mutations | hand | 566 | 5 | 16828 | 49 |
SLC4A4,HIF3A,PREX2,COL5A3,FGFR3 |
2.397e-02 | -3.73 | cholesterol catabolic process | biological process | GO:0006707 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 49 |
NRXN1 |
2.397e-02 | -3.73 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 49 |
CLU |
2.397e-02 | -3.73 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 49 |
ATP13A4 |
2.397e-02 | -3.73 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | sterol catabolic process | biological process | GO:0016127 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 49 |
CLU |
2.397e-02 | -3.73 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 49 |
RYR3 |
2.397e-02 | -3.73 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 49 |
ATP1A2 |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.407e-02 | -3.73 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 44 |
ABLIM1 |
2.408e-02 | -3.73 | ion binding | molecular function | GO:0043167 | 6007 | 23 | 18094 | 48 |
SPARCL1,NRXN1,PAMR1,CAMK2G,NTRK2,PITPNC1,ACSS1,RORA,ZNRF3,ATP1A2,BMPR1B,SLC1A2,APOE,SLC1A3,ABLIM1,DTNA,TNIK,FGFR3,ZBTB20,ATP13A4,CPE,MACF1,RYR3 |
2.411e-02 | -3.73 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 49 |
FGFR3,APOE,PREX2,ATP1A2,RYR3,TNIK |
2.420e-02 | -3.72 | ACTG1 (actin gamma 1) | protein interactions | 71 | 429 | 4 | 19454 | 50 |
TNIK,ABLIM1,APOE,FMN2 |
2.422e-02 | -3.72 | calcium ion homeostasis | biological process | GO:0055074 | 231 | 3 | 18204 | 49 |
RYR3,ATP13A4,APOE |
2.430e-02 | -3.72 | protein binding | molecular function | GO:0005515 | 13983 | 43 | 18094 | 48 |
GPM6A,NPAS3,MSI2,NRXN1,ZNRF3,ATP1A2,SLC1A2,BMPR1B,PTPRZ1,ACSS1,CTNND2,FGFR3,CDH20,SOX5,ABLIM1,LSAMP,FMN2,CST3,HIF3A,SORBS1,MACF1,SLC25A18,SPARCL1,CLU,SFXN5,RORA,SLC1A3,APOE,NTM,NTRK2,SLC4A4,CAMK2G,PITPNC1,NRG3,TNIK,DTNA,CTNNA2,GPC5,RANBP3L,CPE,COL5A3,NEBL,RYR3 |
2.435e-02 | -3.72 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 50 |
TNIK,ABLIM1 |
2.435e-02 | -3.72 | TTR (transthyretin) | protein interactions | 7276 | 94 | 2 | 19454 | 50 |
CTNND2,CLU |
2.438e-02 | -3.71 | postsynapse | cellular component | GO:0098794 | 646 | 5 | 19108 | 49 |
CTNND2,ATP1A2,TNIK,NTRK2,GPM6A |
2.446e-02 | -3.71 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
2.449e-02 | -3.71 | connective tissue development | biological process | GO:0061448 | 232 | 3 | 18204 | 49 |
BMPR1B,SOX5,FGFR3 |
2.452e-02 | -3.71 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 49 |
SLC4A4 |
2.452e-02 | -3.71 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 49 |
BMPR1B |
2.469e-02 | -3.70 | neck | COSMIC cancer mutations | neck | 1231 | 8 | 16828 | 49 |
GPC5,COL5A3,FGFR3,TRPM3,ATP1A2,CTNND2,PREX2,ATP13A4 |
2.470e-02 | -3.70 | EGF-like_dom | interpro domains | IPR000742 | 232 | 3 | 18521 | 50 |
PAMR1,NRXN1,NRG3 |
2.470e-02 | -3.70 | positive regulation of signal transduction | biological process | GO:0009967 | 1593 | 9 | 18204 | 49 |
MACF1,NRXN1,NTRK2,TNIK,GPC5,SORBS1,APOE,FGFR3,BMPR1B |
2.476e-02 | -3.70 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | WikiPathways | WP706 | 162 | 3 | 5310 | 21 |
NTRK2,SLC1A3,RORA |
2.483e-02 | -3.70 | STRIP1 (striatin interacting protein 1) | protein interactions | 85369 | 95 | 2 | 19454 | 50 |
TNIK,CAMK2G |
2.484e-02 | -3.70 | vesicle | cellular component | GO:0031982 | 4141 | 17 | 19108 | 49 |
ATP1A2,NTRK2,SLC1A3,FMN2,NRXN1,CST3,GPM6A,APOE,CLU,ATP13A4,NEBL,CPE,CAMK2G,SLC1A2,TNIK,SLC4A4,FGFR3 |
2.495e-02 | -3.69 | axon | cellular component | GO:0030424 | 650 | 5 | 19108 | 49 |
GPM6A,NTRK2,DTNA,SLC1A2,CTNNA2 |
2.496e-02 | -3.69 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 49 |
ZBTB20,SLC4A4 |
2.501e-02 | -3.69 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 44 |
BMPR1B |
2.504e-02 | -3.69 | upper_aerodigestive_tract-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-carcinoma | 383 | 4 | 16828 | 49 |
NTRK2,FGFR3,TNIK,CAMK2G |
2.504e-02 | -3.69 | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-head_neck-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
CAMK2G,TNIK,FGFR3,NTRK2 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
FGFR3,CAMK2G,TNIK,NTRK2 |
2.504e-02 | -3.69 | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-lymph_node-carcinoma-adenoid_cystic_carcinoma | 383 | 4 | 16828 | 49 |
NTRK2,FGFR3,CAMK2G,TNIK |
2.504e-02 | -3.69 | salivary_gland-carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma | 383 | 4 | 16828 | 49 |
NTRK2,TNIK,CAMK2G,FGFR3 |
2.521e-02 | -3.68 | sarcoplasm | cellular component | GO:0016528 | 96 | 2 | 19108 | 49 |
CAMK2G,RYR3 |
2.523e-02 | -3.68 | cation binding | molecular function | GO:0043169 | 4341 | 18 | 18094 | 48 |
NRXN1,SPARCL1,PAMR1,ACSS1,SLC1A2,APOE,SLC1A3,BMPR1B,ATP1A2,ZNRF3,RORA,DTNA,ABLIM1,ATP13A4,ZBTB20,RYR3,MACF1,CPE |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | SERPINB11 (serpin family B member 11) | protein interactions | 89778 | 10 | 1 | 19454 | 50 |
CPE |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.547e-02 | -3.67 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 7 | 19454 | 50 |
APOE,PITPNC1,MACF1,ABLIM1,CAMK2G,NHSL1,SORBS1 |
2.548e-02 | -3.67 | protein tetramerization | biological process | GO:0051262 | 92 | 2 | 18204 | 49 |
RYR3,TRPM3 |
2.548e-02 | -3.67 | hormone secretion | biological process | GO:0046879 | 92 | 2 | 18204 | 49 |
CPE,CAMK2G |
2.566e-02 | -3.66 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 36 |
MACF1 |
2.566e-02 | -3.66 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 36 |
BMPR1B |
2.566e-02 | -3.66 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 12 | 16828 | 49 |
CTNND2,ATP1A2,SLC1A2,FMN2,TRPM3,ZBTB20,NTRK2,NRG3,ZNRF3,PTPRZ1,SOX5,NHSL1 |
2.574e-02 | -3.66 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 2 | 7161 | 24 |
ATP1A2,CAMK2G |
2.574e-02 | -3.66 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 2 | 7161 | 24 |
ATP1A2,CAMK2G |
2.581e-02 | -3.66 | BTG3 (BTG anti-proliferation factor 3) | protein interactions | 10950 | 97 | 2 | 19454 | 50 |
SPARCL1,CLU |
2.586e-02 | -3.66 | parotid | COSMIC cancer mutations | parotid | 578 | 5 | 16828 | 49 |
NTRK2,FGFR3,CAMK2G,TNIK,RYR3 |
2.589e-02 | -3.65 | shoulder | COSMIC cancer mutations | shoulder | 387 | 4 | 16828 | 49 |
MACF1,FGFR3,PREX2,CPE |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.599e-02 | -3.65 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 5 | 18204 | 49 |
BMPR1B,NRG3,NTRK2,FGFR3,SORBS1 |
2.599e-02 | -3.65 | regulation of extent of cell growth | biological process | GO:0061387 | 93 | 2 | 18204 | 49 |
APOE,MACF1 |
2.616e-02 | -3.64 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 49 |
DTNA,RYR3,ATP1A2 |
2.618e-02 | -3.64 | secretion by cell | biological process | GO:0032940 | 420 | 4 | 18204 | 49 |
NRXN1,CPE,NTRK2,CAMK2G |
2.618e-02 | -3.64 | axon development | biological process | GO:0061564 | 420 | 4 | 18204 | 49 |
CTNNA2,NRXN1,PTPRZ1,BMPR1B |
2.621e-02 | -3.64 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 44 | 16828 | 49 |
ZBTB20,NTRK2,CTNND2,TNIK,LSAMP,CLU,PREX2,NTM,TRPM3,RANBP3L,SPARCL1,PAMR1,SFXN5,NKAIN3,ATP13A4,RYR3,GPM6A,SORBS1,SLC25A18,COL5A3,NPAS3,NRXN1,SLC1A2,CDH20,NHSL1,GPC5,ZNRF3,NRG3,HIF3A,ATP1A2,FGFR3,BMPR1B,CAMK2G,CST3,MACF1,CPE,RORA,SLC4A4,ACSS1,SOX5,NEBL,SLC1A3,FMN2,PTPRZ1 |
2.622e-02 | -3.64 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 48 |
ATP13A4 |
2.622e-02 | -3.64 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 48 |
PITPNC1 |
2.622e-02 | -3.64 | neurotrophin binding | molecular function | GO:0043121 | 10 | 1 | 18094 | 48 |
NTRK2 |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
LSAMP,GPM6A |
2.646e-02 | -3.63 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 50 |
SFXN5 |
2.646e-02 | -3.63 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 50 |
NRXN1 |
2.651e-02 | -3.63 | mitochondrial transmembrane transport | biological process | GO:1990542 | 94 | 2 | 18204 | 49 |
SLC25A18,SFXN5 |
2.660e-02 | -3.63 | negative regulation of cholesterol biosynthetic process | biological process | GO:0045541 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | retinal rod cell development | biological process | GO:0046548 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | substrate-independent telencephalic tangential migration | biological process | GO:0021826 | 10 | 1 | 18204 | 49 |
NRG3 |
2.660e-02 | -3.63 | regulation of behavioral fear response | biological process | GO:2000822 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | trans-synaptic signaling, modulating synaptic transmission | biological process | GO:0099550 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | regulation of CoA-transferase activity | biological process | GO:1905918 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | nitric oxide-cGMP-mediated signaling | biological process | GO:0038060 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.660e-02 | -3.63 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.660e-02 | -3.63 | substrate-independent telencephalic tangential interneuron migration | biological process | GO:0021843 | 10 | 1 | 18204 | 49 |
NRG3 |
2.660e-02 | -3.63 | negative regulation of sterol biosynthetic process | biological process | GO:0106119 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | high-density lipoprotein particle assembly | biological process | GO:0034380 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | cellular response to brain-derived neurotrophic factor stimulus | biological process | GO:1990416 | 10 | 1 | 18204 | 49 |
NTRK2 |
2.660e-02 | -3.63 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 49 |
SOX5 |
2.660e-02 | -3.63 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 49 |
RYR3 |
2.660e-02 | -3.63 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 49 |
NRXN1 |
2.666e-02 | -3.62 | TGFBR1 (transforming growth factor beta receptor 1) | protein interactions | 7046 | 251 | 3 | 19454 | 50 |
BMPR1B,CLU,PREX2 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | MIR_motif | interpro domains | IPR016093 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 21 |
SOX5,FGFR3 |
2.678e-02 | -3.62 | HSP90AA1 (heat shock protein 90 alpha family class A member 1) | protein interactions | 3320 | 1150 | 7 | 19454 | 50 |
CLU,ZBTB20,CAMK2G,APOE,HIF3A,NTRK2,FGFR3 |
2.681e-02 | -3.62 | Terminal pathway of complement | REACTOME pathways | R-HSA-166665 | 9 | 1 | 10285 | 31 |
CLU |
2.683e-02 | -3.62 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
2.697e-02 | -3.61 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 3 | 10285 | 31 |
SLC1A3,CAMK2G,SLC1A2 |
2.701e-02 | -3.61 | anchoring junction | cellular component | GO:0070161 | 902 | 6 | 19108 | 49 |
CTNNA2,ATP1A2,CDH20,SORBS1,CTNND2,FGFR3 |
2.702e-02 | -3.61 | cell motility | biological process | GO:0048870 | 1101 | 7 | 18204 | 49 |
GPC5,NTRK2,CDH20,GPM6A,CTNNA2,FMN2,NRG3 |
2.705e-02 | -3.61 | LIM_DOMAIN_2 | prosite domains | PS50023 | 71 | 2 | 12186 | 44 |
ABLIM1,NEBL |
2.705e-02 | -3.61 | LIM_DOMAIN_1 | prosite domains | PS00478 | 71 | 2 | 12186 | 44 |
ABLIM1,NEBL |
2.719e-02 | -3.60 | Tyr_kinase_AS | interpro domains | IPR008266 | 95 | 2 | 18521 | 50 |
NTRK2,FGFR3 |
2.720e-02 | -3.60 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 49 |
NPAS3 |
2.720e-02 | -3.60 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 49 |
SLC4A4 |
2.720e-02 | -3.60 | MIR | pfam domains | PF02815 | 10 | 1 | 17795 | 49 |
RYR3 |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
ATP1A2,GPM6A |
2.731e-02 | -3.60 | APBA1 (amyloid beta precursor protein binding family A member 1) | protein interactions | 320 | 100 | 2 | 19454 | 50 |
NRXN1,ABLIM1 |
2.780e-02 | -3.58 | cell surface receptor protein tyrosine kinase signaling pathway | biological process | GO:0007169 | 428 | 4 | 18204 | 49 |
NRG3,NTRK2,SORBS1,FGFR3 |
2.781e-02 | -3.58 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 50 |
CTNNA2,FGFR3 |
2.783e-02 | -3.58 | NGF signalling via TRKA from the plasma membrane | REACTOME pathways | R-HSA-187037 | 387 | 4 | 10285 | 31 |
NTRK2,NRG3,CAMK2G,FGFR3 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.788e-02 | -3.58 | regulation of neuron apoptotic process | biological process | GO:0043523 | 244 | 3 | 18204 | 49 |
NTRK2,PTPRZ1,CLU |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | NTS (neurotensin) | protein interactions | 4922 | 11 | 1 | 19454 | 50 |
CPE |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.792e-02 | -3.58 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 50 |
NRXN1 |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 50 |
FGFR3 |
2.792e-02 | -3.58 | MSRB1 (methionine sulfoxide reductase B1) | protein interactions | 51734 | 11 | 1 | 19454 | 50 |
CLU |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.806e-02 | -3.57 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | REACTOME pathways | R-HSA-6811558 | 87 | 2 | 10285 | 31 |
FGFR3,NRG3 |
2.826e-02 | -3.57 | LIM | smart domains | SM00132 | 71 | 2 | 9717 | 36 |
NEBL,ABLIM1 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.832e-02 | -3.56 | human chr10p12.31 | chromosome location | human chr10p12.31 | 15 | 1 | 26134 | 50 |
NEBL |
2.842e-02 | -3.56 | SFN (stratifin) | protein interactions | 2810 | 671 | 5 | 19454 | 50 |
TNIK,ABLIM1,MACF1,SORBS1,FMN2 |
2.847e-02 | -3.56 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 3 | 18204 | 49 |
PTPRZ1,MACF1,NTRK2 |
2.851e-02 | -3.56 | PROTEIN_KINASE_DOM | prosite domains | PS50011 | 480 | 5 | 12186 | 44 |
BMPR1B,CAMK2G,TNIK,FGFR3,NTRK2 |
2.853e-02 | -3.56 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 44 |
ABLIM1 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.880e-02 | -3.55 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 48 |
SLC1A2 |
2.880e-02 | -3.55 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 48 |
NRXN1 |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
GPM6A,BMPR1B |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
NTRK2,LSAMP,NTM,FGFR3 |
2.917e-02 | -3.53 | bone morphogenesis | biological process | GO:0060349 | 99 | 2 | 18204 | 49 |
BMPR1B,FGFR3 |
2.917e-02 | -3.53 | phospholipid transport | biological process | GO:0015914 | 99 | 2 | 18204 | 49 |
PITPNC1,APOE |
2.922e-02 | -3.53 | negative regulation of cholesterol metabolic process | biological process | GO:0090206 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 49 |
BMPR1B |
2.922e-02 | -3.53 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 49 |
RYR3 |
2.922e-02 | -3.53 | ectodermal placode morphogenesis | biological process | GO:0071697 | 11 | 1 | 18204 | 49 |
NRG3 |
2.922e-02 | -3.53 | regulation of fear response | biological process | GO:1903365 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 49 |
ATP13A4 |
2.922e-02 | -3.53 | regulation of receptor catabolic process | biological process | GO:2000644 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 49 |
ATP1A2 |
2.922e-02 | -3.53 | negative regulation of neuron migration | biological process | GO:2001223 | 11 | 1 | 18204 | 49 |
NRG3 |
2.922e-02 | -3.53 | ectodermal placode formation | biological process | GO:0060788 | 11 | 1 | 18204 | 49 |
NRG3 |
2.922e-02 | -3.53 | glutamate secretion | biological process | GO:0014047 | 11 | 1 | 18204 | 49 |
NTRK2 |
2.927e-02 | -3.53 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 36 |
ABLIM1 |
2.927e-02 | -3.53 | blood vessel morphogenesis | biological process | GO:0048514 | 435 | 4 | 18204 | 49 |
HIF3A,NTRK2,APOE,RORA |
2.931e-02 | -3.53 | Tyr_kinase_rcpt_2_CS | interpro domains | IPR002011 | 11 | 1 | 18521 | 50 |
NTRK2 |
2.931e-02 | -3.53 | Fib_collagen_C | interpro domains | IPR000885 | 11 | 1 | 18521 | 50 |
COL5A3 |
2.931e-02 | -3.53 | Ran_bind_dom | interpro domains | IPR000156 | 11 | 1 | 18521 | 50 |
RANBP3L |
2.931e-02 | -3.53 | RanBP1-like | interpro domains | IPR045255 | 11 | 1 | 18521 | 50 |
RANBP3L |
2.934e-02 | -3.53 | nervous system process | biological process | GO:0050877 | 1376 | 8 | 18204 | 49 |
ATP1A2,ABLIM1,APOE,PTPRZ1,NTRK2,SLC1A3,CTNNA2,NRXN1 |
2.946e-02 | -3.52 | DIRAS3 (DIRAS family GTPase 3) | protein interactions | 9077 | 261 | 3 | 19454 | 50 |
FMN2,DTNA,MACF1 |
2.975e-02 | -3.52 | amide binding | molecular function | GO:0033218 | 254 | 3 | 18094 | 48 |
APOE,CST3,CLU |
2.975e-02 | -3.51 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 1 | 10285 | 31 |
SLC4A4 |
2.975e-02 | -3.51 | PI3K events in ERBB4 signaling | REACTOME pathways | R-HSA-1250342 | 10 | 1 | 10285 | 31 |
NRG3 |
2.975e-02 | -3.51 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 31 |
FGFR3 |
2.975e-02 | -3.51 | Organic anion transporters | REACTOME pathways | R-HSA-428643 | 10 | 1 | 10285 | 31 |
SLC25A18 |
2.988e-02 | -3.51 | PI3K/AKT Signaling in Cancer | REACTOME pathways | R-HSA-2219528 | 90 | 2 | 10285 | 31 |
FGFR3,NRG3 |
2.988e-02 | -3.51 | Ran_BP1 | pfam domains | PF00638 | 11 | 1 | 17795 | 49 |
RANBP3L |
2.988e-02 | -3.51 | COLFI | pfam domains | PF01410 | 11 | 1 | 17795 | 49 |
COL5A3 |
2.988e-02 | -3.51 | PAS_11 | pfam domains | PF14598 | 11 | 1 | 17795 | 49 |
HIF3A |
2.997e-02 | -3.51 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 49 |
RYR3,TRPM3,GPM6A |
3.000e-02 | -3.51 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 44 |
SLC4A4 |
3.010e-02 | -3.50 | SH3 Domains | gene3d domains | 2.30.30.40 | 223 | 3 | 14470 | 44 |
NEBL,MACF1,SORBS1 |
3.027e-02 | -3.50 | cholesterol homeostasis | biological process | GO:0042632 | 101 | 2 | 18204 | 49 |
APOE,RORA |
3.027e-02 | -3.50 | regulation of glucose metabolic process | biological process | GO:0010906 | 101 | 2 | 18204 | 49 |
RORA,SORBS1 |
3.030e-02 | -3.50 | abdomen | COSMIC cancer mutations | abdomen | 603 | 5 | 16828 | 49 |
FGFR3,FMN2,CTNND2,PREX2,RANBP3L |
3.035e-02 | -3.49 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 8 | 18204 | 49 |
BMPR1B,PTPRZ1,SOX5,APOE,RANBP3L,NTRK2,NRXN1,MACF1 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.035e-02 | -3.49 | fibrillar collagen trimer | cellular component | GO:0005583 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.035e-02 | -3.49 | banded collagen fibril | cellular component | GO:0098643 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.039e-02 | -3.49 | skin-hand-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-hand-carcinoma-squamous_cell_carcinoma | 407 | 4 | 16828 | 49 |
SLC4A4,HIF3A,COL5A3,FGFR3 |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.042e-02 | -3.49 | LGR5 (leucine rich repeat containing G protein-coupled receptor 5) | protein interactions | 8549 | 12 | 1 | 19454 | 50 |
ZNRF3 |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | MMP25 (matrix metallopeptidase 25) | protein interactions | 64386 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | NTF4 (neurotrophin 4) | protein interactions | 4909 | 12 | 1 | 19454 | 50 |
NTRK2 |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
CPE |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.063e-02 | -3.49 | spleen | COSMIC cancer mutations | spleen | 408 | 4 | 16828 | 49 |
NTM,PTPRZ1,SORBS1,TNIK |
3.067e-02 | -3.48 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 2 | 12186 | 44 |
CPE,APOE |
3.082e-02 | -3.48 | sterol homeostasis | biological process | GO:0055092 | 102 | 2 | 18204 | 49 |
RORA,APOE |
3.083e-02 | -3.48 | response to stimulus | biological process | GO:0050896 | 7803 | 28 | 18204 | 49 |
PREX2,RYR3,FGFR3,RORA,NTRK2,SLC1A3,NRXN1,ATP1A2,BMPR1B,SPARCL1,SOX5,APOE,SLC1A2,MACF1,FMN2,ZNRF3,PITPNC1,SORBS1,TNIK,DTNA,CTNND2,NRG3,ZBTB20,CST3,GPM6A,CTNNA2,CLU,CPE |
3.095e-02 | -3.48 | peptide binding | molecular function | GO:0042277 | 258 | 3 | 18094 | 48 |
APOE,CST3,CLU |
3.111e-02 | -3.47 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 31 |
NTM,LSAMP |
3.114e-02 | -3.47 | Laminin | gene3d domains | 2.10.25.10 | 226 | 3 | 14470 | 44 |
NRXN1,NRG3,PAMR1 |
3.138e-02 | -3.46 | hormone transport | biological process | GO:0009914 | 103 | 2 | 18204 | 49 |
CAMK2G,CPE |
3.147e-02 | -3.46 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 50 |
MSI2,RYR3 |
3.147e-02 | -3.46 | BIN1 (bridging integrator 1) | protein interactions | 274 | 108 | 2 | 19454 | 50 |
CLU,GPM6A |
3.151e-02 | -3.46 | VCL (vinculin) | protein interactions | 7414 | 268 | 3 | 19454 | 50 |
MACF1,NEBL,SORBS1 |
3.151e-02 | -3.46 | protein complex oligomerization | biological process | GO:0051259 | 256 | 3 | 18204 | 49 |
RYR3,SLC1A2,TRPM3 |
3.155e-02 | -3.46 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 14 | 18204 | 49 |
NTRK2,NRXN1,SFXN5,RORA,CST3,CAMK2G,CLU,MACF1,BMPR1B,ATP1A2,PTPRZ1,SOX5,ZBTB20,APOE |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.163e-02 | -3.45 | regulation of signal transduction | biological process | GO:0009966 | 3114 | 14 | 18204 | 49 |
GPC5,NTRK2,TNIK,NRXN1,CTNND2,PREX2,FGFR3,RORA,SORBS1,CLU,ZNRF3,MACF1,BMPR1B,APOE |
3.179e-02 | -3.45 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 4 |
RORA |
3.184e-02 | -3.45 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 49 |
SLC1A2 |
3.184e-02 | -3.45 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 49 |
CST3 |
3.184e-02 | -3.45 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.184e-02 | -3.45 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 49 |
CST3 |
3.184e-02 | -3.45 | neurotransmitter-gated ion channel clustering | biological process | GO:0072578 | 12 | 1 | 18204 | 49 |
APOE |
3.184e-02 | -3.45 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.193e-02 | -3.44 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 37 | 16828 | 49 |
TRPM3,NTM,PREX2,MACF1,RANBP3L,CTNND2,ATP1A2,NTRK2,HIF3A,NRG3,LSAMP,TNIK,CAMK2G,MSI2,CDH20,FMN2,SLC1A2,GPC5,ABLIM1,NHSL1,PTPRZ1,RYR3,ATP13A4,NKAIN3,SFXN5,SLC4A4,RORA,PAMR1,SPARCL1,CPE,NPAS3,COL5A3,NRXN1,SLC1A3,SOX5,NEBL,ACSS1 |
3.193e-02 | -3.44 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 37 | 16828 | 49 |
MSI2,LSAMP,TNIK,CAMK2G,HIF3A,NTRK2,NRG3,CTNND2,ATP1A2,RANBP3L,MACF1,PREX2,NTM,TRPM3,NEBL,SOX5,ACSS1,COL5A3,NRXN1,NPAS3,SLC1A3,SLC4A4,SFXN5,NKAIN3,ATP13A4,CPE,SPARCL1,RORA,PAMR1,RYR3,PTPRZ1,ABLIM1,NHSL1,GPC5,CDH20,FMN2,SLC1A2 |
3.194e-02 | -3.44 | regulation of steroid metabolic process | biological process | GO:0019218 | 104 | 2 | 18204 | 49 |
APOE,RORA |
3.200e-02 | -3.44 | PRR20A (proline rich 20A) | protein interactions | 122183 | 109 | 2 | 19454 | 50 |
TRPM3,SOX5 |
3.204e-02 | -3.44 | human chr9q21.33 | chromosome location | human chr9q21.33 | 17 | 1 | 26134 | 50 |
NTRK2 |
3.204e-02 | -3.44 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 44 |
CST3 |
3.207e-02 | -3.44 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 48 | 16828 | 49 |
BMPR1B,CAMK2G,ATP1A2,FGFR3,DTNA,NRG3,HIF3A,CST3,MACF1,SLC1A3,ACSS1,NEBL,SOX5,CPE,RORA,SLC4A4,PTPRZ1,ABLIM1,FMN2,TNIK,LSAMP,CLU,MSI2,APOE,CTNND2,ZBTB20,NTRK2,RANBP3L,TRPM3,PITPNC1,NTM,PREX2,SLC25A18,NRXN1,NPAS3,COL5A3,SORBS1,RYR3,GPM6A,SPARCL1,PAMR1,SFXN5,ATP13A4,GPC5,ZNRF3,NHSL1,SLC1A2,CDH20 |
3.207e-02 | -3.44 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 48 | 16828 | 49 |
SLC25A18,COL5A3,NPAS3,NRXN1,SORBS1,GPM6A,RYR3,PAMR1,SPARCL1,SFXN5,ATP13A4,ZNRF3,GPC5,NHSL1,SLC1A2,CDH20,TNIK,LSAMP,CLU,MSI2,CTNND2,APOE,NTRK2,ZBTB20,RANBP3L,TRPM3,PITPNC1,PREX2,NTM,SLC1A3,ACSS1,NEBL,SOX5,RORA,CPE,SLC4A4,ABLIM1,PTPRZ1,FMN2,BMPR1B,CAMK2G,FGFR3,DTNA,ATP1A2,NRG3,HIF3A,CST3,MACF1 |
3.237e-02 | -3.43 | Negative regulation of the PI3K/AKT network | REACTOME pathways | R-HSA-199418 | 94 | 2 | 10285 | 31 |
NRG3,FGFR3 |
3.245e-02 | -3.43 | Insulin secretion | KEGG pathways | hsa04911 | 85 | 2 | 7161 | 24 |
ATP1A2,CAMK2G |
3.245e-02 | -3.43 | ErbB signaling pathway | KEGG pathways | hsa04012 | 85 | 2 | 7161 | 24 |
CAMK2G,NRG3 |
3.245e-02 | -3.43 | ErbB signaling pathway | KEGG pathways | ko04012 | 85 | 2 | 7161 | 24 |
CAMK2G,NRG3 |
3.251e-02 | -3.43 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 2 | 18204 | 49 |
RORA,SOX5 |
3.256e-02 | -3.42 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 49 |
CPE |
3.264e-02 | -3.42 | functioning | COSMIC cancer mutations | functioning | 1803 | 10 | 16828 | 49 |
NRG3,ZBTB20,NTRK2,FMN2,SLC1A2,TRPM3,PTPRZ1,NHSL1,SOX5,ZNRF3 |
3.264e-02 | -3.42 | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | COSMIC cancer mutations | adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning | 1803 | 10 | 16828 | 49 |
PTPRZ1,SOX5,NHSL1,ZNRF3,NRG3,ZBTB20,NTRK2,SLC1A2,FMN2,TRPM3 |
3.276e-02 | -3.42 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 48 |
RORA,ATP1A2 |
3.276e-02 | -3.42 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 42 | 16828 | 49 |
PTPRZ1,ABLIM1,NHSL1,GPC5,CDH20,SLC1A2,FMN2,SORBS1,SOX5,NEBL,ACSS1,NRXN1,COL5A3,NPAS3,SLC25A18,SLC1A3,ATP13A4,SFXN5,NKAIN3,CPE,SPARCL1,RORA,PAMR1,RYR3,GPM6A,RANBP3L,MACF1,PREX2,NTM,PITPNC1,TRPM3,LSAMP,CLU,BMPR1B,TNIK,HIF3A,ZBTB20,NTRK2,NRG3,CTNND2,ATP1A2,FGFR3 |
3.279e-02 | -3.42 | large_intestine-colon-carcinoma | COSMIC cancer mutations | large_intestine-colon-carcinoma | 2612 | 13 | 16828 | 49 |
RORA,CPE,NRG3,SLC1A3,COL5A3,NRXN1,ACSS1,TRPM3,FMN2,PREX2,GPC5,MACF1,PTPRZ1 |
3.284e-02 | -3.42 | chylomicron | cellular component | GO:0042627 | 13 | 1 | 19108 | 49 |
APOE |
3.287e-02 | -3.42 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 36 |
SPARCL1 |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | ANKH (ANKH inorganic pyrophosphate transport regulator) | protein interactions | 56172 | 13 | 1 | 19454 | 50 |
APOE |
3.291e-02 | -3.41 | PLPPR4 (phospholipid phosphatase related 4) | protein interactions | 9890 | 13 | 1 | 19454 | 50 |
ZNRF3 |
3.291e-02 | -3.41 | NPR2 (natriuretic peptide receptor 2) | protein interactions | 4882 | 13 | 1 | 19454 | 50 |
CAMK2G |
3.291e-02 | -3.41 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 50 |
NRXN1 |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.296e-02 | -3.41 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 44 |
CPE |
3.307e-02 | -3.41 | oogenesis | biological process | GO:0048477 | 106 | 2 | 18204 | 49 |
BMPR1B,FMN2 |
3.349e-02 | -3.40 | phosphate-containing compound metabolic process | biological process | GO:0006796 | 1681 | 9 | 18204 | 49 |
RORA,PTPRZ1,FGFR3,ATP1A2,BMPR1B,TNIK,CAMK2G,NTRK2,ACSS1 |
3.350e-02 | -3.40 | EGF_3 | prosite domains | PS50026 | 196 | 3 | 12186 | 44 |
NRG3,NRXN1,PAMR1 |
3.363e-02 | -3.39 | TSC22D4 (TSC22 domain family member 4) | protein interactions | 81628 | 112 | 2 | 19454 | 50 |
CLU,ABLIM1 |
3.379e-02 | -3.39 | positive regulation of cell differentiation | biological process | GO:0045597 | 906 | 6 | 18204 | 49 |
MACF1,RANBP3L,NTRK2,PTPRZ1,SOX5,BMPR1B |
3.388e-02 | -3.38 | regulation of developmental process | biological process | GO:0050793 | 2540 | 12 | 18204 | 49 |
CST3,MACF1,BMPR1B,APOE,SOX5,PTPRZ1,NTRK2,TNIK,RANBP3L,NRXN1,RORA,FGFR3 |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.395e-02 | -3.38 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 48 |
SLC4A4 |
3.395e-02 | -3.38 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 48 |
BMPR1B |
3.395e-02 | -3.38 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 48 |
ATP1A2 |
3.396e-02 | -3.38 | regulation of nervous system development | biological process | GO:0051960 | 456 | 4 | 18204 | 49 |
NRXN1,PTPRZ1,MACF1,NTRK2 |
3.400e-02 | -3.38 | calcium ion binding | molecular function | GO:0005509 | 683 | 5 | 18094 | 48 |
PAMR1,MACF1,SPARCL1,NRXN1,RYR3 |
3.418e-02 | -3.38 | YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma) | protein interactions | 7532 | 1211 | 7 | 19454 | 50 |
FMN2,MACF1,PITPNC1,NHSL1,ABLIM1,CAMK2G,SORBS1 |
3.418e-02 | -3.38 | GFI1B (growth factor independent 1B transcriptional repressor) | protein interactions | 8328 | 113 | 2 | 19454 | 50 |
ZNRF3,DTNA |
3.425e-02 | -3.37 | ZDHHC17 (zinc finger DHHC-type palmitoyltransferase 17) | protein interactions | 23390 | 277 | 3 | 19454 | 50 |
SLC1A3,GPM6A,NEBL |
3.427e-02 | -3.37 | adrenal_gland | COSMIC cancer mutations | adrenal_gland | 2628 | 13 | 16828 | 49 |
PTPRZ1,SOX5,NHSL1,ZNRF3,NRG3,ZBTB20,NTRK2,FMN2,ATP1A2,SLC1A2,FGFR3,TRPM3,CTNND2 |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.444e-02 | -3.37 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.444e-02 | -3.37 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 49 |
RORA |
3.444e-02 | -3.37 | regulation of dendritic spine maintenance | biological process | GO:1902950 | 13 | 1 | 18204 | 49 |
APOE |
3.444e-02 | -3.37 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 49 |
NRXN1 |
3.444e-02 | -3.37 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 49 |
ATP1A2 |
3.444e-02 | -3.37 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 49 |
CTNNA2 |
3.444e-02 | -3.37 | ectodermal placode development | biological process | GO:0071696 | 13 | 1 | 18204 | 49 |
NRG3 |
3.444e-02 | -3.37 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 49 |
RORA |
3.444e-02 | -3.37 | phospholipid efflux | biological process | GO:0033700 | 13 | 1 | 18204 | 49 |
APOE |
3.455e-02 | -3.37 | phosphotransferase activity, alcohol group as acceptor | molecular function | GO:0016773 | 686 | 5 | 18094 | 48 |
TNIK,NTRK2,CAMK2G,BMPR1B,FGFR3 |
3.459e-02 | -3.36 | plasma membrane raft | cellular component | GO:0044853 | 114 | 2 | 19108 | 49 |
SORBS1,ATP1A2 |
3.459e-02 | -3.36 | small molecule binding | molecular function | GO:0036094 | 6197 | 23 | 18094 | 48 |
NRXN1,PAMR1,ACSS1,ATP1A2,ZNRF3,BMPR1B,SLC1A2,ABLIM1,FGFR3,ZBTB20,ATP13A4,MACF1,SPARCL1,CAMK2G,NTRK2,PITPNC1,RORA,SLC1A3,APOE,DTNA,TNIK,CPE,RYR3 |
3.464e-02 | -3.36 | Lactose Degradation | SMPDB pathways | SMP0000457 | 12 | 1 | 1369 | 4 |
ATP1A2 |
3.464e-02 | -3.36 | Lactose Intolerance | SMPDB pathways | SMP0000458 | 12 | 1 | 1369 | 4 |
ATP1A2 |
3.474e-02 | -3.36 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 50 |
MACF1,ZBTB20 |
3.481e-02 | -3.36 | positive regulation of tumor necrosis factor production | biological process | GO:0032760 | 109 | 2 | 18204 | 49 |
ZBTB20,CLU |
3.500e-02 | -3.35 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 2 | 18521 | 50 |
RYR3,TRPM3 |
3.520e-02 | -3.35 | TyrKc | smart domains | SM00219 | 80 | 2 | 9717 | 36 |
FGFR3,NTRK2 |
3.530e-02 | -3.34 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 2 | 19454 | 50 |
BMPR1B,SOX5 |
3.531e-02 | -3.34 | Protein digestion and absorption | KEGG pathways | ko04974 | 89 | 2 | 7161 | 24 |
ATP1A2,COL5A3 |
3.531e-02 | -3.34 | Protein digestion and absorption | KEGG pathways | hsa04974 | 89 | 2 | 7161 | 24 |
ATP1A2,COL5A3 |
3.532e-02 | -3.34 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 49 |
CLU |
3.538e-02 | -3.34 | phosphatase activity | molecular function | GO:0016791 | 272 | 3 | 18094 | 48 |
CAMK2G,ATP1A2,PTPRZ1 |
3.539e-02 | -3.34 | positive regulation of cell junction assembly | biological process | GO:1901890 | 110 | 2 | 18204 | 49 |
NTRK2,NRXN1 |
3.540e-02 | -3.34 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 50 |
FGFR3 |
3.540e-02 | -3.34 | TPSAB1 (tryptase alpha/beta 1) | protein interactions | 7177 | 14 | 1 | 19454 | 50 |
CAMK2G |
3.540e-02 | -3.34 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 50 |
ZNRF3 |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 1 | 19454 | 50 |
CST3 |
3.540e-02 | -3.34 | BOD1L2 (biorientation of chromosomes in cell division 1 like 2) | protein interactions | 284257 | 14 | 1 | 19454 | 50 |
FMN2 |
3.540e-02 | -3.34 | Stag2 (STAG2 cohesin complex component) | protein interactions | 20843 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | IFNA8 (interferon alpha 8) | protein interactions | 3445 | 14 | 1 | 19454 | 50 |
APOE |
3.540e-02 | -3.34 | Aifm1 (apoptosis-inducing factor, mitochondrion-associated 1) | protein interactions | 26926 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | CHAT (choline O-acetyltransferase) | protein interactions | 1103 | 14 | 1 | 19454 | 50 |
CAMK2G |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 1 | 19454 | 50 |
NRXN1 |
3.540e-02 | -3.34 | regulation of response to stimulus | biological process | GO:0048583 | 4104 | 17 | 18204 | 49 |
APOE,BMPR1B,ZNRF3,MACF1,FMN2,CTNNA2,CLU,CAMK2G,RORA,SORBS1,FGFR3,PREX2,NRXN1,CTNND2,TNIK,NTRK2,GPC5 |
3.545e-02 | -3.34 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 3 | 16828 | 49 |
NRG3,GPC5,NPAS3 |
3.545e-02 | -3.34 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 3 | 16828 | 49 |
NRG3,NPAS3,GPC5 |
3.553e-02 | -3.34 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 48 | 16828 | 49 |
ZNRF3,GPC5,NHSL1,SLC1A2,CDH20,SLC25A18,NPAS3,NRXN1,COL5A3,SORBS1,RYR3,GPM6A,SPARCL1,PAMR1,SFXN5,ATP13A4,NKAIN3,RANBP3L,TRPM3,PITPNC1,NTM,PREX2,TNIK,CLU,LSAMP,MSI2,APOE,CTNND2,ZBTB20,NTRK2,PTPRZ1,ABLIM1,FMN2,SLC1A3,ACSS1,NEBL,SOX5,CPE,RORA,SLC4A4,MACF1,BMPR1B,CAMK2G,ATP1A2,DTNA,FGFR3,NRG3,HIF3A |
3.554e-02 | -3.34 | MIR | prosite domains | PS50919 | 10 | 1 | 12186 | 44 |
RYR3 |
3.559e-02 | -3.34 | Ethanol oxidation | REACTOME pathways | R-HSA-71384 | 12 | 1 | 10285 | 31 |
ACSS1 |
3.559e-02 | -3.34 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 31 |
FGFR3 |
3.559e-02 | -3.34 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 31 |
GPC5 |
3.559e-02 | -3.34 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 31 |
FGFR3 |
3.559e-02 | -3.34 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 31 |
GPC5 |
3.559e-02 | -3.34 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 31 |
HIF3A |
3.561e-02 | -3.34 | regulation of membrane potential | biological process | GO:0042391 | 463 | 4 | 18204 | 49 |
NTRK2,ATP1A2,SLC4A4,NRXN1 |
3.567e-02 | -3.33 | positive regulation of response to stimulus | biological process | GO:0048584 | 2266 | 11 | 18204 | 49 |
GPC5,TNIK,NTRK2,CLU,NRXN1,MACF1,FMN2,BMPR1B,FGFR3,SORBS1,APOE |
3.570e-02 | -3.33 | blood microparticle | cellular component | GO:0072562 | 116 | 2 | 19108 | 49 |
CLU,APOE |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.575e-02 | -3.33 | lung-carcinoma-large_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-large_cell_carcinoma | 849 | 6 | 16828 | 49 |
FGFR3,TNIK,CAMK2G,BMPR1B,NTRK2,PTPRZ1 |
3.575e-02 | -3.33 | large_cell_carcinoma | COSMIC cancer mutations | large_cell_carcinoma | 849 | 6 | 16828 | 49 |
PTPRZ1,NTRK2,BMPR1B,CAMK2G,TNIK,FGFR3 |
3.581e-02 | -3.33 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 3 | 16828 | 49 |
FGFR3,MACF1,PTPRZ1 |
3.586e-02 | -3.33 | RBBP8 (RB binding protein 8, endonuclease) | protein interactions | 5932 | 116 | 2 | 19454 | 50 |
CTNNA2,CLU |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
SPARCL1,MACF1 |
3.590e-02 | -3.33 | - | gene3d domains | 3.10.450.50 | 12 | 1 | 14470 | 44 |
CAMK2G |
3.590e-02 | -3.33 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 44 |
CTNNA2 |
3.603e-02 | -3.32 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 18 | 16828 | 49 |
ACSS1,NEBL,COL5A3,PAMR1,RORA,NRG3,ATP13A4,SLC4A4,FGFR3,ATP1A2,CTNND2,ABLIM1,GPC5,MACF1,PREX2,SLC1A2,FMN2,CDH20 |
3.604e-02 | -3.32 | rhythmic process | biological process | GO:0048511 | 270 | 3 | 18204 | 49 |
BMPR1B,NTRK2,RORA |
3.610e-02 | -3.32 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 13 | 16828 | 49 |
PTPRZ1,PREX2,CDH20,SOX5,NEBL,SLC1A3,NRXN1,LSAMP,NRG3,ATP13A4,ATP1A2,CTNND2,RYR3 |
3.627e-02 | -3.32 | Ion_trans | pfam domains | PF00520 | 109 | 2 | 17795 | 49 |
TRPM3,RYR3 |
3.645e-02 | -3.31 | MIR | smart domains | SM00472 | 10 | 1 | 9717 | 36 |
RYR3 |
3.647e-02 | -3.31 | phosphorus metabolic process | biological process | GO:0006793 | 1707 | 9 | 18204 | 49 |
CAMK2G,TNIK,NTRK2,ACSS1,ATP1A2,BMPR1B,RORA,FGFR3,PTPRZ1 |
3.647e-02 | -3.31 | HYOU1 (hypoxia up-regulated 1) | protein interactions | 10525 | 284 | 3 | 19454 | 50 |
FGFR3,CPE,CLU |
3.647e-02 | -3.31 | Dppa3 (developmental pluripotency-associated 3) | protein interactions | 73708 | 284 | 3 | 19454 | 50 |
MSI2,ATP1A2,CAMK2G |
3.652e-02 | -3.31 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 48 |
MACF1 |
3.661e-02 | -3.31 | SNX27 (sorting nexin 27) | protein interactions | 81609 | 489 | 4 | 19454 | 50 |
COL5A3,ABLIM1,CLU,SLC1A3 |
3.668e-02 | -3.31 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 5 | 19454 | 50 |
MACF1,DTNA,FMN2,TNIK,SLC1A3 |
3.675e-02 | -3.30 | SHC1 events in EGFR signaling | REACTOME pathways | R-HSA-180336 | 245 | 3 | 10285 | 31 |
FGFR3,NRG3,CAMK2G |
3.675e-02 | -3.30 | RAF/MAP kinase cascade | REACTOME pathways | R-HSA-5673001 | 245 | 3 | 10285 | 31 |
NRG3,CAMK2G,FGFR3 |
3.675e-02 | -3.30 | SOS-mediated signalling | REACTOME pathways | R-HSA-112412 | 245 | 3 | 10285 | 31 |
NRG3,CAMK2G,FGFR3 |
3.675e-02 | -3.30 | GRB2 events in EGFR signaling | REACTOME pathways | R-HSA-179812 | 245 | 3 | 10285 | 31 |
FGFR3,CAMK2G,NRG3 |
3.678e-02 | -3.30 | HLH_DNA-bd_sf | interpro domains | IPR036638 | 112 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.678e-02 | -3.30 | bHLH_dom | interpro domains | IPR011598 | 112 | 2 | 18521 | 50 |
NPAS3,HIF3A |
3.691e-02 | -3.30 | Visual phototransduction | REACTOME pathways | R-HSA-2187338 | 101 | 2 | 10285 | 31 |
APOE,GPC5 |
3.704e-02 | -3.30 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 49 |
TNIK,NTRK2,CTNND2,MACF1,CPE,ZNRF3,BMPR1B,NRG3,FGFR3,SORBS1 |
3.704e-02 | -3.30 | acetyl-CoA biosynthetic process | biological process | GO:0006085 | 14 | 1 | 18204 | 49 |
ACSS1 |
3.704e-02 | -3.30 | regulation of skeletal muscle adaptation | biological process | GO:0014733 | 14 | 1 | 18204 | 49 |
CAMK2G |
3.704e-02 | -3.30 | positive regulation of phospholipid transport | biological process | GO:2001140 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.704e-02 | -3.30 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 49 |
ATP1A2 |
3.704e-02 | -3.30 | negative regulation of long-term synaptic potentiation | biological process | GO:1900272 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 49 |
RYR3 |
3.704e-02 | -3.30 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 49 |
SLC1A2 |
3.715e-02 | -3.29 | Neurexin-like | interpro domains | IPR003585 | 14 | 1 | 18521 | 50 |
NRXN1 |
3.717e-02 | -3.29 | positive regulation of tumor necrosis factor superfamily cytokine production | biological process | GO:1903557 | 113 | 2 | 18204 | 49 |
CLU,ZBTB20 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.745e-02 | -3.28 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 3 | 19454 | 50 |
NTRK2,SORBS1,DTNA |
3.749e-02 | -3.28 | Trehalose Degradation | SMPDB pathways | SMP0000467 | 13 | 1 | 1369 | 4 |
ATP1A2 |
3.750e-02 | -3.28 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 2 | 16828 | 49 |
NRG3,GPC5 |
3.756e-02 | -3.28 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 2 | 19454 | 50 |
CLU,APOE |
3.759e-02 | -3.28 | human chr8p21.1 | chromosome location | human chr8p21.1 | 20 | 1 | 26134 | 50 |
CLU |
3.768e-02 | -3.28 | ATP binding | molecular function | GO:0005524 | 1467 | 8 | 18094 | 48 |
TNIK,FGFR3,ATP13A4,CAMK2G,NTRK2,ACSS1,ATP1A2,BMPR1B |
3.774e-02 | -3.28 | gliogenesis | biological process | GO:0042063 | 275 | 3 | 18204 | 49 |
CLU,PTPRZ1,NTRK2 |
3.777e-02 | -3.28 | negative regulation of protein catabolic process | biological process | GO:0042177 | 114 | 2 | 18204 | 49 |
FMN2,CST3 |
3.780e-02 | -3.28 | low-density lipoprotein particle | cellular component | GO:0034362 | 15 | 1 | 19108 | 49 |
APOE |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | XIRP1 (xin actin binding repeat containing 1) | protein interactions | 165904 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | TAFA5 (TAFA chemokine like family member 5) | protein interactions | 25817 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.788e-02 | -3.27 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 1 | 19454 | 50 |
TNIK |
3.788e-02 | -3.27 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 50 |
FGFR3 |
3.806e-02 | -3.27 | positive regulation of MAPK cascade | biological process | GO:0043410 | 473 | 4 | 18204 | 49 |
APOE,FGFR3,NTRK2,TNIK |
3.810e-02 | -3.27 | CEP128 (centrosomal protein 128) | protein interactions | 145508 | 289 | 3 | 19454 | 50 |
ABLIM1,NEBL,SORBS1 |
3.819e-02 | -3.27 | circulatory system development | biological process | GO:0072359 | 933 | 6 | 18204 | 49 |
HIF3A,NTRK2,CPE,APOE,RORA,NEBL |
3.819e-02 | -3.27 | membrane raft | cellular component | GO:0045121 | 290 | 3 | 19108 | 49 |
SORBS1,SLC1A2,ATP1A2 |
3.828e-02 | -3.26 | ARMS-mediated activation | REACTOME pathways | R-HSA-170984 | 249 | 3 | 10285 | 31 |
FGFR3,CAMK2G,NRG3 |
3.828e-02 | -3.26 | Signalling to p38 via RIT and RIN | REACTOME pathways | R-HSA-187706 | 249 | 3 | 10285 | 31 |
FGFR3,NRG3,CAMK2G |
3.850e-02 | -3.26 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 31 |
FGFR3 |
3.850e-02 | -3.26 | ERBB2 Activates PTK6 Signaling | REACTOME pathways | R-HSA-8847993 | 13 | 1 | 10285 | 31 |
NRG3 |
3.867e-02 | -3.25 | Frs2-mediated activation | REACTOME pathways | R-HSA-170968 | 250 | 3 | 10285 | 31 |
FGFR3,CAMK2G,NRG3 |
3.868e-02 | -3.25 | positive regulation of phosphate metabolic process | biological process | GO:0045937 | 697 | 5 | 18204 | 49 |
NTRK2,TNIK,FGFR3,ZBTB20,SLC4A4 |
3.868e-02 | -3.25 | positive regulation of phosphorus metabolic process | biological process | GO:0010562 | 697 | 5 | 18204 | 49 |
FGFR3,ZBTB20,SLC4A4,TNIK,NTRK2 |
3.876e-02 | -3.25 | GOPC (golgi associated PDZ and coiled-coil motif containing) | protein interactions | 57120 | 291 | 3 | 19454 | 50 |
NTRK2,FGFR3,SLC25A18 |
3.878e-02 | -3.25 | actin filament organization | biological process | GO:0007015 | 278 | 3 | 18204 | 49 |
FMN2,SORBS1,NEBL |
3.881e-02 | -3.25 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 49 |
HIF3A,NEBL |
3.885e-02 | -3.25 | membrane microdomain | cellular component | GO:0098857 | 292 | 3 | 19108 | 49 |
SLC1A2,ATP1A2,SORBS1 |
3.888e-02 | -3.25 | Composition of Lipid Particles | WikiPathways | WP3601 | 10 | 1 | 5310 | 21 |
APOE |
3.893e-02 | -3.25 | Stimuli-sensing channels | REACTOME pathways | R-HSA-2672351 | 104 | 2 | 10285 | 31 |
RYR3,TRPM3 |
3.902e-02 | -3.24 | RECEPTOR_TYR_KIN_II | prosite domains | PS00239 | 11 | 1 | 12186 | 44 |
NTRK2 |
3.902e-02 | -3.24 | RANBD1 | prosite domains | PS50196 | 11 | 1 | 12186 | 44 |
RANBP3L |
3.902e-02 | -3.24 | NC1_FIB | prosite domains | PS51461 | 11 | 1 | 12186 | 44 |
COL5A3 |
3.906e-02 | -3.24 | MAPK1/MAPK3 signaling | REACTOME pathways | R-HSA-5684996 | 251 | 3 | 10285 | 31 |
FGFR3,CAMK2G,NRG3 |
3.908e-02 | -3.24 | filamin binding | molecular function | GO:0031005 | 15 | 1 | 18094 | 48 |
NEBL |
3.908e-02 | -3.24 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 48 |
PITPNC1 |
3.908e-02 | -3.24 | AMP binding | molecular function | GO:0016208 | 15 | 1 | 18094 | 48 |
ACSS1 |
3.908e-02 | -3.24 | neurexin family protein binding | molecular function | GO:0042043 | 15 | 1 | 18094 | 48 |
CPE |
3.908e-02 | -3.24 | C4-dicarboxylate transmembrane transporter activity | molecular function | GO:0015556 | 15 | 1 | 18094 | 48 |
SLC25A18 |
3.908e-02 | -3.24 | tropomyosin binding | molecular function | GO:0005523 | 15 | 1 | 18094 | 48 |
NEBL |
3.919e-02 | -3.24 | homeostatic process | biological process | GO:0042592 | 1456 | 8 | 18204 | 49 |
SLC4A4,SLC1A3,ATP13A4,RYR3,ATP1A2,RORA,ZBTB20,APOE |
3.930e-02 | -3.24 | SLMAP (sarcolemma associated protein) | protein interactions | 7871 | 122 | 2 | 19454 | 50 |
CAMK2G,TNIK |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
DTNA,NHSL1 |
3.943e-02 | -3.23 | human chr10q23.1 | chromosome location | human chr10q23.1 | 21 | 1 | 26134 | 50 |
NRG3 |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
CPE |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.945e-02 | -3.23 | Prolonged ERK activation events | REACTOME pathways | R-HSA-169893 | 252 | 3 | 10285 | 31 |
CAMK2G,NRG3,FGFR3 |
3.949e-02 | -3.23 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 21 |
SLC4A4 |
3.959e-02 | -3.23 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 2 | 18204 | 49 |
NTRK2,NRXN1 |
3.964e-02 | -3.23 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | peripheral nervous system neuron development | biological process | GO:0048935 | 15 | 1 | 18204 | 49 |
NTRK2 |
3.964e-02 | -3.23 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 49 |
MACF1 |
3.964e-02 | -3.23 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 49 |
SLC1A2 |
3.964e-02 | -3.23 | lipoprotein catabolic process | biological process | GO:0042159 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 49 |
SOX5 |
3.964e-02 | -3.23 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.964e-02 | -3.23 | positive regulation of glycogen biosynthetic process | biological process | GO:0045725 | 15 | 1 | 18204 | 49 |
SORBS1 |
3.964e-02 | -3.23 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 49 |
RORA |
3.964e-02 | -3.23 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 49 |
FGFR3 |
3.964e-02 | -3.23 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | regulation of phospholipid transport | biological process | GO:2001138 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | peripheral nervous system neuron differentiation | biological process | GO:0048934 | 15 | 1 | 18204 | 49 |
NTRK2 |
3.964e-02 | -3.23 | positive regulation of cholesterol metabolic process | biological process | GO:0090205 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 49 |
ATP1A2 |
3.967e-02 | -3.23 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 46 | 16828 | 49 |
SLC1A3,NEBL,SOX5,ACSS1,SLC4A4,RORA,CPE,ABLIM1,PTPRZ1,FMN2,CAMK2G,BMPR1B,DTNA,FGFR3,ATP1A2,HIF3A,NRG3,MACF1,COL5A3,NRXN1,NPAS3,SLC25A18,SORBS1,GPM6A,RYR3,ATP13A4,NKAIN3,SFXN5,PAMR1,SPARCL1,GPC5,ZNRF3,NHSL1,CDH20,SLC1A2,LSAMP,CLU,TNIK,CTNND2,NTRK2,ZBTB20,RANBP3L,TRPM3,NTM,PREX2,PITPNC1 |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.975e-02 | -3.23 | FH2_Formin_sf | interpro domains | IPR042201 | 15 | 1 | 18521 | 50 |
FMN2 |
3.975e-02 | -3.23 | FH2_Formin | interpro domains | IPR015425 | 15 | 1 | 18521 | 50 |
FMN2 |
3.975e-02 | -3.23 | NTF2-like_dom_sf | interpro domains | IPR032710 | 15 | 1 | 18521 | 50 |
CAMK2G |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.978e-02 | -3.22 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 2 | 7161 | 24 |
SLC4A4,ATP1A2 |
3.978e-02 | -3.22 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 2 | 7161 | 24 |
SLC4A4,ATP1A2 |
3.984e-02 | -3.22 | Signaling by Leptin | REACTOME pathways | R-HSA-2586552 | 253 | 3 | 10285 | 31 |
NRG3,CAMK2G,FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.003e-02 | -3.22 | RanBD | smart domains | SM00160 | 11 | 1 | 9717 | 36 |
RANBP3L |
4.003e-02 | -3.22 | COLFI | smart domains | SM00038 | 11 | 1 | 9717 | 36 |
COL5A3 |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.035e-02 | -3.21 | CYP2C8 (cytochrome P450 family 2 subfamily C member 8) | protein interactions | 1558 | 16 | 1 | 19454 | 50 |
APOE |
4.035e-02 | -3.21 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 50 |
ZNRF3 |
4.035e-02 | -3.21 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | DUS1L (dihydrouridine synthase 1 like) | protein interactions | 64118 | 16 | 1 | 19454 | 50 |
CAMK2G |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | CAMK1G (calcium/calmodulin dependent protein kinase IG) | protein interactions | 57172 | 16 | 1 | 19454 | 50 |
CAMK2G |
4.035e-02 | -3.21 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 1 | 19454 | 50 |
NRXN1 |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
ZBTB20 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.053e-02 | -3.21 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 49 |
TNIK |
4.053e-02 | -3.21 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 49 |
ATP1A2 |
4.053e-02 | -3.21 | FH2 | pfam domains | PF02181 | 15 | 1 | 17795 | 49 |
FMN2 |
4.054e-02 | -3.21 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 2 | 7161 | 24 |
RYR3,CAMK2G |
4.054e-02 | -3.21 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 2 | 7161 | 24 |
RYR3,CAMK2G |
4.063e-02 | -3.20 | Interleukin receptor SHC signaling | REACTOME pathways | R-HSA-912526 | 255 | 3 | 10285 | 31 |
FGFR3,CAMK2G,NRG3 |
4.082e-02 | -3.20 | metal ion binding | molecular function | GO:0046872 | 4239 | 17 | 18094 | 48 |
MACF1,CPE,RYR3,ABLIM1,DTNA,ATP13A4,ZBTB20,ATP1A2,ZNRF3,RORA,APOE,SLC1A2,BMPR1B,SLC1A3,SPARCL1,NRXN1,PAMR1 |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
NTM,FGFR3,LSAMP,NTRK2 |
4.103e-02 | -3.19 | Signalling to RAS | REACTOME pathways | R-HSA-167044 | 256 | 3 | 10285 | 31 |
NRG3,CAMK2G,FGFR3 |
4.114e-02 | -3.19 | protein-containing complex binding | molecular function | GO:0044877 | 1772 | 9 | 18094 | 48 |
CTNNA2,PTPRZ1,APOE,MACF1,NEBL,COL5A3,SPARCL1,ABLIM1,CLU |
4.117e-02 | -3.19 | signaling receptor binding | molecular function | GO:0005102 | 1493 | 8 | 18094 | 48 |
SORBS1,CPE,ZNRF3,PTPRZ1,APOE,NRXN1,CLU,NRG3 |
4.141e-02 | -3.18 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 31 |
ABLIM1 |
4.141e-02 | -3.18 | SHC1 events in ERBB4 signaling | REACTOME pathways | R-HSA-1250347 | 14 | 1 | 10285 | 31 |
NRG3 |
4.145e-02 | -3.18 | skin-acral-malignant_melanoma | COSMIC cancer mutations | skin-acral-malignant_melanoma | 264 | 3 | 16828 | 49 |
COL5A3,CDH20,FMN2 |
4.146e-02 | -3.18 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 6 | 16828 | 49 |
FGFR3,FMN2,PREX2,HIF3A,PAMR1,ACSS1 |
4.163e-02 | -3.18 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 48 |
RORA |
4.163e-02 | -3.18 | misfolded protein binding | molecular function | GO:0051787 | 16 | 1 | 18094 | 48 |
CLU |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
PITPNC1,GPM6A |
4.184e-02 | -3.17 | VEGFR2 mediated cell proliferation | REACTOME pathways | R-HSA-5218921 | 258 | 3 | 10285 | 31 |
CAMK2G,NRG3,FGFR3 |
4.223e-02 | -3.16 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | insulin metabolic process | biological process | GO:1901142 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | short-chain fatty acid metabolic process | biological process | GO:0046459 | 16 | 1 | 18204 | 49 |
ACSS1 |
4.223e-02 | -3.16 | positive regulation of membrane protein ectodomain proteolysis | biological process | GO:0051044 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 49 |
NRXN1 |
4.223e-02 | -3.16 | cardiac left ventricle morphogenesis | biological process | GO:0003214 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 49 |
SLC1A3 |
4.223e-02 | -3.16 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 49 |
ATP1A2 |
4.223e-02 | -3.16 | low-density lipoprotein particle remodeling | biological process | GO:0034374 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 49 |
ZNRF3 |
4.223e-02 | -3.16 | asymmetric cell division | biological process | GO:0008356 | 16 | 1 | 18204 | 49 |
SOX5 |
4.223e-02 | -3.16 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 49 |
SLC1A2 |
4.225e-02 | -3.16 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 44 |
SPARCL1,MACF1,RYR3 |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPE |
4.267e-02 | -3.15 | neuron projection terminus | cellular component | GO:0044306 | 128 | 2 | 19108 | 49 |
NTRK2,SLC1A2 |
4.273e-02 | -3.15 | apical dendrite | cellular component | GO:0097440 | 17 | 1 | 19108 | 49 |
CLU |
4.274e-02 | -3.15 | adenoid_cystic_carcinoma | COSMIC cancer mutations | adenoid_cystic_carcinoma | 1123 | 7 | 16828 | 49 |
NTRK2,RORA,CTNND2,RYR3,FGFR3,TNIK,CAMK2G |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | FAM163B (family with sequence similarity 163 member B) | protein interactions | 642968 | 17 | 1 | 19454 | 50 |
CAMK2G |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | C16orf92 (chromosome 16 open reading frame 92) | protein interactions | 146378 | 17 | 1 | 19454 | 50 |
APOE |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | KRTAP19-3 (keratin associated protein 19-3) | protein interactions | 337970 | 17 | 1 | 19454 | 50 |
CAMK2G |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.286e-02 | -3.15 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 2 | 19454 | 50 |
SOX5,MACF1 |
4.302e-02 | -3.15 | acral | COSMIC cancer mutations | acral | 268 | 3 | 16828 | 49 |
CDH20,COL5A3,FMN2 |
4.304e-02 | -3.15 | SH3DOMAIN | prints domains | PR00452 | 83 | 2 | 5227 | 21 |
SORBS1,NEBL |
4.321e-02 | -3.14 | CARM1 (coactivator associated arginine methyltransferase 1) | protein interactions | 10498 | 304 | 3 | 19454 | 50 |
CAMK2G,RORA,DTNA |
4.346e-02 | -3.14 | POLA2 (DNA polymerase alpha 2, accessory subunit) | protein interactions | 23649 | 129 | 2 | 19454 | 50 |
CPE,FGFR3 |
4.346e-02 | -3.14 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 2 | 19454 | 50 |
ABLIM1,ZBTB20 |
4.346e-02 | -3.14 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 50 |
ZBTB20,SOX5 |
4.347e-02 | -3.14 | Interleukin-2 signaling | REACTOME pathways | R-HSA-451927 | 262 | 3 | 10285 | 31 |
FGFR3,NRG3,CAMK2G |
4.350e-02 | -3.13 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 4 | 18204 | 49 |
NTRK2,BMPR1B,SOX5,FGFR3 |
4.362e-02 | -3.13 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 6 | 16828 | 49 |
NPAS3,FGFR3,ATP1A2,ABLIM1,PTPRZ1,SPARCL1 |
4.388e-02 | -3.13 | Z disc | cellular component | GO:0030018 | 130 | 2 | 19108 | 49 |
RYR3,NEBL |
4.388e-02 | -3.13 | Signalling to ERKs | REACTOME pathways | R-HSA-187687 | 263 | 3 | 10285 | 31 |
CAMK2G,NRG3,FGFR3 |
4.397e-02 | -3.12 | action potential | biological process | GO:0001508 | 124 | 2 | 18204 | 49 |
NTRK2,ATP1A2 |
4.417e-02 | -3.12 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.417e-02 | -3.12 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.424e-02 | -3.12 | Ig-like_fold | interpro domains | IPR013783 | 721 | 5 | 18521 | 50 |
NTM,FGFR3,PTPRZ1,NTRK2,LSAMP |
4.430e-02 | -3.12 | ERBB2 Regulates Cell Motility | REACTOME pathways | R-HSA-6785631 | 15 | 1 | 10285 | 31 |
NRG3 |
4.432e-02 | -3.12 | endomembrane system | cellular component | GO:0012505 | 4764 | 18 | 19108 | 49 |
TNIK,RYR3,FGFR3,GPC5,CLU,APOE,CPE,CAMK2G,MACF1,SPARCL1,ATP13A4,NRXN1,FMN2,COL5A3,CST3,RANBP3L,ATP1A2,NTRK2 |
4.461e-02 | -3.11 | actomyosin structure organization | biological process | GO:0031032 | 125 | 2 | 18204 | 49 |
SORBS1,NEBL |
4.467e-02 | -3.11 | Formin, FH2 domain | gene3d domains | 1.20.58.2220 | 15 | 1 | 14470 | 44 |
FMN2 |
4.472e-02 | -3.11 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 8 | 16828 | 49 |
MACF1,RYR3,CTNND2,ATP1A2,FGFR3,TRPM3,ATP13A4,CPE |
4.472e-02 | -3.11 | FCERI mediated MAPK activation | REACTOME pathways | R-HSA-2871796 | 265 | 3 | 10285 | 31 |
FGFR3,NRG3,CAMK2G |
4.477e-02 | -3.11 | Helix-loop-helix DNA-binding domain | gene3d domains | 4.10.280.10 | 111 | 2 | 14470 | 44 |
HIF3A,NPAS3 |
4.481e-02 | -3.11 | cell population proliferation | biological process | GO:0008283 | 726 | 5 | 18204 | 49 |
ZNRF3,RORA,SOX5,FGFR3,CLU |
4.481e-02 | -3.11 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 49 |
TNIK |
4.481e-02 | -3.11 | high-density lipoprotein particle remodeling | biological process | GO:0034375 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 49 |
CTNNA2 |
4.481e-02 | -3.11 | negative regulation of triglyceride metabolic process | biological process | GO:0090209 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | regulation of inclusion body assembly | biological process | GO:0090083 | 17 | 1 | 18204 | 49 |
CLU |
4.481e-02 | -3.11 | retinal rod cell differentiation | biological process | GO:0060221 | 17 | 1 | 18204 | 49 |
NTRK2 |
4.481e-02 | -3.11 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 49 |
RORA |
4.481e-02 | -3.11 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 49 |
SLC1A2 |
4.481e-02 | -3.11 | fatty acid homeostasis | biological process | GO:0055089 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 49 |
RYR3 |
4.481e-02 | -3.11 | positive regulation of vascular permeability | biological process | GO:0043117 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | positive regulation of glycogen metabolic process | biological process | GO:0070875 | 17 | 1 | 18204 | 49 |
SORBS1 |
4.481e-02 | -3.11 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.481e-02 | -3.11 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 49 |
ATP1A2 |
4.493e-02 | -3.10 | regulation of ERK1 and ERK2 cascade | biological process | GO:0070372 | 295 | 3 | 18204 | 49 |
NTRK2,APOE,FGFR3 |
4.493e-02 | -3.10 | AMP-bd_C | interpro domains | IPR025110 | 17 | 1 | 18521 | 50 |
ACSS1 |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 50 |
HIF3A |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
NTRK2,ZBTB20,CTNND2,APOE,MSI2,TNIK,LSAMP,CLU,PITPNC1,PREX2,NTM,TRPM3,RANBP3L,PAMR1,SPARCL1,SFXN5,ATP13A4,NKAIN3,GPM6A,RYR3,SORBS1,SLC25A18,COL5A3,NRXN1,NPAS3,SLC1A2,CDH20,NHSL1,GPC5,ZNRF3,NRG3,HIF3A,FGFR3,DTNA,ATP1A2,BMPR1B,CAMK2G,CST3,MACF1,RORA,CPE,SLC4A4,ACSS1,SOX5,NEBL,SLC1A3,FMN2,ABLIM1,PTPRZ1 |
4.514e-02 | -3.10 | skeletal system development | biological process | GO:0001501 | 500 | 4 | 18204 | 49 |
RANBP3L,BMPR1B,SOX5,FGFR3 |
4.517e-02 | -3.10 | PROTEIN_KINASE_TYR | prosite domains | PS00109 | 94 | 2 | 12186 | 44 |
NTRK2,FGFR3 |
4.525e-02 | -3.10 | kinase activity | molecular function | GO:0016301 | 739 | 5 | 18094 | 48 |
CAMK2G,NTRK2,TNIK,FGFR3,BMPR1B |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 50 |
FGFR3 |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | ACAP1 (ArfGAP with coiled-coil, ankyrin repeat and PH domains 1) | protein interactions | 9744 | 18 | 1 | 19454 | 50 |
NEBL |
4.529e-02 | -3.09 | Lck (lymphocyte protein tyrosine kinase) | protein interactions | 16818 | 18 | 1 | 19454 | 50 |
APOE |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | CYP2E1 (cytochrome P450 family 2 subfamily E member 1) | protein interactions | 1571 | 18 | 1 | 19454 | 50 |
CLU |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.530e-02 | -3.09 | GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) | protein interactions | 338328 | 132 | 2 | 19454 | 50 |
CPE,FGFR3 |
4.530e-02 | -3.09 | STRN (striatin) | protein interactions | 6801 | 132 | 2 | 19454 | 50 |
TNIK,CAMK2G |
4.547e-02 | -3.09 | phosphorylation | biological process | GO:0016310 | 729 | 5 | 18204 | 49 |
FGFR3,CAMK2G,NTRK2,TNIK,BMPR1B |
4.557e-02 | -3.09 | salivary_gland | COSMIC cancer mutations | salivary_gland | 1139 | 7 | 16828 | 49 |
NTRK2,RORA,RYR3,CTNND2,FGFR3,CAMK2G,TNIK |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.569e-02 | -3.09 | muscle system process | biological process | GO:0003012 | 297 | 3 | 18204 | 49 |
RYR3,ATP1A2,DTNA |
4.574e-02 | -3.08 | SH3 | prosite domains | PS50002 | 222 | 3 | 12186 | 44 |
MACF1,NEBL,SORBS1 |
4.581e-02 | -3.08 | AMP-binding_C | pfam domains | PF13193 | 17 | 1 | 17795 | 49 |
ACSS1 |
4.581e-02 | -3.08 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 49 |
CST3 |
4.581e-02 | -3.08 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 49 |
DTNA |
4.581e-02 | -3.08 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 49 |
PTPRZ1 |
4.590e-02 | -3.08 | response to amino acid | biological process | GO:0043200 | 127 | 2 | 18204 | 49 |
NTRK2,SLC1A2 |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 44 |
CPE |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 44 |
CPE |
4.606e-02 | -3.08 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 6 | 16828 | 49 |
ABLIM1,PTPRZ1,SPARCL1,NPAS3,FGFR3,ATP1A2 |
4.621e-02 | -3.07 | adenyl ribonucleotide binding | molecular function | GO:0032559 | 1528 | 8 | 18094 | 48 |
NTRK2,CAMK2G,ACSS1,ATP1A2,BMPR1B,TNIK,FGFR3,ATP13A4 |
4.623e-02 | -3.07 | intracellular signal transduction | biological process | GO:0035556 | 1505 | 8 | 18204 | 49 |
FGFR3,APOE,ATP1A2,PREX2,RYR3,NRG3,FMN2,TNIK |
4.649e-02 | -3.07 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 21 |
RYR3 |
4.649e-02 | -3.07 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 21 |
BMPR1B |
4.652e-02 | -3.07 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 49 |
SORBS1,SLC1A3,SLC1A2,RYR3 |
4.655e-02 | -3.07 | glial cell development | biological process | GO:0021782 | 128 | 2 | 18204 | 49 |
NTRK2,CLU |
4.655e-02 | -3.07 | myelination | biological process | GO:0042552 | 128 | 2 | 18204 | 49 |
CLU,NTRK2 |
4.671e-02 | -3.06 | heparan sulfate proteoglycan binding | molecular function | GO:0043395 | 18 | 1 | 18094 | 48 |
APOE |
4.671e-02 | -3.06 | transmembrane receptor protein tyrosine kinase activator activity | molecular function | GO:0030297 | 18 | 1 | 18094 | 48 |
NRG3 |
4.671e-02 | -3.06 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 48 |
PITPNC1 |
4.671e-02 | -3.06 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 1 | 18094 | 48 |
RYR3 |
4.674e-02 | -3.06 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 5 | 19454 | 50 |
CLU,FGFR3,NTRK2,SLC1A2,MSI2 |
4.683e-02 | -3.06 | RET signaling | REACTOME pathways | R-HSA-8853659 | 270 | 3 | 10285 | 31 |
NRG3,CAMK2G,FGFR3 |
4.716e-02 | -3.05 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 2 | 19454 | 50 |
ABLIM1,CAMK2G |
4.716e-02 | -3.05 | BMP4 (bone morphogenetic protein 4) | protein interactions | 652 | 135 | 2 | 19454 | 50 |
CLU,BMPR1B |
4.718e-02 | -3.05 | GRB2 events in ERBB2 signaling | REACTOME pathways | R-HSA-1963640 | 16 | 1 | 10285 | 31 |
NRG3 |
4.718e-02 | -3.05 | PI3K events in ERBB2 signaling | REACTOME pathways | R-HSA-1963642 | 16 | 1 | 10285 | 31 |
NRG3 |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
RYR3,GPM6A,SPARCL1,PAMR1,NKAIN3,ATP13A4,SFXN5,SLC25A18,NPAS3,NRXN1,COL5A3,SORBS1,SLC1A2,CDH20,GPC5,ZNRF3,NHSL1,APOE,CTNND2,ZBTB20,NTRK2,TNIK,CLU,LSAMP,MSI2,TRPM3,PITPNC1,PREX2,NTM,RANBP3L,CPE,RORA,SLC4A4,SLC1A3,ACSS1,NEBL,SOX5,FMN2,PTPRZ1,ABLIM1,ATP1A2,DTNA,FGFR3,NRG3,HIF3A,CAMK2G,BMPR1B,CST3,MACF1 |
4.726e-02 | -3.05 | Interleukin-3, 5 and GM-CSF signaling | REACTOME pathways | R-HSA-512988 | 271 | 3 | 10285 | 31 |
FGFR3,CAMK2G,NRG3 |
4.738e-02 | -3.05 | myelin maintenance | biological process | GO:0043217 | 18 | 1 | 18204 | 49 |
CLU |
4.738e-02 | -3.05 | response to misfolded protein | biological process | GO:0051788 | 18 | 1 | 18204 | 49 |
CLU |
4.738e-02 | -3.05 | receptor catabolic process | biological process | GO:0032801 | 18 | 1 | 18204 | 49 |
ZNRF3 |
4.738e-02 | -3.05 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 49 |
CTNND2 |
4.738e-02 | -3.05 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 49 |
CST3 |
4.738e-02 | -3.05 | cardiac myofibril assembly | biological process | GO:0055003 | 18 | 1 | 18204 | 49 |
NEBL |
4.738e-02 | -3.05 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 49 |
ATP1A2 |
4.738e-02 | -3.05 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 49 |
RORA |
4.738e-02 | -3.05 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 49 |
APOE |
4.738e-02 | -3.05 | negative regulation of anoikis | biological process | GO:2000811 | 18 | 1 | 18204 | 49 |
NTRK2 |
4.761e-02 | -3.04 | postsynaptic density | cellular component | GO:0014069 | 317 | 3 | 19108 | 49 |
NTRK2,TNIK,CTNND2 |
4.764e-02 | -3.04 | astrocyte projection | cellular component | GO:0097449 | 19 | 1 | 19108 | 49 |
SLC1A2 |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.772e-02 | -3.04 | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-abdomen-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 120 | 2 | 16828 | 49 |
CTNND2,FMN2 |
4.774e-02 | -3.04 | FBXO27 (F-box protein 27) | protein interactions | 126433 | 19 | 1 | 19454 | 50 |
CLU |
4.774e-02 | -3.04 | RRAD (RRAD, Ras related glycolysis inhibitor and calcium channel regulator) | protein interactions | 6236 | 19 | 1 | 19454 | 50 |
CAMK2G |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.774e-02 | -3.04 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 50 |
ZBTB20 |
4.774e-02 | -3.04 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 50 |
NRXN1 |
4.774e-02 | -3.04 | OSM (oncostatin M) | protein interactions | 5008 | 19 | 1 | 19454 | 50 |
TRPM3 |
4.774e-02 | -3.04 | Mtx1 (metaxin 1) | protein interactions | 17827 | 19 | 1 | 19454 | 50 |
CAMK2G |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.774e-02 | -3.04 | GCHFR (GTP cyclohydrolase I feedback regulator) | protein interactions | 2644 | 19 | 1 | 19454 | 50 |
NEBL |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | LTC4S (leukotriene C4 synthase) | protein interactions | 4056 | 19 | 1 | 19454 | 50 |
CAMK2G |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.786e-02 | -3.04 | axon ensheathment | biological process | GO:0008366 | 130 | 2 | 18204 | 49 |
NTRK2,CLU |
4.786e-02 | -3.04 | ensheathment of neurons | biological process | GO:0007272 | 130 | 2 | 18204 | 49 |
NTRK2,CLU |
4.793e-02 | -3.04 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 3 | 16828 | 49 |
PREX2,TNIK,ATP1A2 |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.856e-02 | -3.02 | protein-folding chaperone binding | molecular function | GO:0051087 | 133 | 2 | 18094 | 48 |
ATP1A2,CLU |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.924e-02 | -3.01 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 48 |
BMPR1B |
4.924e-02 | -3.01 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 48 |
ATP1A2 |
4.937e-02 | -3.01 | positive regulation of cellular component biogenesis | biological process | GO:0044089 | 515 | 4 | 18204 | 49 |
NTRK2,GPM6A,NRXN1,CLU |
4.940e-02 | -3.01 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 3 | 19454 | 50 |
DTNA,SORBS1,MACF1 |
4.944e-02 | -3.01 | NCAM signaling for neurite out-growth | REACTOME pathways | R-HSA-375165 | 276 | 3 | 10285 | 31 |
FGFR3,CAMK2G,NRG3 |
4.968e-02 | -3.00 | KRTAP9-3 (keratin associated protein 9-3) | protein interactions | 83900 | 139 | 2 | 19454 | 50 |
SLC25A18,NTM |
4.968e-02 | -3.00 | NEFM (neurofilament medium chain) | protein interactions | 4741 | 139 | 2 | 19454 | 50 |
APOE,TNIK |
4.985e-02 | -3.00 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 2 | 18204 | 49 |
ATP1A2,RYR3 |
4.995e-02 | -3.00 | cerebellar Purkinje cell layer morphogenesis | biological process | GO:0021692 | 19 | 1 | 18204 | 49 |
RORA |
4.995e-02 | -3.00 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 1 | 18204 | 49 |
APOE |
4.995e-02 | -3.00 | excitatory synapse assembly | biological process | GO:1904861 | 19 | 1 | 18204 | 49 |
NRXN1 |
4.995e-02 | -3.00 | vocalization behavior | biological process | GO:0071625 | 19 | 1 | 18204 | 49 |
NRXN1 |
4.995e-02 | -3.00 | regulation of neurotransmitter uptake | biological process | GO:0051580 | 19 | 1 | 18204 | 49 |
ATP1A2 |
4.995e-02 | -3.00 | response to potassium ion | biological process | GO:0035864 | 19 | 1 | 18204 | 49 |
ATP1A2 |
4.995e-02 | -3.00 | microvillus organization | biological process | GO:0032528 | 19 | 1 | 18204 | 49 |
TNIK |